The effect of L-dopa and neuroprotective agents on

cell replacement therapy for Parkinson’s disease. by Elabi, Osama
 The effect of L-dopa and neuroprotective agents on 
cell replacement therapy for Parkinson’s disease. 
 
 
This thesis is submitted for the degree of Doctor of Philosophy at 
Cardiff University  
 
by 
 
Osama Falah Elabi  
 
Supervisors: 
Dr Emma L. Lane  
Prof Stephen B. Dunnett 
 
 
 
School of Pharmacy and Pharmaceutical Sciences  
Cardiff University  
July 2017 
 
i 
 
 
DECLARATION 
 
This work has not been submitted in substance for any other degree or award at this or any 
other university or place of learning, nor is being submitted concurrently in candidature for 
any degree or other award. 
 
Signed ……………………………………………(candidate)     Date ………………….…………… 
 
 
STATEMENT 1 
 
This thesis is being submitted in partial fulfillment of the requirements for the degree of 
………(insert MCh, MD, MPhil, PhD etc, as appropriate) 
 
Signed ………………………………………….(candidate)     Date …………………………….… 
 
 
STATEMENT 2 
 
This thesis is the result of my own independent work/investigation, except where otherwise 
stated, and the thesis has not been edited by a third party beyond what is permitted by Cardiff 
University’s Policy on the Use of Third Party Editors by Research Degree Students. Other 
sources are acknowledged by explicit references.  The views expressed are my own. 
 
Signed ………………………………………….(candidate)       Date …………………….……… 
 
 
STATEMENT 3 
 
I hereby give consent for my thesis, if accepted, to be available online in the University’s Open 
Access repository and for inter-library loan, and for the title and summary to be made 
available to outside organisations. 
 
Signed ……………………………………………(candidate)       Date ……………………………… 
 
 
  
ii 
 
SUMMARY 
Parkinson disease PD is the second most common neurodegenerative disease affecting 1.8% 
of population aged over 65 years. The current medications that control the symptoms of the 
disease are associated with limited efficacy and induction of side effects (dyskinesia) at later 
stages of the disease. One promising future therapy in PD is cell replacement therapy, 
however clinical trials declared inconsistent outcomes and developing dyskinesia related to 
the graft. Studies later suggested suboptimal conditions contributed on these outcomes. This 
thesis builds on this knowledge endeavouring to support cell transplantian therapy in 
Parkinson disease in models that are more closely aligned to the clinic thorough considering 
anti-parkinsonian medications in the model. It is addressed the low survival and efficacy 
problem of the transplanted cells examining neuroprotective agents that have previously 
shown the ability to protect nigrostriatal dopaminergic neurons against toxic challenges. In 
addition, this thesis characterises stem cell transplantation, the potential cell source for 
transplantation that can overcome the many practical and ethical issues surrounding foetal 
tissue.  
In the first part of the thesis, the investigations on finding neuroprotective agents to support 
graft survival and efficacy was achieved in the unilateral 6-OHDA lesioned rat model, treated 
with chronic L-dopa, (the gold standard anti- Parkinson medication), prior to, and following, 
cell transplantation. The results revealed for the first time that Glucagon Like Peptide-1 (GLP-
1) receptor agonists (exendin-4 and liraglutide) were capable of improving graft size and the 
motor and behaviour recovery results from peripheral administration. Importantly, this 
protection was affected by the presence or absence of L-dopa treatment, as exendin-4 
supported the graft only in absence of L-dopa while liraglutide supported the graft only in the 
presence of L-dopa. While other neuroprotective agents (ghrelin and ghrelin receptor agonist) 
failed to support graft survival or efficacy in the same animal model. In the second part of the 
thesis, the characterisation of different source of stem cells derived dopaminergic neurons 
revealed for the first time that these cells can survive and function in the striatum of 6-OHDA 
rat model primed with chronic L-dopa treatment and exposed to L-dopa treatment for 16 
weeks after transplantation. I show, for the first time, that these cells are capable of 
ameliorating L-dopa induced dyskinesia.  
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1 Chapter 1: General Introduction   
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 Parkinson Disease 
Parkinson disease (PD) is a progressive neurodegenerative disease causing a movement 
disorder, described for the first time by James Parkinson in 1817 (Parkinson 1817). It mostly 
affects people in later life with an average age of onset of 61±10 years (Marras et al. 2005). 
The prevalence of the disease is about 1.8% of the population aged over 65; with the rate 
increasing from 0.6% at ages 65-69 years to 2.6% at ages 85-89 years (de Rijk et al. 2000). It 
is reported that its incidence in the western world is about 1:10,000 of population per a year 
(Foltynie et al. 2004).  
 Diagnosis 
Despite it being two centuries since the first description of PD, it’s clinical diagnosis is still 
dependent upon physical examination and medical history. To diagnose PD, at least two of 
its four major cardinal features should be established. Firstly, resting tremor, which is a 
highly typical feature of PD, present at the resting state and ceasing during voluntary 
movement. This is usually recognised unilaterally in a hand, jaw and sometimes in the leg 
(Sonsalla, 1997). The another feature is bradykinesia which refers to extreme slowness of 
movement and is considered a highly disabling symptom because it affects all motor systems 
leading to difficulties in facial expression, gesturing, swallowing and blinking; in addition to 
reduced or absence of arm swing during walking (Jankovic 2008; Sonsalla 1997). The 
progression of the bradykinesia may lead to cessation of some actions like finger tapping, or 
cause intermediate immobility (freezing) which specifically occurs in crowded places or 
narrow doorways (Giladi et al. 1992). The third cardinal feature is rigidity which is an increase 
in muscle resistance causing a jerky movement described as being like a cogwheel movement 
(Sonsalla 1997). The last cardinal feature is postural instability which is considered as one of 
the most severely disabling symptoms in PD because it directly contributes to falls (Nelson 
et al. 2005). Although PD is predominantly described as a motor disorder, a number of non-
motor symptoms can also be detected throughout the progression of the disease including 
deficits in cognition, mood, autonomic function and sleep (Garcia-Ruiz et al. 2014).  This wide 
spectrum of symptoms between motor and non-motor signs indicates the pathologic 
complexity of PD which may include more than one region of the CNS or even PNS, despite 
its main pathologic feature involving dopaminergic neuron degeneration in the basal ganglia.  
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 Pathophysiology: 
The main pathologic feature of PD is the loss of dopamine neurons (DA) of the substantia 
nigra pars compacta (SNpc). The neurological deficit in PD starts after the loss of around 70-
80% of nigral dopaminergic neuron (DA) projections that supply the caudate putamen 
(Bernheimer et al. 1973). This high threshold level is attributed to the compensatory 
mechanisms which involve an increased synthesis and release of dopamine by the remaining 
neurons, in addition to a decrease in DA turnover (Zigmond et al. 1990). The reduction in DA 
neurons causes a disturbance in the basal ganglia circuitry, consequently leads to decreased 
activation of the frontal cortex and the existence of the motor symptoms. DA neurons affect 
this circuit through two pathways. Activation of D1 receptors in the direct output pathway 
from the putamen leads to release of the inhibitory neurotransmitter GABA and its cofactor 
substance P to the globus palludius interna (GPi) and substantia nigra pars reticula (SNr). 
While, the indirect pathway is maintained through the interaction of dopamine with D2 
receptor in the caudate putamen. Stimulation of the D2 receptor causes suppression of the 
release of the GABA and enkephalin, inhibitory neurotransmitters, to the globus pallidus 
externa (GPe) which cause activation to release of an inhibitory impulse to the Subthalamic 
nucleus (STN), which in turn causes a decreased level of the excitatory impulses to the GPi. 
So, the later receives a balanced level of inhibitory signal, from the direct pathway, and 
excitatory impulses, from the indirect pathway, which determines its transmission of the 
GABAergic efferent neurons to the ventro-lateral and ventro-anterior thalamus which is 
sending a a glutamatergic output to the frontal cortex (Alexander GE1 1990; Albin, R. L., 
Young, A. B., and Penney 1989; DeLong 1990) 
In the case of PD, the level of dopamine and the stimulation of D1 and D2 receptors in the 
putamen is reduced. Consequently, the signals received by GPi from the inhibitory pathway 
(direct pathway) decline, while they are boosted from the excitatory pathway (indirect 
pathway) resulting in the stimulation of the inhibitory neurotransmitter to the thalamus 
which in turn over inhibits the release of glutamate signals in the cerebral cortex (Figure 1). 
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Figure 1: (A) shows a normal physiological role of SNpc DA neurons in the direct and indirect 
pathways; (B) illustrates the consequences of losing dopaminergic neurons on both pathways 
(modified from (Nelson et al. 2005)). (abbreviations: D1, D2 dopamine receptors; SNpc, substantia 
nigra pars compacta; GPi, globus palludius interna; GPe= Globus pallidus externa; SNr, substantia 
nigra reticula; STN, subthalmic nucleus)  
Another hallmark of PD pathology is the inclusion of eosinophilic proteins forming structures 
known as Lewy bodies. These are found in neurons of the midbrain in addition to their 
existence in other multiple brain regions like neocortex, diencephalon, spinal cord, and even 
in peripheral neurons (Gibb et al. 1991; Schulz-Schaeffer 2010). These inclusions are mainly 
composed of aggregated α-synuclein and other cellular proteins like ubiquitin, elements of 
the proteasome, and synphilin (Kuzuhara et al. 1988; Ii et al. 1997; Mukaetova-Ladinska & 
McKeith 2006; Wakabayashi et al. 2000). Although, the biological role of the Lewy body is 
not well understood yet, there is speculation about its role in damaging,  protecting or simply 
marking neuronal cell damage (Harrower et al. 2005). α-Synuclein, which normally exists as 
a protein monomer, has a role in neuroprotection and maintaining the function of the 
dopaminergic synapse (Marques & Outeiro 2012). However, in PD α-synuclein protein is 
misfolded and exists in oligomers or filaments and its aggregation is suggested to be 
responsible for the neurodegeneration of the dopaminergic neurons (Schulz-Schaeffer 
2010). 
Different pathogenic mechanisms have been suggested for the degeneration of the nigral 
dopaminergic neurons included protein aggregation as described above, increased oxidative 
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stress, endoplasmic reticular stress, Ca++ level dysregulation, mitochondrial dysfunction, 
neuroinflammation and low trophic support. Misfolded α-synuclein, resulting from gene 
mutations, interacts with intracellular organelles and membranes and is involved in the 
increase in oxidative stress and elevation of intracellular Ca++ level (Lindholm et al. 2016). 
Endoplasmic reticulum (ER) controls the misfolded protein levels intracellularly via the 
Unfold Protein Response (UPR) process. However, the prolonged activation of UPR leads to 
ER stress and fails to maintain protein folding, ended with inducing the apoptotic cascade 
and subsequent cell death (Liu & Randal 2011). ER stress is one of the pathological 
mechanisms of neurodegeneration in PD; and UPR markers were also detected in the Lewy 
body components of PD patients with dementia (Lindholm et al. 2006; Baek et al. 2016). 
Dysfunctional mitochondria and impairment of mitochondrial quality control also 
contributed in the pathological mechanisms. Mitochondrial function normally maintains cell 
metabolism, intracellular Ca++ homeostasis, and the intrinsic death pathway. While in PD, 
dysfunctional mitochondria have been reported in the pathology of the disease and is the 
cause of the increase in oxidative stress, reactive oxygen species and alterations in the 
mitochondrial dynamics (Henchcliffe & Beal 2008). The damaged mitochondria are normally 
removed from the cells via mitophagy while a failure in clearing the damaged mitochondria 
leads to the release of cytochrome C, a key cell death component, in to the cytosol and 
induction of  apoptosis (Suen et al. 2008). In familial PD (discussed below 1.4.2), mutations 
of genes Parkin and PTEN-induced putative kinase 1 (Pink1), which encode proteins required 
in the ubiquitin-protease system of mitophagy process, give evidence to the involvement of  
mitochondrial quality control in the pathology of the disease (Truban et al. 2016). 
Neuroinflammatory reactions and accumulation of activated microglia in the SN were other 
signs recognized in the pathology of PD (Ouchi et al. 2009). Activated microglia is responsible 
for the release of pro-inflammatory cytokines like TNFα, IL1β, and INFλ which can exacerbate 
the oxidative stress and the induction the apoptosis. it has been reported that extracellular 
α-synuclein participates in stimulation of the neuroinflammatory reaction and the secretion 
the pro-inflammatory cytokines (Marques & Outeiro 2012).   
 Aetiology 
PD was described for a long time as a prototypic and non-genetic disorder. However, in the 
early 1980s, 1-methyl-4-phenyl-1, 2, 3, 6,-tetrahydropyridine (MPTP), which has a structure 
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similar to the herbicide Paraquat, was identified as the cause of PD chronic motor symptoms 
and selective degenerative of nigral DA neurons in a small group of drug addicts accidentally 
exposed to this drug. This finding shed light on the role of environmental exposures in the 
incidence of PD (Langston et al. 1983). Later, identification of inherited forms of PD 
suggested a genetic role in the pathological mechanism, which is confirmed after 
distinguishing the role of some of these genes in PD pathology. This is expanded in more 
details in the following sections 
1.4.1 Environmental factors: 
Many hospital and population control studies were conducted to validate a correlation 
between specific categories of pesticide use and the incidence of PD. Some of these studies 
have reported an increase in the risk of PD with frequent exposure to these chemicals, while 
others did not report a significant correlation (reviewed in (Wirdefeldt et al. 2011)). 
Paraquat, which is a herbicide, has been tested on mice and has a dose dependent 
degenerative effect on the nigral neurons when given intraperitoneally  and frequently 
(McCormack et al. 2002). Rotenone, which is an insecticide, caused degeneration to the 
nigrostriatal dopaminergic neurons combined with motor activity disorder and existence of 
Lewy body in the rats (Betarbet et al. 2000). Similarly , Dieldrin, which is an organochlorine 
pesticide, caused disturbance in the nigral dopaminergic system and increase α-synuclein 
level in experimental mice (Corrigan et al. 2000; Hatcher et al. 2007). Many other 
environmental factors have been implicated in the incidence of PD, including drinking well 
water, rural residence, heavy metal exposure, magnetic field and others; On the other hand, 
other factors shows a protection against the incidence of PD like intake tea and coffee, 
smoke cigarettes and utilising non-steroidal anti-inflammatory drugs (NSAIDs) reviewed in 
(reviewed in (Wirdefeldt et al. 2011)).  However, there were no absolute evidence of these 
factors contribution in the PD aetiology.  
1.4.2 Genetic factors: 
In a few families there is clear genetic linkage driving inherited forms of PD. Many family 
studies have reported that the acquisition of PD from first degree relatives ranged between 
1.6 to 10.4% ( review, Wirdefeldt et al., 2011). These findings have led to a distinction 
between the familial form of PD and the sporadic form. However, both of these types closely  
follow the same clinical and neuropathological features with the exception that familial PD 
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generally occurs at younger age of onset (Schiesling et al. 2008; Latourelle et al. 2009). Since 
the late 1990s, several genes were reported to be responsible for inherited forms of the 
disease.  In 1997, α-synuclein was the first gene to be associated with familial PD with a 
specific A53T substation mutation identified as the pathological trigger (Polymeropoulos et 
al. 1997). Following this, Kitada and colleagues found that a mutation in the protein Parkin 
were responsible for a form of autosomal recessive early onset PD (Kitada et al. 1998). 
Similarly mutations in  DJ-1 (Bonifati et al. 2003) and PINK-1 (Valente et al. 2004) cause an 
early onset autosomal recessive PD. Leucine-rich repeat kinase (LRRK2) is another identified 
gene responsible on an autosomal dominant late- onset PD and causes the most common 
feature of the typical PD (Zimprich et al. 2004). Recent findings suggest more genes 
associated with PD like Vacuolar protein sorting-associated protein 35(VPS35) (Vilariño-Güell 
et al. 2011) and eukaryotic translation initiation factor 4 Gamma 1 EIF4G1 (Chartier-Harlin et 
al. 2011). The abnormal expression of some of these genes are not only restricted to familial 
PD but can also be detected in some cases of sporadic PD (described in the table 1.1). This 
overlap may be attributed to the gene susceptibility concept which involves gene-gene or 
gene-environment interaction in sporadic PD (Schiesling et al. 2008). Generally, these 
mutations exert their pathogenic mechanisms on PD via interfering with the function of the 
mitochondria, ubiquitin- proteasome system and/or phosphorylation process causing 
downstream cell death mechanisms like programmed cell death, accumulation of oxidative 
stress, abnormal protein aggregation or energy depletion (Savitt, J. M. et al. 2007). 
Table 1 prevalence of PD cases of the known mutant genes form in the familial and sporadic PD 
(modified from (Schiesling et al. 2008)) 
Mutated protein Familial PD Sporadic PD 
α-synculein < 0.5% Non 
Parkin ~10-20% ~20% of early onset PD 
PINK1 ~1-7% Rare, but limited data 
DJ-1 ~1-2% Unknown  
LRRK2 ~5-10 % ~2% 
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 Treatment: 
The main medications used currently for the management of PD is dependent on addressing 
the dopamine deficiency in the putamen by administration of dopamine precursors, 
dopamine receptor agonists and dopamine breakdown inhibitors (COMT and MAO-B). These 
medications are not curative and they only relieve the motor symptoms of the disease. 
Although, these medications show success in controlling most of cardinal features of the 
disease, they showed limitations on late stages of the disease with developing a disabling 
side effect. However, new therapeutic approaches have emerged that may carry new 
possibilities and promises in providing more convenient results for the PD patients like deep 
brain stimulation, gene therapy, disease modifying approaches and cell replacement 
therapy. These approaches are currently either in animal models, clinical trials or approved 
by FDA. Below is a brief description for the classical pharmacological treatments and the new 
approaches with an emphasis on cell replacement therapy, the cornerstone of this thesis.   
1.5.1 Classical treatments 
Since the discovery of dopamine deficiency in the putamen as the main cause of PD, a new 
era of the treatment had been revealed (Marsden 1990). Because dopamine cannot 
penetrate the blood brain barrier, L-dihydroxyphenylalanine (L-dopa) was the first agent 
used for replacing the dopamine in 1967 (Cotzias et al. 1967). It showed effectiveness in 
reliving all the cardinal symptoms of the disease and it is still used effectively today (Nutt & 
Holford 1996). It is given in combination with peripheral aromatic amino acid decarboxylase 
(AADC) enzyme inhibitors (benserazide or carbidopa), to avoid its peripheral metabolism, 
decrease its peripheral side effects and increase its central bioavailability (Sonsalla 1997). L-
dopa is converted to dopamine by the action of AADC enzyme then stored and released to 
the synapses to act on the post-synaptic receptors followed by rapid termination to their 
action by dopamine transporter DAT. Then, the dopamine is either restored or degraded 
intracellularly or extracellularly by monoamine oxidase-B (MAO-B) or catechol-o-methyl 
transferase (COMT) (Sonsalla 1997) (dopamine synthesis, release and metabolism see Figure 
2). With progression of the disease, the duration of the effectiveness of L-dopa gradually 
decreases with fluctuations in effectiveness between a good response “on phase” and bad 
response “off phase” (Obeso et al. 2000). In addition, with chronic administration a striking 
set of disabling involuntary movements is developed during the on phase which is called L-
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dopa-induced dyskinesia (see below 1.5.2).  It was suggested that this decline of L-dopa 
effectiveness is due to further loss of the dopaminergic neurons and reduction in the pre-
synaptic storage capacity of the dopamine. Adjusting the dose of L-dopa to small and 
frequent doses can sometimes be beneficial to relieve the dyskinesia symptoms. However, 
with further progression of the disease, this correction to the dose administration becomes 
more difficult because the lowest dose to avoid existence of dyskinesia is not capable of 
relieving the PD symptoms (Thanvi et al. 2007). Specifically, the problems with L-dopa are 
that it has a short half-life and its release is controlled by firstly DA neurons then non-DA 
neurons causing the problems in later PD.  Other anti-parkinsonian medications were 
developed to overcome these problems with fluctuations include dopamine receptor 
agonists, MAO-B inhibitors and COMT- inhibitors. Dopamine receptor agonists, like 
pramipexole and ropinirole, showed effectiveness in alleviating the motor symptoms with 
fewer fluctuations in their effects and reduced prevalence of dyskinesia due to their longer 
half-lives. However, they exert a major autonomic and psychiatric side effects. MAO- 
inhibitors, like rasagiline and selegiline, which inhibit dopamine break down, are also 
effective in treating PD symptoms as monotherapy in early stages of the disease and it used 
to prolong the effectiveness of L-dopa with less fluctuation at late stages (Pires et al. 2017). 
COMT- inhibitors, which inhibit L-dopa metabolism, like tolcapone and entacapone, also 
show beneficial effects when used as adjuncts to L-dopa at advanced stages, to prolong 
efficacy and reduce ‘off’ time and fluctuation (Pires et al. 2017).  
10 
 
 
 
Figure 2: Mechanism of DA synthesis, release, metabolism and reuptake in DA neurons (modified 
from Nelson et al. 2005). (abbreviations: D1, D2& D3, dopamine receptors; L-dopa, L-
dihydroxyphenylalanine; TH, tyrosin hydroxylase; COMT, catechol- o- methyl transferase; 3OMD, 3-
O-methyldopa; LAAD, L-amino acid decarboxylase; MAO-B, mono amino oxidase; DOPAC, dihydroxy 
phenyl acetic acid; HVA, 3 methoxy-4-hydroxy-phenylacetic acid; AD, aldehyde dehydrogenase; DA, 
dopamine; breaking arrow, feedback regulatory)  
1.5.2 L-dopa induced dyskinesia 
L-dopa-induced dyskinesia (LID) is characterised by choreiform abnormal involuntary 
movements affecting the neck, trunk and upper extremities in addition to dystonia affecting 
the legs. It is classified in two different forms according to their appearance after L-dopa 
treatment: peak-dose dyskinesia (on phase dyskinesia), appearing at the peak effect of L-
dopa (relatively high L-dopa plasma level);  diphasic dyskinesia (off phase), appearing at the 
onset and the decline of L-dopa’s effect (Muenter et al. 1977; Thanvi et al. 2007). It has been 
suggested that L-dopa induced dyskinesia originated from the fluctuation in the synaptic 
level of dopamine which cause a repetitive pulsatile stimulation to the dopamine receptors. 
It has been hypothesized also that serotonergic neurons uses L-dopa and release the 
dopamine as a false transmitter without ability to control its termination due to the lack of 
the dopamine transporter DAT (Maeda et al. 2005). This pulsatile and excessive stimulation 
of the D1 receptor causes sensitisation of the receptor and leads to abnormalities in the 
intracellular signalling of the striatal medium spiny neurons MSN. This abnormality includes 
changes in the translational and transcriptional downstream molecules that have no direct 
relation to the dopaminergic transmission, for example extracellular signal regulated kinase 
(ERK) and mammalian target rapamycin complex (mTORC) (Feyder et al. 2011). Different 
other hypotheses illustrate the involvement of multiple systems in the development of LID 
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like the glutamatergic, adenosine and cholinergic, opioid and inflammatory hypotheses 
reviewed in (Bastide et al. 2015; Niccolini et al. 2014; Carta et al. 2016) 
Some therapeutic agents either in animal models or that have progressed to clinical trials 
have shown the ability to manage LID without affecting the efficacy of L-dopa to alleviate 
motor symptoms. A double blind placebo controlled clinical study reports that amantadine, 
which has NMDA antagonist properties, can reduce LID severity by 60% when compared to 
placebo (Verhagen Metman et al. 1998). In addition, preclinical trial showed that 5HT1A/1B 
receptor agonist can ameliorate LID severity in rodent and non-human primate experimental 
models of PD (Shin, Tronci, et al. 2012).  
1.5.3 New therapy approaches: 
1.5.3.1 Deep Brain Stimulation (DBS) 
This approach passed phase 3 of clinical trial and was approved by the FDA in 2002. It is 
based on chronic stimulation of the STN and GPi, by implantation of a small electrode. This 
therapeutic method showed a remarkable success in ameliorating all the cardinal symptoms 
of advanced PD without causing dyskinesia or fluctuations in the motor pattern during their 
use. In addition, the DBS strategy leads to a decrease in the use of regular medications and 
consequently  decrease their side effects, including LID (Benabid 2005). However, it does not 
have a beneficial effect in relieving non-motor symptoms and could not stop the underlying 
neurodegenerative progression of the disease (Buttery & Barker 2014). Furthermore, some 
clinical trial, reported significant side effects, speech and vision problems predominate, in 
addition to cognitive and psychiatric issues like apathy, depression, emotional stress and 
suicidal attempts (reviewed in (Pires et al. 2017)).  
1.5.3.2 Gene therapy  
Gene therapy in Parkinson disease is based on the transference of a gene to a specific area 
in the brain via viral vectors to induce specific protein expression that can generate 
mechanism to relieve either the degenerative process or the side effects including LID. Three 
therapeutic strategies have reached clinical trials targeted gene therapy: First, glutamic acid 
decarboxylase (GAD) enzyme directed to the STN will increase synthesis of GABA, an 
inhibitory mediator, trying to achieve the same effects as STN-DBS; second, supplying 
molecular mechanisms to synthesis DA in the medium spiny striatal neurons. This will enable 
them to release their own dopamine to stimulate dopaminergic receptors and normalise the 
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basal ganglia circuit.  The last strategy gave attention to halting progression of the disease 
by providing trophic factors to protect the cells from degeneration (Buttery & Barker 2014). 
All these strategies illustrated encouraging results in in pre-clinical trials but efficacy ranging 
from none to moderate in clinical trials, with the exception of the first strategy which 
illustrated significant improvement in motor symptoms and is currently in phase 3 of clinical 
trials (LeWitt et al. 2011; Christine et al. 2009; Marks et al. 2008) 
1.5.3.3 Disease modifying approaches therapy  
Disease modifying therapies are aimed at halting progression of the disease and protect the 
nigral dopaminergic neurons via targeting the histopathological mechanisms that’s caused 
the degeneration of the dopaminergic neurons like α-synuclein aggregation, ER stress, 
mitochondrial dysfunction and quality control, neuroinflammation, oxidative stress, in 
addition to trophic support. Currently some of these strategies showed significant 
effectiveness in animal models and passed to clinical trials like: hindrance disease 
progression via immunization strategy to target oligomerization and aggregation of α-
synculein (Lindström et al. 2014); protecting nigral dopaminergic neurons with using some 
anti-diabetic agents like exendin-4 and pioglitazone, this possibly due to an interference with 
neuroinflammation, mitochondrial function or having anti-apoptotic properties (exendin-4 
discussed in details in chapter 4) (Swanson et al. 2011; Aviles-Olmos et al. 2014); or providing 
trophic factors (delivered through gene therapy). Others agents in pre-clinical trials also 
showed protection to the dopaminergic neurons like: agonists targeting a non-opioid 
intracellular receptor in MAM (Mitochondria Associated endoplasmic reticulum Membrane); 
PACAP (pituitary adenylate cyclase-activating polypeptide) via immunomodulation; MANF 
(mesencephalic astrocyte-derived neurotrophic factor) trophic factor possibly reduced 
endoplasmic reticulum stress (reviewed in (Lindholm et al. 2016). 
 Cell replacement therapy in PD 
Cell therapy is another promising treatment to achieve long lasting relief of the motor 
symptoms of PD. It is based on transplanting new dopaminergic cells, capable of supplying 
the putamen with dopamine, to replace that lost through the degenerated nigrostriatal 
dopaminergic neurons. The first evidence of successful cell transplantation in animal models 
was published in the 1970s when Bjorklund and colleagues transplanted small pieces of 
primary tissues (including dopaminergic, serotonergic and noradrenergic neurons) into the 
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cerebral cortex and hippocampus of intact adult rats. The transplanted cells showed the 
ability of the cells to survive and produce projecting fibres (Bjorklund A, Stenevi U 1976; 
Stenevi et al. 1976). At that time, a rat model of PD had been established using the toxin 6-
hyrodxydopmaine (6-OHDA) to degenerate nigrostriatal dopaminergic neurons producing 
motor and behavioural deficits quantifiable through an asymmetric rotational response 
following administration of amphetamine (Ungerstedt & Arbuthnott 1970). This encouraged 
two separate groups to conduct experiments to explore the possibility of transplanting 
pieces of tissue including dopaminergic neurons adjacent to the striatum in rodents (cerebral 
cortex, lateral ventricle). Both of these studies confirmed the success of the cell 
transplantation concept with innervation demonstrated in the striatum alongside the 
recovery of motor deficits (Perlow et al. 1979; Björklund et al. 1980). A couple of years later, 
papers had been published showing that using a dissociated cell suspension for 
transplantation at multiple sites inside the striatum lead to much more widespread 
innervation through the striatum with better recovery not only in the behavioural rotation 
tests but also in sensorimotor tests (Schmidt et al. 1983; Björklund et al. 1983).  
These successes in experimental animal models were then shifted to human clinical trials. In 
1987, a clinical study was carried out by auto-grafting a fragment of the patients’ adrenal 
medulla into the right caudate nucleus producing a reported improvement in Parkinson’s 
symptoms (Madrazo et al., 1987). Later in 1989, a multicentre study illustrated that these 
improvements were minimal and transient (Goetz et al. 1989). In addition, it involved a 
highly risky procedure which included two major surgeries (abdominal AND stereotactic 
neurosurgery). Subsequently, in the early 1990s, foetal ventral mesencephalic tissue was 
found to be a more effective source of dopaminergic neurons (Lindvall et al., 1992) 
compared to autologous adrenal medulla and open label clinical studies were conducted in 
small groups of PD patients with advanced disease. 18F-DOPA PET scan and the unified PD 
rating scale (UPDRS) were used to assess graft function and outcomes ranged from 
‘beneficial’ (Levivier et al. 1997; Mendez et al. 2002; Freed et al. 1992; López-Lozano et al. 
1997) to ‘variable’ and ‘unsatisfactory’ (Defer et al. 1996; Peschanski et al. 1994). In 2001, 
Freed and colleagues used a sham-controlled double blind study to transplant VM cells and 
their data initially found no beneficial effect of the graft. Subsequent analysis split the 
patients into age-based cohorts and identified that the younger patients achieved greater 
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improvements than older patients. However, in patients who had improvement, many of 
them experienced a novel form of dyskinesia, which, unusually, was most apparent when 
patients were assessed in the absence of L-dopa treatment (Freed et al. 2001). These results 
were supported later by another double blind, controlled-placebo trial conducted in 2003 
(Olanow & Goetz 2003). Again, these so-called graft-induced dyskinesia (GID) were also 
identified in 13 out of 23 patients. In parallel, an EU based open label trial was occurring 
reported increase dyskinesia level in 6 patients out of 14 during L-dopa off phase post-
transplantation (Hagell et al. 2002) (discussed in section 1.6.4). Thus, a heated argument 
emerged about the validity and safety of cell therapy in the treatment of PD and ended with 
the stopping of clinical trials. This persisted despite evidence from the PET scans and autopsy 
studies which illustrated that the transplanted cells survived and were functional in the host 
brain.  
However, studies later suggested that suboptimal conditions in the controlled placebo 
clinical trials were the reasons for the inconsistent results. For instance, in Freed et al 2001 
trial, the cells were stored for up to 4 weeks before transplantation and they did not choose 
to use any form of immunosuppressant agent after transplantation. In the Olanow et al study 
2003, they used immunosuppressant agents for only 6 months before withdrawal. An 
autopsy study performed on 5 patients of Olanow et al trial (two died due to unrelated 
causes during the study and 3 during 29 months follow up study) detected a significant 
presence of immunological reaction around the graft which highlighted the possible 
interference of an inflammatory reaction with graft survival, function and in the induction of 
GID. Later Piccini and colleagues suggested that the limitations in clinical outcomes could be 
related to the extent of dopaminergic denervation outside the graft area as the patients who 
had denervation of dopaminergic neurons in the ventral striatum (area outside the graft site) 
had no recovery of the graft while patients with no denervation had improvement in clinical 
assessment. They also showed that long term immunosuppression (for up to 29 months) had 
no effect on cell survival and function (Piccini et al. 2005). They concluded that although the 
data itself was not wholly conclusive, a successful outcome appeared to depend upon 
patient selection (depending on the disease stage) and putting the patients on a longer 
period of immunosuppression therapy post-transplantation. Clinical trials ceased but 
preclinical work then continued to uncover what was precipitating GID. The idea of improved 
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patient selection being key was given weight by a published paper showed that the GID might 
be linked to the history of LID, suggesting that at selection LID severity history should be 
considered (Lane et al. 2009). Another clinical key paper came from Politis and colleague 
clarifying that the patients who experienced GID had high innervation of serotonergic 
neurons in the graft and the dyskinesia score reduced by using anti-serotonergic release 
treatments. Although this lacks any control data of patients with successful grafts without 
GID, this data suggested that the GID may be due to the contamination of graft material with 
serotonergic neurons as a result of wide VM dissections of the primary tissue (Politis 2010). 
Importantly for the success of transplantation when effective, a more recent paper of long 
term patient monitoring showed that transplanted cells had very long term benefits in 
reliving motor complications up to 18 years post transplantation without need to use anti-
parkinsonian medications (Kefalopoulou et al. 2014).  
These studies all encouraged the revisiting of the cell therapy approach in clinical trials with 
considering optimisation the suboptimal conditions. Currently, a new clinical trial has 
commenced in Europe, under the name of TransEuro, to transplant primary foetal VM 
dopaminergic neurons into the putamen of PD patients. In this trial an optimised protocol of 
cell processing with minimized serotoninergic neuron contamination of the transplanted 
cells has been considered. In addition, patient selection is dependent on stage of the disease 
with a high expression of LID being an exclusion criteria (www.transeuro.org.uk). The study 
has not concluded yet and the results will be important to determine the future of cell 
therapy in PD.  
1.6.1 Cell survival and efficacy 
The caudate putamen is topographically heterogenous in controlling specific motor tasks 
(Dunnett & Iversen 1982). This underlines the importance of the graft to have a sufficient 
fibre innervation capacity to reach across the brain area to reverse motor complications. 
Studies have shown that both the graft innervation capacity and amelioration of motor 
complications depend on the number of dopaminergic neurons in the graft (Schierle et al. 
1999; Nakao et al. 1995).  The clinical and pre-clinical trial clarified that there is a low survival 
rate of transplanted cells and only small proportions of the dopaminergic neurons remaining 
in the graft ranged between 1-20% of the transplanted cells, reviewed in (Brundin et al. 
2000). Open clinical trials showed that in order to achieve therapeutic efficacy, cells obtained 
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from 3-5 VM sections were needed for transplantation on each side of the brain (reviewed 
in (Hagell & Brundin 2001)). This creates a practical hurdle as obtaining several VMs at the 
time of transplantation is logistically complex. Especially, prolonged periods of cells storage 
lead to reduces viability and efficacy of the cells. Importantly, as described above, reducing 
cell loss will improve graft efficiency and the reduce number of cells required for 
transplantation. The loss then occurs at the point of transplantation and post-
transplantation, particularly in the early post-implantation period. The following is a 
description of the main factors contributing to cell loss and/ or efficacy of the cell 
transplantation.  
1.6.1.1 Pre-transplantation cell loss 
Preparing the primary cells for transplantation pass through different steps, starting from 
collecting the embryos, dissecting out the VM piece and the cells dissociation process. 
Through this process the cells are exposed to hypoxic, hypoglycaemic and mechanical stress 
environments resulting in the death of some of the cells. This issue has been addressed by 
different studies clarifying that using suitable culture media like DMEM (Watts et al. 1998), 
storing the cells in a cool place (Watts et al. 1998), and reduced mechanical stress on the 
cells, as well as transplanting fragmented cells suspension rather than single cells suspension 
(Nikkhah et al. 2009) will lead to significantly improved cell survival. Once this process is 
complete, further loss is then occurring through loss of cells inside the cannula mainly due 
to incomplete delivery or traumatic effect on the cells. Using smaller cannula size (inner 
diameter 0.26 mm) may increase the survival of dopaminergic neurons in the graft compared 
to larger cannula (inner diameter 0.9) (Steiner et al. 2008). In single cell suspension 
transplantation, using glass capillary cannula (outer diameter 50 µm) lead to increased cells 
survival of four times compared to metal cannula (inner diameter 0.26 mm) (Nikkhah et al. 
2009). It also has been suggested that the smaller cannula causes less damage to the host 
cells, consequently this cause less inflammatory and excitotoxicity reaction to the graft. 
However, the practicalities and safety issues of a glass cannula in patients make this an 
unlikely development to translate into clinic. 
1.6.1.2 Early cell death post-transplantation  
Inside the caudate putamen, different factors are suggested to be involved in cell death, 
including brain injury during the surgical intervention, low trophic factor expression within 
the diseased adult host environment and inflammatory reactions to the transplanted cells. 
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Inserting the cannula during surgical intervention causes injury to the host neurons which 
may induce excitotoxic peptides, oxidative reaction and free radicals to the environment 
around the graft and this increase cell vulnerability and propensity to induce apoptosis 
(reviewed in (Patrik Brundin et al. 2000)). A delay in the release of the transplanted cells in 
the host brain from the cannula by 1 hr after placing them inside the brain may lead to 
increased cells survival rate by 3 times which suggested that there are acute but fast 
recovering changes in the host environment (Sinclair et al. 1999). Moreover, other studies 
illustrate that the majority of cell loss occurs throughout the first week of transplantation 
(Emgård et al. 1999; Barker et al. 1996). Some studies showed that treating the cells, in cell 
preparation and prior to transplantation, with neuroprotective agents like Tirilazad Mesylate 
as anti-oxidants  (Björklund et al. 1997) and Ca++ blocker to reduce excitotoxicity (Kaminski 
Schierle et al. 1999) lead to a significant improvements in cells survival.  
1.6.1.3 Low trophic factor tone of host environment  
The other concern in the death of transplanted cell is the low trophic factor environment of 
the adult caudate putamen to support the survival of the newly implanted dopaminergic 
neurons. An in vitro study showed that trophic factors released from the striatum can 
support the survival of dopaminergic neurons at early stages of its development (E15 
embryonic VM rats) but they had no effect on its survival at late stage (E17 VM rats) while 
autocrine acting growth factors (like GDNF and BDNF) improved dopaminergic neuron 
survival at late stages of VM development (Engele 1998). In vivo, various studies show a 
significant increase in dopaminergic neuronal survival after enrichment of the host 
environment with the trophic factor GDNF, using different methods like direct infusion into 
the striatum (Yurek 1998), engraftment of capsules continually releasing GDNF in the graft 
(Sautter et al. 1998), co-grafting cells programmed to produce and release the trophic factors 
(Wilby et al. 1999), or genetically overexpression the GDNF in the striatum itself using viral 
technology (Yurek et al. 2009). VM transplantation in the striatum of younger rats provides 
a better cell survival than transplantation in older rats while co-grafted Schwann cells, as a 
source for trophic factors, in the older group leads to an improvement in survival and 
behavioural outcomes (Collier et al. 1999). Moreover, it has been suggested that older 
patients have lower trophic tone than the younger patients, explaining why cells survival is 
lower in older patients/rats (Thompson & Björklund 2012).  
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1.6.1.4 Neuroinflammation  
The detection of a significant increase of activated microglial around the graft in the Olanow 
et al double blind clinical study in 2003 shed light on the importance of inflammation on the 
optimization of graft survival and efficacy (Olanow & Goetz 2003). The innate immune 
system, as a defence mechanism, reacts to the foreign cells by activation of the microglia to 
release pro-inflammatory molecules and cytokines like TNF-α, IL-1β, and INF-λ, inducing 
apoptosis. However, the inflammatory reaction is complex and involves different phases 
after initiation of the cascade. After the pro-inflammatory phase, the innate immune system 
passes through a ‘resolution and repair’ phase to maintain normal tissue homeostasis and 
this involves alteration of the microglial phenotype from pro-inflammatory microglia to 
neuroprotective microglia which release neuroprotective cytokines like IL-4, IL-10 and TGF-
β (reviewed in (Colton 2009). Immunosuppressant agents gave the first evidence as to the 
role of inflammation on cell survival. As in animal models, their use with xenografts produces 
a significant improvement in cell survival and prevention of graft rejection. For instance, 
monoclonal antibodies against CD4 treatments prolong graft survival dramatically (Wood et 
al. 1996) and the treatment with monoclonal anti-IL2 receptor (anti-CD25 mAb) or 
cyclosporine A improved survival significantly compared to the control group (Honey & Shen 
1999) (Pakzaban & Isacson 1994). Other evidence came from experiments which induced an 
inflammatory response to challenge the survival of VM allografts showing that the 
stimulation of a peripheral inflammatory reaction can lead to compromised survival in the 
brain. For instance, transplanting an orthotropic allogenic skin graft before or after allogenic 
VM striatal transplantation from the same donor strain caused a significant reduction in 
dopaminergic neuronal survival in the case of post-grafting immunization whilst rejection of 
the VM graft was caused by pre-grafting immunization. An alternate approach to exploring 
this was to inject spleen cells of the donor strain peripherally after transplantation to cause 
a significant increase in the immune response around the graft (MHC II level) and reduced 
DA survival by 64% (without significant difference, p=0.09) (Soderstrom & Meredith 2008). 
Duan and colleagues compared the time course of the inflammatory reaction toward 
syngeneic, allogenic and xenogeneic grafts in the rat model without adding 
immunosuppressant agents or peripheral inflammatory stimulation. Increase activated 
microglia, infiltration of lymphocyte and elevated MHC expression around the syngeneic and 
allogenic grafts appeared over the first 4 days but most of these inflammatory signs had 
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disappeared by week 6 while xenografting had a heavier presence of these inflammatory 
signs after the first 4 days and the grafts had been rejected by week 6 (Duan et al. 1995). 
Overall this appears to show that the host immune response had negative effect on cell 
survival and long term use of immunosuppressant agents could have a positive impact on 
cell survival and graft function. Some clinical trial data now appears to suggest that there is 
a possible gain to a functional graft of long term immunosuppression of up to 2 years 
improving the long term motor symptom relief (Kefalopoulou et al. 2014; Piccini et al. 2005).  
1.6.1.5 Graft location  
Graft location is another area that has been considered in cell therapy optimisation. Ectopic 
transplantation in the striatum has been preferred over intra-nigral transplantation for 
numerous reasons; the latter shows insufficient striatal innervation and low cell survival 
compared to intra-striatal transplantation unless external trophic agents are added to 
support its survival and fibre outgrowth, even then innervation of the human striatum is 
unlikely (Thompson et al. 2009; Nikkhah, Cunningham, et al. 1994; Nikkhah, Bentlage, et al. 
1994). Redmond and colleagues characterised VM cell transplantation at different sites in 
the striatum and they found there was no difference in cell survival or innervation capacity 
in the caudate or the putamen in non-human primate model, however they found that 
putamenal grafts produced better behavioural recovery (Redmond et al. 2008). 
Transplantation of the graft across multiple sites and more than one deposit has also been 
shown to yield wider innervation of the striatum and better behavioural improvement in the 
rat 6-OHDA lesioned rat model (Falkenstein et al. 2009). Interestingly, single site, small graft 
transplantation induced forelimb-facial dyskinesia stereotypies in one study, contrasting 
with the case in multiple site transplantation suggested that focal transplantation are 
inducing factor for the GID (Maries et al. 2006a).  
1.6.1.6 Dopaminergic neurons subtype 
Dopaminergic neuron subtype is another factor found to have influence on graft efficacy. 
The transplanted VM cells population includes a mix of midbrain dopaminergic neurons 
subtypes mainly A9, which is the nigral phenotype innervating the putamen, and the A10 
subtype which is the developing VTA (innervating the caudate and frontal cortex) (Mendez 
et al. 2005; Thompson et al. 2005). A9 dopaminergic neurons are the most vulnerable 
population in PD with a relative sparing of the A10 population (Damier , Hirsch , Agid , 1999). 
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Grealish and colleagues found that the A9 subtype in the VM graft is actually the one 
responsible for reversal of the motor deficits while the A10 subtype may have limited 
influence. They suggest that the A9 subtype has the exceptional ability to target the motor 
area of the striatum (dorsolateral area) (Grealish et al. 2010). These finding highlight the 
importance of the relative proportion of A9 to A10 subtypes to reverse the motor 
complications and graft efficacy. Later, a study identified that the birth of A9 subtype during 
ventral midbrain neurogenesis is earlier than the A10 subtype and clarified that 
transplantation of younger VM cells leads to an A9 enriched graft with larger innervation to 
the dorsolateral area of the striatum and better motor recovery (Bye et al. 2012). A recent 
published study showed that the dorsal striatal environment preferentially supports the 
survival and innervation of the A9 subtype over A10 of younger VM cells (E12) (Fjodorova et 
al. 2017). These findings support the advice of using a younger VM age for transplantation in 
the ongoing foetal tissue clinical trials.  
1.6.1.7 Synaptic integration  
Boosting proper synaptic integration between the graft fibres and the striatal dendrites was 
another target in the optimisation of graft efficacy. A recent paper showed that 
administration of estradiol systemically into hemiparkinson rats lead to enhanced synaptic 
integration of the transplanted dopaminergic neurons in the striatum via stimulation 
expression of the integrin α5β1 molecule, which is a cell adhesion molecule on the striatal 
cells and innervated by midbrain dopaminergic neurons. This enhancement in synaptic 
integration was reflected in a significant improvement in the behavioural test (Nishimura et 
al. 2016). Similarly, targeted preservation of the host dendritic spine after transplanting VM 
cells in a rodent model of PD using, the Ca++ channel blocker Nimodipine, caused a significant 
improvement in some behavioural tests compared to controls (Soderstrom et al. 2010).  
1.6.1.8 Lewy body existence around the graft    
A recent issue raised from an autopsy study for a patient who received a VM graft 24 years 
prior to his death showed the existence of α-synuclein and ubiquitin positive deposits, 
appearing with Lewy body-like features around the graft. There was extensive fibre 
innervation in the putamen after 24 years, however the patients’ monitoring history was 
recorded as a gradual loss of the recovery of motor complications after 14 years post-
transplantation. The authors suggested that a wide spread degeneration could lead to the 
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loss of efficacy of the graft (Li et al. 2016). The presence of these Lewy bodies is however still 
very low.  Cell transplantation in model needs considering the presence of α-synuclein and 
its degenerative effect on the transplanted cells and evaluation of the efficacy of the graft in 
this environment. 
1.6.2 Neuroprotective agents to support cell transplantation  
1.6.2.1 Mechanisms of Cell death  
As described above, the cell death in transplantation therapy occurs at different stages of 
transplantation process either in cell preparations, during transplantation or post-
transplantation. Generally, cells death happens in two different patterns either necrosis or 
apoptosis, each has different features and mechanisms. Necrotic cell death results from 
acute injury characterised by swelling of the cell plasma membrane and organelle leakage 
followed by inflammation (Wyllie et al. 1980). Conversely, apoptotic cell death 
characteristics include shrinkage of the cell and nuclear chromatin condensation, DNA 
fragmentation, intact plasma membrane with blebs (apoptotic bodies), terminated by 
phagocytosis, no leakage of cell component and no local inflammation (Raff et al. 1993). The 
process of apoptosis is stimulated through activation of a caspase cascade, a protease family 
that mediate cell death. It is activated through two pathways: external activation mediated 
from direct stimuli to surface receptor lead to activation caspase 9; internal activation, 
mediated through release cytochrome C from the mitochondria which in turn activate 
caspase 8. The release of cytochrome C from mitochondria controlled by the Bcl-2 protein 
family which either inhibit release cytochrome C and suppress the apoptosis like Bcl-2, Bcl-
xl and Mcl , or induce release cytochrome C like Bax and Bak proteins and activate apoptosis 
(Troy & Salvesen 2002; Suen et al. 2008).  
Both processes, apoptosis and necrosis, were identified to be involved in the death of 
transplanted VM cells in animal models. Emgard et al tracked the pattern of VM cell death 
at different time points post transplantation (90 min, 1, 3, 6 and 45 days). They identified 
that apoptosis marker (anti-caspases 3) and necrosis marker (calpain activity) were both high 
at 90 min and first day post-transplantation. They then noticed that necrosis level reduced 
dramatically on day 3 with the persistence of apoptosis which lowered significantly on day 6 
(Emgård et al. 2003). Sortwell et al. also identified that a higher rate of apoptosis (labelled 
with TUNEL-positive nuclei) in the first week of VM transplantation followed by a significant 
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reduction (Sortwell 2003; Sortwell et al. 2001; Sortwell et al. 2000). Both studies concluded 
that the apoptosis happened in 3 stages: early stage loss resulted from cell dissociation, 
preparation, mechanical stress, hypoxia and hypoglycaemia; second stage cell death related 
to the host environment including cytokine release from the damaged striatum or low 
trophic factor tone and oxidative stress; late stage had a low incidence of apoptosis.  
1.6.2.2 Neurotrophic factor  
Since one of the suggested causes of cell death is low neurotrophic tone in the striatum, 
several studies have explored the value of suppling external neurotrophic factors to support 
graft survival. Some of them were identified to have protection for VM cell in cell culture and 
in animal models. Glial cell line-drived neurotrophic factor (GDNF) illustrated a great 
influence on increasing survival of VM cells in cell culture and animal model. It can increase 
survival rate from double to 13 times depending on method of administration,  intra-striatal 
administration post-grafting or in combination during cell processing and transplantation 
(reviewed in (Brundin et al. 2000). Brain derived neurotrophic factor (BDNF) and 
neurotrophic factor 4/5 (NT-4/5) are other trophic factors showing the ability to protect VM 
dopaminergic neurons in cull culture (Hyman et al. 1991; Studer et al. 1995) but they do not 
support survival in vivo (Haque et al. 1996; Yurek et al. 1996). Trophic factors not only 
support cell survival but also stimulate the axonal outgrowth of the graft which is also 
important for expanding coverage of the striatum and consequent graft function (Haque et 
al. 1996; Yurek et al. 1996; Sinclair et al. 1996).  
1.6.2.3 Anti-apoptotic agents 
Modulating apoptotic mechanisms to prevent cell death was targeted through using caspase 
inhibitors or modulating the intracellular level of Bcl-2 family. One study showed that 
inclusion Ac-YVAD-cmk (anti-caspase-1) during VM cell processing and in transplanted 
vehicle causes double the survival of VM cells transplanted in 6-OHDA parkinsonian rats 
(Schierle, Hansson, et al. 1999a). However, a study later failed to replicate this effect of using 
same agent in similar model which diminished its possible effectiveness (Hurelbrink et al. 
2001). Other study targeted inhibition of c-Jun-N-terminal Kinase (JNK) to improve VM cells 
survival. JNK is an activator for caspase and apoptosis under cellular stress and DNA damage. 
The results showed that infusion of SP600125 , JNK inhibitor, intra-striatal for 4 days post-
transplantation lead to increase survival of VM dopaminergic neurons more than double 
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(Rawal et al. 2007). Using similar model, investigation of overexpressing the anti-apoptotic 
Bcl-2 molecule in the transplanted VM cells demonstrated limit effect on cell survival but 
rather it has significance on promoting axonal outgrowth (G S Schierle, Leist, et al. 1999; 
Holm et al. 2001) 
1.6.2.4 Anti-oxidants  
As described above one of the expected reasons of death the transplanted cells is influx of 
reactive oxygen free radicals like superoxide (O2*) and nitric oxide (No*) around the graft due 
to neural injury. The free radicals can invade different targets intracellularly including 
proteins and DNA lead to cellular dysfunction (Floyd & Carney 1992). In addition, they can 
interfere with lipid membranes creating lipid peroxidation chain and lipid free radical 
formation (Halliwell 1992). Study showed that overexpression of Cu/Zn superoxide 
dismutase (SOD), used for oxygen free radicals’ suppression, in the VM cell before 
transplantation causes increase cell survival of dopaminergic neurons up to 4 times (Nakao 
et al. 1995). This followed by studies used lazaroids compounds, lipid peroxidation inhibitors 
like tirilazad mesylate (Grasbon-Frodl et al. 1996), demonstrated significant support for VM 
graft survival when administered in cell processing and prior transplantation (Nakao et al. 
1994; Grasbon-Frodl et al. 1996; Hansson et al. 2000).  
1.6.2.5 Excitotoxicity inhibitors  
It was also hypothesised that the surgical intervention may cause neural injury, leading to 
release of glutamate that may possibly induce excitotoxity in the transplanted cells. 
However, a study demonstrated that treating the VM cell before transplantation with the 
NMDA receptor antagonist (MK- 801) has no effect cell survival. This study weakened the 
hypothesis of a role for glutamate in cell death in these circumstances (Schierle et al. 1998).  
1.6.2.6 Calcium channel blocker  
Other studies explored whether Ca++ channel blockade can help to protect transplanted 
dopaminergic neurons. Neuro injury associated with excessive influx of Ca++ intracellularly 
leads to mitochondrial damage, increase free radical formation, and enzymatic activation 
which participate on cell death (Orrenius et al. 1989). A study treated VM cells during cell 
processing with flunarizine, a voltage dependent Ca++ channels blocker, which lead to a 
doubling of cell survival of the transplanted VM dopaminergic neurons (Kaminski Schierle et 
al. 1999).  
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Although the above neuroprotective agents demonstrated effectiveness in improving 
survival of transplanted VM dopaminergic neurons in animal models, they only partially solve 
the problem and the largest proportion of the cells still die. As described above, the survival 
rate of VM transplantation ranges from 1-10% and 4-5 foetus are needed to produce an 
effective graft. Thus, even with these neuroprotective agents which improved dopaminergic 
neuronal survival by double or triple in most cases, multiple VM donors would still be 
required. The other concern with these neuroprotective agents is the practical difficulty of 
using them in clinic. The method of delivery of these agents required surgical intervention 
with each dose administration. In addition, although they produced effectiveness from single 
or short term administration. However, the presence of long term of inflammation around 
the graft and the long-time requirement for graft maturation (several months), this may limit 
their usefulness.   
1.6.3 Rodent models for assessment of cell therapy in PD 
In order to explore these therapies thoroughly, it has been necessary to employ the use of 
in vivo animal models. PD has complex etiological and pathological features, which make the 
creation of an ideal animal that mimics all the features of the disease in one model difficult 
to obtain. Current models depend mainly on inducing the main hallmark of the disease, the 
loss of nigrostriatal dopaminergic neurons. This lesion, combined with scalable motor and 
behavioural deficits form the essence of many of the commonly used models. Different 
factors can be used to degenerate the nigrostriatal dopaminergic neurons including 
neurotoxins and environmental and genetic etiological factors depending on the 
experimental intention. In cell transplantation models, the most commonly used factors are 
6-hydroxydopamine (6-OHDA) and MPTP neurotoxins. MPTP is a neurotoxin that is able to 
selectively deplete nigral dopaminergic neurons in many mammalian species when 
administered peripherally and reproduces the disease’s cardinal features. However, rats 
have a low sensitivity to the toxin and this makes it less favourable for use in this species 
(Giovanni et al. 1994; Przedborski et al. 2001). 6-OHDA, another neurotoxic agent, is the 
most commonly used in rodent models. It has been utilised to degenerate catecholaminergic 
neurons since 1968 (Ungerstedt 1968). It has a chemical structure similar to dopamine and 
crosses the cell wall via the dopamine transporter system causing an elevation of the 
oxidative stress levels and subsequent cell death (Blum et al. 2001). Because it is unable to 
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cross the blood brain barrier, it is administered stereotaxically into the site of the required 
lesion. Unilateral lesion rather than bilateral is preferred in the assessment of cell 
transplantation efficacy. Unilateral administration provides good welfare for the animals 
(bilateral lesion can affect the ability to eat and drink) (Marshall et al. 1974) and offers an 
innate control for each animal as motor activity between the lesioned and intact sides can 
be compared. Moreover, the imbalance in dopamine between the intact and lesioned 
hemispheres allows for exploitation in the rotational behavioural test (Ungerstedt & 
Arbuthnott 1970). Many studies show that the most suitable target for inducing complete 
and fast lesions in the nigrostriatal dopaminergic neurons is the median forebrain bundle 
(O’Keeffe et al. 2008; Lane, Brundin, et al. 2009; Torres et al. 2011).  
The evaluation of the extent of the nigral dopaminergic neuron loss and the functionality of 
the graft is indicated by the use of several behavioural and motor function tests. The rats 
have postural bias toward the ipsilateral side of the depleted striatum which is evident in 
lesioned animals but which is exaggerated by the administration of amphetamine. 
Amphetamine boosts release of dopamine in the intact striatum and the resulting imbalance 
in dopamine drives rotational motor behaviour measurable using automated rotometers. 
Apomorphine, a non-selective dopamine receptor agonist, also causes rotation of the rats 
but toward contralateral side. This is due to the supersensitivity of dopamine receptors on 
the lesion side which increases responding to sub threshold levels of receptor stimulation 
(Ungerstedt & Arbuthnott 1970; Ungerstedt 1971a; Ungerstedt 1971b). The number of 
rotations is correlated with the severity of the nigral dopaminergic cell loss and striatal 
dopamine depletion (Hefti et al. 1980). The behavioural rotation assessment depends on 
exogenous stimuli to trigger behavioural response, while naturally PD symptoms exist 
spontaneously. So, some studies are designed to assess the natural asymmetric motor 
deficits that appear in unilateral 6-OHDA lesioned rats. These tests depend on the reduced 
ability or neglect of the unilaterally lesioned rats to use the contralateral forelimb. Examples 
of this include the vibrissae test where contacting the rats’ whisker with a bench edge in the 
ipsilateral side, followed normally by paw placing reflex over bench surface; while touching 
the whiskers of the contralateral side accompanied by limit or no reaction (Dunnett 2005). 
The evaluation of dopaminergic graft efficacy is dependent on the ability to reverse the 
observed deficits in these motor and behavioural tasks. For instance, the ability of the graft 
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to release dopamine in the depleted side is measured by its efficiency in reducing the 
ipsilateral rotational response to amphetamine or even sometimes evoking a contralateral 
response when a big graft is yielded. This demonstrates the ability of the transplanted cells 
to release dopamine, whilst the reversal of the naturalistic motor asymmetric behaviour 
gives additional evidence of the therapeutic value to improve complex motor complications.   
1.6.4 Graft induced dyskinesia  
1.6.4.1 Clinical evidence  
GID are choric and dystonic movements which exist on the face, upper limb or generalised 
over the body and appeared in PD patients transplanted with human foetal VM. Importantly, 
the movements were observed in the absence of L-dopa in the clinically defined ‘off phase’, 
suggesting that GID is not related to L-dopa, unlike LID, but resulted directly from the graft. 
This was reported for the first time in the first controlled, double blind clinical study of foetal 
cell transplantation where it affected 15% of the transplanted patients (Freed et al. 2001). 
Then, in the Lund open clinical trial, 14 patients had VM cell transplantation for 11 years 
retrospectively analysed. The post-transplantation data demonstrated a significant increase 
in abnormal involuntary movements during off phase in 6 patients (Hagell et al. 2002). The 
second double blind clinical trial confirmed the existence of GID, they reported that 13 out 
of 23 patients had stereotypic rhythmic movements in the either in the upper or lower 
extremities during the off phase (Olanow & Goetz 2003).  Initially, it has been suggested that 
hyper-innervation of the transplanted grafts in the putamen may be the cause for GID (Freed 
et al. 2001). This theory was weakened by a follow up study using [18F] fluorodopa (FDOPA) 
and positron emission tomography (PET) scan to compare FDOPA uptake by the graft in the 
GID and non GID developed patients. The results illustrated that size of these grafts had not 
reached levels of overgrowth in any of the affected patients. However, it has been suggested 
that even in the incomplete extent of re-innervation, there may be a threshold of the graft 
size to precipitate dyskinesia (Ma et al. 2002). In the same study, instead of hyper-
innervation theory, a correlation of GID with the site of the transplantation and unbalanced 
dopamine release within the transplanted putamen region was suggested (Ma et al. 2002). 
However, in the Olanow et al study, no evidence was found of a regional imbalance in 
dopamine release in the grafted striatum was detected using FDOPA and PET scan. They 
rather suggested incomplete or aberrant striatal innervation lead to the existence of GID 
which may have resulted from suboptimal graft conditions like graft variability, uneven 
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striatal innervation, inflammatory reaction and aberrant synapse formation. They explain 
that the inhomogeneity of innervation causes dopamine pulsatile stimulation to adjacent 
supersensitive receptor area leads to exist the GID.  (Olanow & Goetz 2003).  
Later, another theory was suggested based on the heterogeneity of the transplanted cells 
themselves. Two transplanted patients which showed GID underwent PET and single photon 
emission computed tomography (SPECT) scans to determine the amount of 5-HT in the 
striatum and serotonin/dopamine reuptake transporter ratio. The study produced 
indications of a hyper innervation of serotoninergic neurons around the grafted area and an 
increase in the serotonin: dopamine reuptake transporter ratio. Furthermore studies by the 
same group also demonstrated that administration of buspirone, a 5HT1A agonist, reduced 
expression of GID, postulated as being a direct result of reduced serotonergic activity (Politis 
et al. 2011; Politis 2010). The hypothesis on the role of 5-HT in GID supposes that 
serotonergic neurons are capable of using the secreted dopamine from the transplanted 
dopaminergic neurons and release it as a false transmitter.  Without regulated turnover of 
the neurotransmitters, stimulation of the supersensitive striatal dopamine receptors could 
then trigger abnormal movements (Shin, Tronci, et al. 2012). Importantly however, 
transplanted patients without GID have never been scanned in the same way to specifically 
implicate 5-HT in the generation of GID, the data only supports the idea that there is 
significant 5HT neuronal content in the grafts. In addition, buspirone (the 5-HT1A agonist) 
also has partial dopamine D2 receptor agonist activity (meaning that it can behave as an 
antagonist in the presence of the full agonist for the dopamine receptor). It is entirely 
possible that the observed reduction in GID is through the action of the drug on 
supersensitive dopamine receptors (described below).  
The appearance of inflammatory signs around the grafted area and the existence of GID 
symptoms after withdrawal of the immunosuppressant agents also implicates a role for 
inflammation in the development and existence of this motor side effect (Olanow & Goetz 
2003; Piccini et al. 2005). In the Lund-based open label clinical trial, immunosuppressant 
combination of cyclosporine, azathioprine and prednisolone was administered for 2 years. 
The study reported that the GID increased at the time of immunosuppression withdrawal 
(Piccini et al. 2005). In Olanow et al, cyclosporine-A was used as an immunosuppressant for 
6 months before withdrawal. Even this study did not state an obvious association between 
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GID and immunosuppression withdrawal, however they reported that the GID were first 
identified in the period between 6-12 months post-transplantation (ie during the withdrawal 
period). Olanow and colleagues also reported the detection of inflammatory signs around 
the graft and they suggest that inflammation could have a role in developing the GID (Olanow 
& Goetz 2003). This may suggest that immunosuppression may reduce the existence of GID 
possibly through reduction of the inflammatory response and protection of the graft.  
1.6.4.2 Evaluation of GID in animal models 
To explore the different hypotheses that have emerged as to the cause of GID, an animal 
model was needed. However, graft assessment in unilateral 6-OHDA rat model showed that 
observing spontaneous abnormal involuntary movements produced by the graft comparable 
to those in clinical trials was sporadic with minor severity. This reduced the effectiveness of 
the model on assessing spontaneous GID (Lane et al. 2006). Instead, a fortuitous observation 
found that some grafted animals expressed AIMs in response to amphetamine which was 
used in this model to evaluate GID in both rats and mice. Amphetamine causes release the 
dopamine of the graft and reduce dopamine re-uptake. Its administration to the grafted rats 
leads to produce abnormal involuntary movements (AIMs) similar to those induced by L-
dopa but directly related to the graft (Lane et al. 2006). Other assessment methods have 
been reported and rely on observing forelimb-facial stereotypies and forelimb tapping 
stereotype movement in response to L-dopa administration. These movements observed 
after allogenic graft transplantation and disappeared after rejection the graft suggested its 
relation to the graft (Steece-Collier et al. 2009).  
Two early studies explored the key features that might relate to GID that emerged from the 
clinical trials, graft size and graft location. Lane and colleagues pointed to the importance of 
graft size in developing GID showing in a rodent model that larger grafts produces more 
striking AIMs compared to small grafts in response to amphetamine administration (Lane et 
al. 2006). Carlsson and colleagues used the same model to investigate the relationship 
between GID and the site of transplantation in the striatum. They found that the 
transplantation of VM in the caudal part of the head of the striatum triggered the 
appearance of GID and that severity of GID was correlated with the amount transplanted in 
the caudal compared to those in the rostral part (Carlsson et al. 2006). 
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Another animal study investigated the effect of serotonergic neurons agonists on developing 
the GID. The study followed the clinical trial data described above and demonstrated that 
administration of buspirone and another more selective 5-HT1A agonist lead to reduce levels 
of AIMs induced by amphetamine regardless of the contamination of the VM graft with 
serotonergic neurons. However, lesion of the endogenous serotoninergic neurons with 
specific toxin halts the effect of the selective 5-HT1A agonist but not buspirone on reducing 
the AIMs. The study showed that buspirone action is also not affected by administration of 
5-HT1A antagonists. This suggested an important role of  the endogenous serotonergic 
system on modulation GID and illustrated that the 5-HT1A agonist drug buspirone may 
maintain its effect by blocking the D2 receptor instead of 5-HT1A receptors (Shin, Garcia, et 
al. 2012). Lane and colleague had previously demonstrated that both 5HT1A agonists and 
dopamine receptors antagonist reduced GID driven by amphetamine stimulation (Lane, 
Brundin, et al. 2009). 
An important link between LID and GID was identified in two studies highlighting that the 
severity of LID before transplantation was a risk factor for the development of GID (García 
et al. 2011b; Lane, Vercammen, et al. 2009). The reason behind this may relate to the 
changes evoked in dopamine receptor signalling in LID. Once LID is established, alterations 
in the intracellular signalling molecules companied by increases in Δfosβ immediate early 
gene levels, which act as transcriptional activator, increase cellular responding to dopamine 
levels and trigger LID (Feyder et al. 2011). Importantly this change intracellular Δfosβ level 
and responses to dopamine in the caudate putamen is sustained even after long periods of 
withdrawal from L-dopa (Andersson et al. 2003). Another study also pointed to the 
involvement of D1 and D2 dopamine receptors in the existence of GID, when low doses of 
dopamine receptor antagonists nearly abolished all GID symptoms in rats (Lane, Brundin, et 
al. 2009; Shin et al. 2014; Shin, Tronci, et al. 2012; Shin, Garcia, et al. 2012). 
The role of inflammation on inducing GID was explored in two studies used different probe 
for assessing the graft related dyskinesia. Lane et al used amphetamine to stimulate the graft 
related dyskinesia. In their experiments, they did not find a correlation between the 
inflammatory response and GID when IL-2 was used as a pro-inflammatory mediator, despite 
confirming the inflammatory signs around the graft (Lane et al. 2008). Conversely, 
Soderstrom and colleagues depended on the stereotypic motor abnormality in response to 
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L-dopa (described above) as a proxy for GID, to assess the appearance and severity of the 
dyskinesia. They used a peripheral injection of spleen cells from the same donor as the 
allogenic neuronal graft to stimulate a generalised inflammatory response. They found that 
the total GID was transiently augmented after spleen cell injection with only tapping forelimb 
dyskinesia behaviour significantly increased after a second spleen injection. In this study also, 
the ultra-structural analysis clarified that the grafted dopaminergic cells make atypical 
synapses with their targets and these aberrant synapses are increased in the spleen cell 
injected subjects and positively correlated with GID (Soderstrom & Meredith 2008). The  
difference in the results of the two studies suggested that could be the abnormal movements 
produced by the graft due to the effect of inflammation can be detected by L-dopa induced 
movements but not with amphetamine induced AIMs (Lane & Smith 2010).  
A definitive cause of the emergence of GID is still yet to identified. However, the clinical and 
animal studies provided important evidence to predict possible risk factors for GID. These 
led to confidence in protocol adaptations in the design of the current clinical trial (TransEuro) 
aiming to avoid or reduce possible incidence of GID which included reduction of grafted cells 
contamination with serotonergic neurons, selection of patients with none or low severity of 
LID, and optimise transplanted cells innervation in the striatum.    
1.6.5 Stem cells derived dopaminergic neurons for cell therapy in PD  
Despite the issues of GID, early clinical trials in individuals showed the potential benefits of 
cell transplantation as a therapeutic approach. However, there are significant sustainability 
issues in using foetal cell transplantation as a main stream therapy. More than one piece of 
VM and therefore more than one foetus is needed to transplant into the striatum of one 
patient, 4-6 pieces per hemisphere is typically required.  There are logistical problems to 
obtaining enough VM pieces with the required properties like the appropriate age, quality, 
and availability at the same time (Brundin et al. 2010). In addition, changes in the process of 
many terminations from largely surgical to medical involving the use of hormone based 
medications is used. The impact of this shift in procedure on the viability of VM dopaminergic 
neurons was uncertain. However, specific study have been carried out to confirm that 
products from medical terminations of pregnancy can be used (Kelly et al. 2011). Moreover, 
based on religious and ethical reasons, some countries have banned the use of foetal tissue 
while others, who have accepted their use, have introduced legislation (the EU Human Tissue 
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Act) which adds significant logistical hurdles to obtaining the tissue, around consent, 
management and tracking of the tissue. In addition, the great demand for using foetal tissue, 
that would emerge from a more widely available therapy, raises concerns about another 
crucial moral issue, the motivation for elective abortions (Boer & Peschanski 1994).  
Alternative sources of dopaminergic neurons are therefore being explored. Pluripotent and 
multipotent stem cells have been looked to produce dopaminergic neuros that can replace 
VM cells transplantation. Embryonic stem cells (ESCs) is one of the pluripotent stem cells that 
is effectively generates dopaminergic neurons for transplantation (Kirkeby et al. 2012)(Kriks 
et al. 2011). These cells are created from inner mass of the blastocyst of early stage embryos 
and have proliferative capacity for extended periods of expansion with the maintenance of 
karyotypic stability in vitro (Amit et al. 2000). These cells can theoretically therefore provide 
a limitless number of cells for transplantation (Xiao et al. 2006).  Protocols have been 
established to produce the ESCs under good manufacturing practice (GMP) and for cell 
banking (Tabar & Studer 2014). Another type of pluripotent stem cell successfully using in the 
generation of dopaminergic neurons is induced pluripotent stem cells (iPSCs) (Sundberg et al. 
2013; Doi et al. 2014). The iPSCs are generated from reprogramming the adult fibroblast and 
they have the same proliferative and self-renewal potency of ESCs (Takahashi & Yamanaka 
2006; Takahashi et al. 2007). They can be used for autologous transplantation providing the 
advantage of minimum immunological complications, however it also has disadvantage of the 
intrinsic vulnerability to the patients’ main pathology. The other reprogrammed stem cells 
used for developing dopaminergic neurons is the induced neurons (iNs) (Kim et al. 2011). 
These cells directly converted from fibroblast to other differentiated cells without passing the 
pluripotent stage (Vierbuchen et al. 2010). Unlike pluripotent stem cells, they lack the 
limitless self-renewal capacity but can still produce an expandable source of neurons (Grealish 
et al. 2016). Foetal brain neural stem cells NSCs are a multipotent stem cell isolated from the 
brain of embryos and can be differentiated into neurons, astrocyte and oligodendrocyte. The 
isolated NSCs from the midbrain of embryos have been successfully converted to 
dopaminergic neurons. However, these cells need longer time of expansion in culture with 
less supply of cells and lower differentiation capacity (Yasuhara et al. 2006; Madhavan et al. 
2012).  
32 
 
In principle, dopaminergic neurons derived from stem cells can solve many of the practical 
and ethical challenges of primary foetal tissues, they can be prepared in the lab, scaled up to 
high levels of production, and provided ready for the patients at time of surgery with fewer 
ethical hurdles. However, stem cell derived dopaminergic neurons have yet to demonstrate 
their ability to compete with primary cells in terms of efficacy and that they can be safely 
hosted by the PD brain. As yet there have only been studies in animal models and there is 
some way to go to demonstrate long term survival and efficacy, before going into clinical 
trials.  
The main requirements of the transplanted cells are to be safe and able to survive, innervate 
a significant area of the striatum, form appropriate synapses and function adequately to 
produce sufficient dopamine to elicit recovery of motor deficits. Initially problems emerged 
in the technology and understanding of differentiation protocols to guide the cells towards a 
dopaminergic phenotype and in the timing of transplantation to create viable grafts.  Various 
protocols have been designed and improved to generate reliable populations of dopaminergic 
neuron that have a midbrain phenotype of in term of transcriptional profile, protein 
expression, electrophysiological activity, and dopamine release. Early experiments succeeded 
in generating dopaminergic neurons from hESCs. However, the generated dopaminergic 
neurons didn’t carry the essential protein expression of the midbrain dopaminergic neurons 
like LIM homeobox transcription factor 1, alpha (LMX1A) and forkhead box protein A2 
(FOXA2)  (Yang et al. 2008; Park et al. 2005) (Emborg et al. 2013). This was followed by 
protocols directing the fate of the embryonic stem cells to floor plate using dual SMAD 
inhibition followed by the induction of midbrain regional specification of dopaminergic 
neurons. Now, there are well described protocols to get authentic dopaminergic neurons 
which are indistinguishable from midbrain equivalent primary cells (Kriks et al. 2011) (Kirkeby 
et al. 2012). These cells can achieve behavioural recovery in different animal models of PD. 
For instance, Kriks and colleagues have described protocols based on directing the hESC to be 
floor plate derived dopaminergic neurons precursors using SHH and WNT signalling to yield 
dopaminergic neurons over a period of 25 days. These neurons showed a robust survival and 
behavioural functioning in three different animal models of PD (6-OHDA lesioned rat, 6-OHDA 
lesioned -mice and MPTP-treated non-human primates) (Kriks et al. 2011). Another successful 
protocol described by Kirkeby and colleagues is based on embryoid body formation with dual 
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SMAD inhibition followed by dose-dependent activation of WNT signalling and SHH activation 
to generate dopaminergic neurons. Similarly, these have been shown to be capable of 
reversing motor deficit in the 6-OHDA lesioned rat (Kirkeby et al. 2012). In comparing the 
efficiency of dopaminergic neurons derived from stem cells and human primary foetal cells, 
both grafts have the same apparent efficacy in reversing motor deficits (Grealish, Diguet, et 
al. 2014). Similar success with alternative ‘starter cells’ have also been successful in 
generating dopaminergic neurons and producing behavioural efficacy in animal models. This 
includes reprogrammed cells including induced pluripotent stem cells (iPSCs), direct 
conversion into induced neurons iNS and induced neural progenitor cells iNPCs (reviewed in 
(Grealish et al. 2016). Currently there is a global consortium under the name of “G-force PD” 
which shares the challenges and the solutions to pave the way for clinical trials to 
transplanting dopaminergic neurons directed from stem cells (Barker et al. 2015). Recently a 
company called  “International Stem Cell Corporation (ISCO)” declared that they were 
conducting a clinical trial in the Royal Melbourne Hospital in Melbourne, Australia in which 
they are transplanting neural stem cells differentiated from a pluripotent parthenogenetic 
cell (hpNSC) in moderate to severe PD patients (International Stem Cell Coporation, 2015). 
This trial has created a lot of conflict in the field, especially as there is no clear evidence from 
pre-clinical studies about the safety and efficiency of these cells. One concern is that these 
cells express PAX6, while midbrain dopaminergic neurons are negative for this particular 
marker, raising the issue of  what phenotype of the cells transplanted and the anticipated 
mechanism of action of these cells (reviewed in (Barker et al. 2016). The translation of stem 
cells as a source to transplantation in PD to clinical trial should be considered with caution 
and takes all the lessons from the previous clinical trials of primary cells transplantation to 
avoid possible inconsistency results that would have negative impact on the future of cell 
therapy. Several important features of stem cell transplantation have not yet been fully 
explored in the basic animal models deployed thus far.  
1.6.6 Real world animal model of PD 
Most of the animal models used to evaluate cell therapy have ignored the fact that PD 
patients are exposed to long term anti-parkinsonian medications, especially L-dopa 
treatment. These therapies continue for a prolonged period of time after transplantation, 
until reductions in medication can be introduced once the transplanted cells have matured 
enough to have independent therapeutic efficacy. As described above L-dopa elicits many 
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changes in striatal neurochemistry interfering with the molecular and synaptic plasticity of 
the host brain. It also causes changes in blood brain barrier permeability and inducing 
angiogenesis (Westin et al. 2006), all of which have the potential to influence graft outcomes. 
For instance the developed dyskinesia due to L-dopa treatment suggested to be precipitating 
factor for the development of GID (García et al. 2011b; Lane, Vercammen, et al. 2009). 
Moreover, the change in BBB permeability increase possibility of changing the inflammatory 
figure around the graft. In addition, L-dopa treatment has been suggested to increase the 
oxidative stress load in the brain because it is increase dopamine level which may lead to 
increase its oxidative metabolite (Felten DL, Felten SY, Steece-Collier K, Date I 1992). On the 
other hand, there is speculation that L-dopa could have a positive effect on the graft via 
modulation the inflammatory pattern from pro-inflammatory to protective phenotype (Carr 
et al. 2003; Nakano et al. 2009). 
1.6.7 Peptides have neuroprotective properties for the midbrain dopaminergic 
neurons: 
Recently some peptides illustrated that they can protect the nigrostriatal dopaminergic 
neurons in different animal models. Ghrelin, a stomach peptide, is one of these peptides that 
protected the nigral dopaminergic neurons in cell culture and animal model when challenged 
with different toxins (Moon et al. 2009a; Andrews et al. 2009). Its neuroprotection effect 
was accompanied with anti-apoptotic, anti-inflammatory ant anti-oxidant properties (Dong 
et al. 2009b; Jiang et al. 2008). The other peptides are Glucagon like peptide-1 GLP-1 receptor 
agonists (exendin-4 and liraglutide). These peptides are used to treat type 2 diabetes mellites 
T2DM. They also showed a neuroprotection property, anti-inflammatory and anti-apoptotic 
criteria (Perry 2002; Sharma et al. 2014; McClean et al. 2011). Exendin-4 illustrated ability to 
protect the nigral dopaminergic neurons in different PD animal models and cell culture 
models (Kim et al. 2009a). These peptides can cross blood brain barrier and some of the them 
has approved for clinical use (exendin-4 and liraglutide) which encouraged to use exendin-4 
for clinical trial to treat parkinsonian patients (Aviles-Olmos et al. 2014). These 
neuroprotective agents (ghrelin and GLP-1R agonists) haven’t tested yet if they have ability 
to protect transplanted dopaminergic neurons. Since the inflammation, oxidative stress and 
apoptotic cell death are the main causes of cell death of the transplanted cells in the host 
striatum (see section 1.6.1), these agents could have a potential to protect the transplanted 
cells and improve graft function. Especially, the transplanted cells (VM cells or stem cells 
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derived dopaminergic neurons) are phenotypes of the midbrain dopaminergic neurons 
which they protected by these peptides.   
 Thesis aims   
Although many studies have tried to optimise cell therapy in animal models of PD, low cell 
survival rates and insufficient efficacy are still the major challenges that need to be 
overcome. In this thesis, I have tried to identify neuroprotective agents that may be able to 
support transplanted cell survival and efficacy, targeting the transplanted cells in the host 
brain through peripheral administration. Two key themes then follow, the first to apply the 
principles of an animal model more closely mimicking the reality of a PD patient thus far 
never considered, by involving anti-parkinsonian mediations such as L-dopa. Stem cell-
derived dopaminergic neurons as an alternative source for cell therapy, these cells have not 
yet been tested in animal models that consider the clinical issue of exposing the cells to the 
ongoing anti-parkinsonian medications before and after transplantation that is the reality of 
cell transplantation. The key concern is how could these medications affect graft survival, 
function and safety. So, the second theme of this thesis is to understand survival and function 
of two different stem cells having different started cell source and different histological graft 
features in “real world animal model” using L-dopa treatment. A hitherto unaddressed issue 
is also the ability of hESC derived grafts to reduced LID. 
The underlying hypothesis for this thesis is that using neuroprotective agents can improve of 
transplanted foetal and hESC derived dopaminergic neurons survival and efficacy, and L-
dopa administration may compromise the survival of the transplanted foetal and hESC 
derived dopaminergic neurons. 
The main aims of this thesis therefore were to:  
1. Optimise cell transplantation therapy using neuroprotective agents to support cells 
survival and efficacy (addressed in chapters 3, 4, 5 and 6) 
2. Understand the efficacy and histological features of human embryonic stem cell 
derived dopaminergic grafts (addressed in chapters 5 and 6).  
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3. Determine the effect of implementing a “real world animal model” (ie including the 
administration of L-dopa), on the efficacy of cell transplants and the impact of 
neuroprotective agents (addressed in chapters 4, 5 and 6). 
4. Evaluate the ability of hESC derived dopaminergic neuronal grafts to improve LID 
(addressed in chapters 5 and 6) 
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2 Chapter 2: Methodology   
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 Animal husbandry  
Adult female Sprague Dawley and time mated pregnant Wistar rats, obtained from Envigo, 
were used in the experiments. At the start of each experiment, they had a weight range 
between 190-250 g and placed in an animal house at room temperature (20-22 0C). A 
humidity of 45-65% with a light cycle of 12 hours on and 12 hours off were maintained at the 
holding room. Four rats were housed per cage (L: 54 cm, W: 37 cm, D: 21 cm) and supplied 
with hygienic animal bedding with ad libitum access to food (14% protein, Harlan) and water. 
The Sprague Dawley rats were acclimatised to one week before starting the experiments. All 
the experiments were performed in agreement with the Animals Scientific Procedure Act 
1996 and Home Office regulations (PPL: 30/3316; PIL: ISS4A938B). 
 Surgical Procedures:  
All the surgical procedures were carried out in aseptic and equipped surgery room.  Rats 
were anaesthetised with isoflurane at a concentration of 4-5% plus 8% oxygen for the 
induction then maintained at 2-3% isoflurane plus 8% oxygen and 4% nitrous oxide. All the 
surgeries were performed on a Kopf stereotactic frame which holds the rat’s head in a fixed 
position and ensured precise moving of a drill or a cannula to a targeted point. A Harvard 
micro-drive infusion pump was used to infuse the 6-OHDA (details 2.2.1) solution or the 
transplanted cells suspension at a suitable infusion rate (details in 2.2.2). During the surgery, 
rats were covered by sterilised plastic sheets to keep them warm. At the end of the 
intervention, all rats were sutured with vicryl 4-0 sutures and injected with 3 µl Metacam (5 
mg/ml) and 5 ml normal saline subcutaneously. Finally, they were transferred to a recovery 
chamber at 30 0C for few hours before returning them to their cages. The health and the 
weight of the animals were checked daily for 3 days following the surgery and then once 
weekly. 
2.2.1  6-hydroxydopamine lesion  
A fresh 5 mg vial of 6-HODA containing 0.2 mg of ascorbic acid was reconstituted for the 
lesion the nigrostriatal dopaminergic neurons. It was stored at -20 0C and reconstituted with 
800 µl of a cooled normal saline to obtain a concentration of 25 mM. For long term storage, 
it was stored in aluminium foiled aliquots at -20 0C while during the surgery it was kept in an 
ice box. A 30-gauge stainless steel cannula was used to deliver the 6-OHDA solution. The 
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cannula was inserted into the medial forebrain bundle (MFB) of the right hemisphere on the 
following coordinates from the bregma: - 4 mm of the Anterior-Posterior axis (AP); - 1.3 mm 
of the Medial-Lateral axis (ML); - 7 mm under the Dura of the Dorso-Ventral line (DV) with 
the nose bar set at -4.5 (Ungerstedt 1968; Torres et al. 2011). After that, 3 µl of the 6-OHDA 
solution was infused over 3 min and then the cannula was left for 2 min before withdrawing 
to allow a complete diffusion.     
2.2.2  Cells transplantation  
Primary foetal dopaminergic neurons and stem cells derived dopaminergic neurons were 
used for transplantation in hemi-parkinsonian rats through different experiments of this 
thesis. They were grafted at one site of two deposits inside the dopamine depleted striatum 
of the right hemisphere according to the following coordinators from the bregma: AP: - 0.5 
mm; ML: - 3 mm; DV - 5 mm and - 4 mm, while the nose set bar was at - 4.5 mm. The following 
is details of cells obtaining, preparation and transplantation details for each type of these 
cells.  
2.2.2.1 Ventral Mesencephalon dopaminergic neurons: 
E14 Wistar time-mated pregnant rats were ordered to obtain their embryos. They were 
anesthetised by administration a 500mg/kg of pentobarbitone (Euthatal®) i.p. followed by 
embryo collection and mother’s termination via neck dislocation. The crown-rump-length 
(CRL) was checked to confirm the embryo’s age (10.5-11 mm for E14). Then, embryo 
decapitation was carried out in a petri dish filled with Hanks’ balanced salt solution (HBSS) 
solution. In a similar media, the ventral mesencephalon (VM) pieces were dissected under 
microscope using fine cutting edge scissors (2.5-3mm) and forceps with fine tips (0.1 x 0.06 
mm) (see Figure 3). After that, the VM sections were transferred into a medium Dulbecco’s 
minimum Eagle medium (DMEM) in 1.5 ml Eppendorf tube then a standard protocol was 
followed to make a single cell or cluster of cells suspension (Björklund et al. 1983; Torres et 
al. 2007). The VM sections were washed 3 times with DMEM solution followed by incubation 
with 1.5 ml of TryplE™ express solution and 30 µl of DNase solution at 37 0 C for 20 min (tube 
agitated gently after 10 min). This was followed by three washes of DMEM/DNase solution 
(14ml DMEM + 280µl DNase). After that, a 500 µl of DMEM/DNase solution was added to 
the dissected VM tissues and a mechanical dissociation process was applied to break them 
down using a few gentle trituration by 1000 µl Gilson pipette set at 200 µl then by 200 µl 
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Gilson pipette set at 200ul. The viability and count of the cells were checked under a 
microscope by staining a 2 µl sample of the suspension with a 0.04% trypan blue on a 
haemocytometer slide. After that, the suspension was centrifuged at a rate of 380 G for 3 
min at room temperature. After removing the supernatant, the pellet was re-suspended with 
enough quantity of (DMEM/DNase) solution to achieve a concentration of two thirds of each 
VM section per two µl of the suspension (for instance, if 6 VMs sections were dissected, the 
pellet would be suspended with 18 µl of DMEM/DNase solution). On the same day, the 
suspension transferred to the surgical room and kept at room temperature during the 
surgical procedure. A 2 µl of the suspension was infused into the striatum (1 µl at each 
deposit) at a rate of 1 µl/ 90 sec. A 23-gauge stainless steel cannula connected to a 
Polyethylene tube which in turn joined to a 10 µl Hamilton syringe was used to deliver the 
cells. After the infusion, the cannula was left inside the striatum for 3 min before retraction 
to ensure a complete infusion. 
 
Figure 3 steps of VM dissection: 1. CRL measurement which is the distance between the highest and 
lowest point of the embryo and it is about 10.5-11 mm for E14 rat’s embryo; 2. Neck dislocation; 3. 
Cutting above the eye and under the base of the brain using fine cutting edge scissor 4. Separating 
the brain, moving away skin and skull; 5. Peeling away all covering layers and meninges; 6. The 
drawing lines around the VM section is showing the cutting angles; 7. Releasing the VM tissue which 
have a butterfly shape (modified from (Dunnett & Bjourklund 2000)). 
2.2.2.2 Stem cells derived dopaminergic neurons  
two different types of stem cell-derived dopaminergic neurons were used in this thesis. Each 
type was developed at a different lab and followed a different protocol and this thesis is not 
involved in their generation or developing and the cells were received prior to transplantation 
procedure. The following is a brief description of the concept of generation with reference to 
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the lab or the group who created them in addition to details of transferring, and procedures 
of cells preparation for transplantation. 
2.2.2.2.1 Stem cell derived dopaminergic neurons according to (Kirkeby et al. 2012) 
protocol: 
Midbrain dopaminergic neurons generated from H9 hESCs was used as a cell source for 
transplantation in chapter 5. These cells were generated in Lund University in Kirkeby and 
colleagues’ labs, and this thesis is not involved in the cells generation. In brief, a published 
protocol described the method of generation of these cells which involved formation of 
embroyed body with a dual SMAD inhibition to get neural progenitors. Then the cells regional 
specification was controlled by adding chemical inhibitors to glycogen synthase kinase 3 
GSK3(CT99021) in a dose dependent pattern which activate canonical WNT signalling. A 
higher dose (1-4µM) was patterned the cells toward hindbrain characteristics while lower 
dose (less than 1 µM) gave more rostral criteria to the cells. Midbrain cell identities were 
obtained at a narrow range of CT99021 concentration between 0.7µM to 0.8µM while their 
fate to get more ventral properties controlled by adding the pattering factor SHH-C2411 
(Kirkeby et al. 2012). Cell verification before sending for transplantation was performed at 
Lund University which involved plated cells on day 14 of differentiation to be stained with 
FOXA2, LMX1a and Otx2 markers (verification data is not available in this thesis).  
Fresh cells were used for transplantation. On day 16 of differentiation, plated cells were 
transferred from Lund-Sweden using transport incubator to Cardiff university-UK, where 
transplantation surgery was performed, and they were kept overnight in the lab incubator 
(37 0C, 5% CO2). On day 17 the cells underwent a procedure of dissociation and making cells 
ready for transplantation. They were washed twice with PBS solution before adding 200µl of 
accutase solution per well and left for 10 min in the incubator at 37 0C. Then the cells were 
dissociated thoroughly with a 1ml pipette and transferred to 10 ml tube containing 7-10 ml 
of DMEM: F12+B27 medium followed by centrifugation at 400 G for 5 min. The supernatant 
was removed and 1 ml of HBSS + dornase alfa (6:1) plus 10 µl of DMEM: F12+B27 were added 
and transferred to 1.5ml tube. 10 µl aliquot were taken for cells counting and viability 
assessment. Then, the cells were spun down at 400 G for 5 min and re-suspended with HBSS 
+ Dornase alfa solution to achieve a concentration of 75,000 cells/ µl. Three batches of cells 
suspensions were prepared for transplantation and kept on ice during the surgical procedure 
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for no longer than 3hrs. Transfer of the cells from Lund to Cardiff and re-suspension procedure 
were done by Sarah Nolbrant, PhD student at Lund University.  
A 10 µl Hamilton syringe connected to 26-G stainless steel Hamilton needle (19132-u, Sigma) 
was used to deliver the cells inside the striatum. they were infused at rate of 1 µl/min with 
leaving the cannula for 3 min before retraction. 4 µl of the cells suspension (300,000 cells) 
were transplanted in each depleted striatum (2 µl per deposit).  
2.2.2.2.2 Stem cell derived dopaminergic neurons according to non-published work done by 
Tilo Kunath group at University of Edinburgh:  
hESCs (RC17)- derived dopaminergic neurons were used as cell source for transplantation in 
chapter 6. This thesis is not involved in generation these cells and they generated in Tilo 
Kunath and colleagues’ labs, Edinburgh University. According to presented work of this group 
in Parkinson’s’ UK conference 2014, The method of generation involved using dual SMAD 
signalling inhibition with an early strong SHH activation and controlling to the FGF signalling. 
At the start of differentiation, FGF signalling was inhibited with PD0325901 followed by 
adding FGF8 and an appropriate WNT activation (Tilo Kunath, personal communication, 
Parkinsons’ UK 2014). 
On day 11 of differentiation, the cells were frozen in a stem cell banker with ROCK inhibitor. 
Before shipping the frozen cells for transplantation, sample of frozen cells was thawed and 
cultured until day 16 for counting and evaluating the cells quality and criteria by measuring 
TFF3 level using ELISA; CORIN level using Fluorescence-Activated Cells Sorting (FACS); and 
immunostaining of FOXA2/LMX1a/CORIN. After cells quality verification, they were shipped 
from Edinburgh to Cardiff. The cells were thawed and plated (day 11) followed by feeding on 
day 14 (thawing and feeding procedures were accomplished by Dr Nicola Drummond, 
Edinburgh University). On day 16, the wells were rinsed with Accutase before incubating them 
in 0.5 ml of Accutase solution at 37 0C for 10 min. then in the Accutase media, they were 
pipetted up and down 10 times to make a single cell suspension. After that, the suspension 
was transferred to 5-fold volume of DMEM media. Then, they were centrifuged and re-
suspended with appropriate volume of DMEM to get a concentration of 250,000 cells/µl (cells 
preparation for transplantation was performed by Dr Ngoc-Nga Vinh, Cardiff University). Two 
µl of the cells suspension were grafted inside the striatum (1 µl at each deposit) on a rate of 
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1 µl/ min with leaving the cannula for 3 min before retraction.  Hamilton syringe connected 
to 26-G stainless steel Hamilton needle was used to deliver the cells.  
 
 
Table 2 summary for stem cells derived dopaminergic neurons details which used for 
transplantation. 
Referring group Kirkeby et al. 2012 cells Tilo Kunath group cells 
hES Cell line H9 RC17 
Differentiation 
Protocol 
Dual SMAD inhibition+ 
dosed dependent 
activation of WNT 
signalling + SHH 
activation 
Dual SMAD inhibition+ 
early SHH activation+ 
FGF modulation 
Storage and transfer Fresh cells Frozen and thawed cells 
Cannula size and type 26-G Hamilton needle 26-G Hamilton needle 
Site of transplantation One site of 2 deposits 
at coordinators AP: 
+0.5; ML: +3; DV +5 
and +4 from bregma 
One site of 2 deposits at 
coordinators AP: +0.5; 
ML: +3; DV +5 and +4 
from bregma 
Cells suspension 
concentration 
75,000 cells/ µl 250,000 cells/µl 
Infusion rate 1 µl/ min 1 µl/ min 
Dose of 
transplantation per 
striatum 
300,000 cells 500,000 cells 
 
 Behavioural assessments 
2.3.1  Amphetamine induced rotation test 
Meth- amphetamine powder was dissolved with 0.9% normal saline to make a concentration 
of 2.5mg/ ml. Each rat was received 2.5 mg/ kg i.p. of amphetamine solution and placed 
immediately in a Perspex cylinder. The rats were harnessed  to an automated rotometer 
connected to software set to count the number of  fractions of rotation fractions toward 
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either direction (clock-wise or anti-clock wise) (Ungerstedt & Arbuthnott 1970). The net 
number of rotations and direction was determined by counting the number of one-eighth 
rotations toward ipsilateral direction subtracted from the number of one-eighth rotations 
towards contralateral side during 90 or 180 min (test running time) divided by 8 (fractions of 
one full rotation). The total rotation per 1 min was determined by dividing the net rotation 
by the test running time. A successful 6-OHDA lesioned rat was assessed 2-3 weeks after 
lesion by amphetamine induced rotation test. Rats who rotated ipsilaterally more than 6 
rotations per a minute were considered to have more than 90% lesioned nigral dopaminergic 
neurons (Torres et al. 2011).   
2.3.2 Apomorphine rotation test  
Apomorphine powder was dissolved with 0.9% of normal saline obtaining a concentration of 
0.05 mg/ ml prior to use and kept in dark containers to avoid drug oxidation. The rats were 
injected with a dose of 0.05 mg/ kg subcutaneously (s.c.) and placed immediately in the 
Perspex cylinder connected to automated rotometer. The rotometer was set in the same way 
described in amphetamine induced rotation test (see 2.3.1) to count the number and 
direction of rats’ rotations. This test was run for 1 hr post drug administration. This test used 
in chapter 5 and 6, and only at the last time point of behavioural assessments post-
transplantation.  
2.3.3  Motor tests 
The stepping, vibrissae and cylinder tests were used to evaluate the asymmetrical motor 
behaviour of the rats at different time points before and after cells transplantation surgery. 
These tests were conducted during light phase. It is expected that the rats with right 
hemisphere nigral-striatal dopaminergic neurons lesion lose the ability to use the 
contralateral forelimb during these tests while a successful and efficient dopaminergic cells 
transplantation should be able to reverse this deficit. 
2.3.3.1 Stepping test 
Each rat was placed on the surface of a bench and hold in a manner that let one forelimb 
make a contact with the surface and support the body weight while the other forelimb 
restrained (see Figure 4 ). Then the researcher moved the rat over one meter of the surface 
during 10 sec forward. After that, the same process was repeated with the other forelimb. 
The percentage of left forelimb steps (contralateral side) from the right forelimb (ipsilateral 
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side) steps was determined and considered as the value for the rats’ performances in 
stepping test.  
 
Figure 4 stepping test: images from A to D showing the way of constrain a rat and moving a 
contralateral forelimb over one meter of the surface bench.  
2.3.4 Vibrissae (whisker) test 
The researcher held the body and hind limbs of the rat to restrain one forelimb and let the 
other move freely. The rats were moved gently upward from a point under the bench and 
adjacent to the edge letting the rat’s whisker make contact with the edge. The paw placing 
reflex on the bench surface, which stimulated from whisker contact, were counted (see 
Figure 5). This movement was repeated 10 times for each forelimb then the percentage of 
contralateral placing reflex of the ipsilateral side was calculated and considered as the value 
of whisker test.  
 
Figure 5 Vibrissae (whisker) test: images from A to C showing the way of holding the rat and passing 
it from under the bench closer to its edge allowing a contact the whiskers and inducing the paw 
placing reflex over the bench surface.  
2.3.5 Cylinder test 
Each rat was placed inside a Perspex cylinder (high: 33.5 cm, diameter 19 cm) and 
surrounded by two connected mirrors by an angle of 90o which allowed easily seeing the 
forelimb paws touches on the cylinder surface from all view directions (see Figure 6). A video 
camera was placed in front of the cylinder to record these touches and repeat recording if 
needed. The percentage of contralateral paw touches out of the first 20 total touches 
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(ipsilateral and contralateral) was calculated and considered as a value for rat’s performance 
in the cylinder.     
 
Figure 6 cylinder test 
 L-dopa induced abnormal behavioural and motors movements  
2.4.1 L-dopa treatment: 
A reconstituted powder of L-3,4-Dihydroxyphenylalainine Methylester (L-DOPA) was used for 
peripheral administration in combination with benserazide hydrochloride, which is a 
peripheral aromatic amino acid decarboxylase (AADC) enzyme inhibitor preventing 
conversion of L-dopa to dopamine in the periphery. The 2 drugs were mixed together and 
stored at -20 0 C for no longer than 4 days before dissolving with 0.9% normal saline and 
injected s.c. in the rats. The dose of administration and proportions of each drug in the 
combination in addition to dose frequency and duration of treatment will be stated in the 
method of the chapters where it is appropriate.  
2.4.2 L-DOPA induced rotation:  
As with amphetamine, the L-dopa injected rats were putted immediately in perspex cylinder 
and joined to an automated rotometer. Number of rat’s rotations with either clockwise or 
anti-clock wise direction were counted via a software program linked to the rotometer. The 
program was set to count number of one-eighth rotation at each direction during 180 minutes 
of injecting the rat. The total number of rotations per minute were determined by subtracting 
the total one-eight rotations toward clockwise (ipsilateral side) from the total one-eight 
rotations anti-clockwise (contralateral side) divided by 8 (fractions to complete one rotation) 
and by 180 (the duration time of running the experiment in minutes). 
Mirror  
Perspex 
cylinder   
Counted 
touch   
Rat’s 
number  
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2.4.3 Abnormal involuntary movements (AIMs) rating scale: 
The comparison between different AIMs scales which performed by Breger and colleagues 
(2013) was considered to choose an appropriate scale to assess the AIMs induced by L-dopa 
injection. They found that developing of the AIMs score described by Winkler and colleagues 
scale ( Winkler, Kirik, Björklund, & Cenci, 2002) is more sensitive in response to doubling the 
dose of L-dopa or alleviation the dyskinesia by using amantadine (anti-dyskinesia agent) than 
other scales. They also showed that hind-limb movements  described (Steece-Collier et al. 
2003) is correlated with doubling L-dopa dose and increase the significance of amantadine 
effect (Breger et al. 2013). The AIMs scale used in this thesis involved evaluating the duration 
and intensity of dyskinesia movements of the forelimb, hind limb, trunk and mouth which is 
performed concurrent with L-dopa induced rotation test. The examiner observed each rat for 
one minute every 20 minutes during 180 minutes starting immediately after L-dopa injection. 
At each observation, the duration and the intensity of the abnormal movements were scored 
as described in Table 3 and some images in Figure 7. The total AIMs score is the summation 
of the multiplying of the intensity score with duration score at each observation point. AIMs 
scoring test were started 3 weeks post 6-OHDA lesion surgery and repeated several times 
before and after cell transplantation surgery, more details about frequency of performing the 
test and dose of L-dopa administration are stated in the next chapters where it is appropriate.  
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Table 3 Abnormal Involuntary Movements (AIMs) rating scale as described by Breger et al., 2013 
Dyskinesia  Score = Intensity Description  Score = duration  
Forelimb  1= Tiny oscillatory movements of the paw and the 
distal forelimb around a fixed position 
2= Movements of low amplitude but causing visible 
translocation of both distal and proximal parts of 
the limb. 
3= Translocation of the whole limb with visible 
contraction of shoulder muscles 
4= Vigorous limb and shoulder movements of 
maximal amplitude. 
 
0= none 
 
1= occasional: 
less than 50% of 
the time. 
 
2= frequent: 
more than 50 % 
of the time. 
 
3= continuous 
but interrupted 
by strong sensor 
stimuli. 
 
4= continues but 
uninterrupted by 
strong sensor 
stimuli.  
Hind limb  1= abnormal posturing of limb 
2= sustained posturing of the limb, mildly extended 
in abnormal posture. 
3= severely hyperextended in abnormal position  
4= hind limb fully extended, causing the rat to lose 
balance. 
Axial  1= lateral deviation of head and neck <30  
2= lateral deviation of head and neck 30-60 
3= lateral deviation or torsion of head, neck and 
upper trunk 60-90 
4= torsion of neck and trunk at >90 causing the rat 
to lose balance. 
Oro-lingual  1=jaw movements and facial grimacing  
2= tongue protrusion 
locomotion No intensity score  
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Figure 7 images of Abnormal Involuntary Movements observations during AIMs scoring: image (A) 
shows jaw movement; following the paw position between the images (B and C) figured out the way 
of paw oscillation; image (D) showing axial dystonia where the head and the neck deviated about 90 
degree of the normal posture. 
 Rats perfusion and Fixed Brain extraction 
Rats were anesthetized prior to perfusion by injecting a 0.7 ml of 200mg/ml Euthatal solution 
(i.p.). They were perfused transcardially with a pre-wash of phosphate-buffered saline PBS 
solution (90 g disodium phosphate, 45 g sodium chloride, 5 L DW, and adjusted with ortho-
phosphoric acid at PH 7.4) at a rate of 25 ml per minute for 2 min using an infusion pump. At 
the same rate, the pump was switched to infuse 4% para-formaldehyde PFA solution (200 g 
of PFA in 5 L of pre-wash solution) for 4 min. Following perfusion, the heads were cut off and 
the brains were extracted and post-fixed in 4% PFA solution for 4 hours. After that, the PFA 
solution were replaced by 25% sucrose solution (250 g of sucrose dissolved in the pre-wash 
solution) till they saturated and sunk followed by cutting the brain or storing at 4 0C.  A freeze 
microtome was used to slice the brains to coronal sections with a thickness of 30µm. The 
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brain sections in 1:12 series were kept in a 1 ml tube filled with an anti-freeze solution (sodium 
monophosphate 8.72g, sodium diphosphate 2.52g, D.W. 640 ml, ethylene glycol 480 ml, 
glycerol 480 ml) and stored at 4 0C till use for histological analysis.   
 Fresh brain dissection and other organ tissues collection 
Fresh samples of striatum, substantia nigra, hippocampus and frontal cortex were dissected 
from 3 normal rats. The rats were anaesthetised by injecting 0.8 ml of Euthatal i.p. (200 
mg/ml) before decapitation using a guillotine. The rat brains were extracted and put inside 
rat’s brain mould on ice and dissected by inserting blades through the brain on the following 
distances from the front of the brain: 3 mm, 7 mm, 11 mm and 14 mm. The striatum was 
dissected from the sections between 3 mm and 11 mm while the frontal cortex was dissected 
from 0-3 mm. The section between 11 mm and 14 mm was used to dissect the hippocampus 
and to pinch out a piece of tissue including substantia nigra by using 4 mm pinch pen. The 
samples were immediately placed in 1.5 ml tubes and kept on dry ice then stored at – 80 0 C 
till use for protein extraction and western blotting. Other fresh tissue samples were snipped 
from liver, pancreas, muscles and adipose tissue from normal rats or rats used in the 
experiments of chapters 4, 5 and  6 and they were yielded prior to perfusion of the rats. They 
were kept immediately in dry ice and then stored at – 80 0 C for western blotting and 
histological analysis.  
 VM Primary cells plating down and fixation  
VM cell culturing and fixation was operated in sterilised cell culture cabinet. The process was 
started by preparing a sterile 24 wells plate covered with sterile 13 mm glass coverslips and 
coated with 500 µl 0.01% Poly-lysine PLL to improve adherence. Then VM sections obtained 
from E14 Wistar rat embryos was dissociated to a single cell suspension by following the same 
protocol described in section (2.2.2.1). The cells were suspended with a culture media (50 ml 
DMEM, 1 ml B27 (2%) and 500 µl Foetal Bovine Serum (1%)) to yield a concentration of 50,000 
cells per 30 µl. Before seeding the cells, each well was washed 3 times with a sterile distilled 
water and left under UV light for 30 min to dry. Then 30 µl of the cell suspension was dropped 
in the centre of the coverslip of each well and left in an incubator at 37 0 C for 3 hrs. The wells 
were then washed with culture media 3 times before adding a 500 µl of 4% PFA solution in 
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each well for and left for 10 min. After that, the cells were washed with BPS solution and 
stored at 4 0 C.  
 Plasma collection and analysis: 
2.8.1 Blood samples collection  
Blood samples were collected immediately before trans-cardial perfusion from the left 
ventricles of the rats in the experiments of chapters 4, 5, and 6. All rats were food restricted 
for 9-11 hrs and they were received their regular treatments 80 min before gathering the 
samples (except in chapter 6, there was no treatment before collecting the blood). 2-3 ml of 
the blood samples were collected using 23 Gx1’’ needle and putted immediately in EDTA 
tubes (VACUET lavender, greiner bio-one) with 200 µl of Aprotinin solution and mixed 
thoroughly. They were centrifuged at 2000 G for 15 min using cooling centrifuge system, 
Eppendorf – 5841. Then plasma supernatant was taken and stored in -80 0 C.  
2.8.2 Glucose analysis: 
Plasma glucose level measured by using YSI 2300 STAT PLUS™ analyser. The analyser 
automatically withdrew 25 µl of plasma samples and gave two readings of glucose level 
(mmol/ L) for each sample then the average value was considered.  
2.8.3 Luminex assay: 
Luminex xMAP technology were used to determine plasma levels of insulin, endogenous 
GLP1, IL-6 and TNF-a. Rat Metabolic Magnetic Bead Panel from Millipore Company 
(RMHMAG-84k) and Bio-Plex 200 system powered by luminex x-map TM technology were 
used analyse the plasma samples. The panel includes magnetic beads of anti-insulin, anti-GLP-
1, anti- IL-6 and anti-TNFα antibodies in addition to other reagents including standard, quality 
control, 96-well plate, assay buffer, serum matrix, bead diluent, 10 times wash buffer, 
detection antibodies, streptavidin-phycoerythrin and mixing bottle. The well plate was 
divided to include double wells for each sample and double wells for 7 standards, 2 quality 
controls and one background. The antibody beads were mixed together in a bottle then the 
reagent solutions which include standard, quality control and blank solutions were prepared 
according to Milliplex map kit guidelines (Milliplex map Kit 2015). Then the Milliplex 
immunoassay procedure was followed which included adding 200 µl of the Assay Buffer into 
each well of the plate with shaking for 10 min at room temp. This was then decanted and 25 
µl of serum matrix solution added to the background, standard and control wells. A 25 µl of 
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Assay Buffer was added to the background and sample wells then a 25 µl of the standard, 
control or sample was putted in the appropriate wells. After that, the mixed antibody beads 
were vortexed and 25 µl were put in each well followed by sealing the plated and incubating 
it at 4 0 C overnight. Next day all the well contents were washed 3 times with wash buffer then 
50 µl of detection antibodies were added and incubated on plate shaker for 30 min at room 
temp. 50 µl of streptavidin- Phycoerythrin was then added to each well without decanting the 
detection antibodies and incubated for 30 min at room temp followed by removing all well 
contents and washing 3 times with the washing buffer.  After that, a 100 µl of Luminex Sheath 
Fluid (which used to drive the samples to the optic component of the Bio-plex machine) was 
added to each well before putting the plate inside the machine. Bio-Plex machine set up with 
all the required information before running which involved: beads region and name of each 
analyte; concentration of the standards of each analyte; location of the standards, controls, 
backgrounds and samples in the well map; concentration of the quality controls; sample 
information (like number of sample for the appropriate well). After running, reports of the 
results were obtained including standards, controls, background and samples concentrations 
for each target. 
 Protein lysis and Western blots: 
2.9.1 Protein lysis: 
Frozen tissue samples obtained from fresh organs (described in section 2.6) were mixed with 
a Lysis buffer (see Table 4) in different proportions (see Table 5 ) in 2 ml tube containing 
ceramic beads. Then a protease inhibitor 30 µg/ml and phosphatase inhibitor 60 µg/ml were 
added to the mixture which kept in ice box during all the procedure time. After that, the tubes 
were homogenised in a Precellys® 24 homogenizer which was ran 3 cycles at a rate of 5500 
rpm for 20 second at each cycle to yield a grinded homogenate of the tissue sample. Then the 
suspension transferred to 1 ml tube without ceramic beads and centrifuged with a pre-cooled 
centrifuge (Eppendorf 5810R) at a rate of 17000 G for 60 min. then the supernatant was kept 
for protein denaturation and protein concentration validation before storing at –20 0 C or 
using in western blotting. Protein solution were mixed with an equal volume of Laemmli Lysis-
buffer (see Table 4) and heated at 90 0 C for 5 min for denaturation.   
53 
 
2.9.2 Protein concentration validation: 
Bicinchoninc acid (BCA) assay kit was used to detect the protein concentration of each 
sample. Protein samples were diluted with deionized water in 1:10 ratio then 10 µl of each 
sample were loaded in double wells of 96 wells plate. 10 µl of 7 standard concentrations of 
BSA protein [2, 1, 0.5, 0.125, 0.0625, 0.03, 0.015] mg/ml was also added in double wells of 
the plate and 10 µl of deionized water was loaded in 2 wells to background. After that, 200 µl 
of BCA reagents which was prepared in ration of 50 of reagent A to 1 of reagent B (see Table 
4) were loaded on all the wells of the samples, standards and blanks followed by incubating 
the plate for 30 min at 37 0 C. Labtech Microplate Reader LT-5000 ® NS set up on wave length 
560 was used to measure the wells absorbance values. Then the samples concentrations were 
estimated from a protein concentration vs absorbance chart. The chart was created by 
applying standard samples absorbance (recorded by the machine) with their knowing 
concentration then form the chart the equation to estimate sample concentration from it 
absorbance can be obtained (as described in this chart).  
 
2.9.3 Western Blot: 
10 % SDS-PAGE running gel (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophorese) (see 
Table 4) and stacking gel (composition: see Table 4) were used for separating the protein 
samples. After defrosting, the samples were denatured by heating to 70 0 C prior to loading in 
the gel and placed in electrophoresis chamber (Bio-Rad Laboratories) containing a proper 
volume of running buffer (composition, see Table 4) then run at 200 v for 1-3 hrs. Separated 
proteins were transferred from the gel to a Nitrocellulose blotting membrane (0.2 µm) using 
54 
 
a semi-dry membrane transfer at 39 A for 1 hr which involve scaffolding the gel and the 
blotting paper with filter papers soaked with semi-dry blotting buffer (composition, see Table 
4)  inside an electric field. The blotting membrane was then blocked with either 5% non-fat 
milk (NFM) or 5% BSA in TBST solution (composition: see Table 4) for 1 hr at room 
temperature. Then the membrane was incubated with a primary antibody at proper dilution 
in 5% NFM blocking solution and kept overnight at 4 0 C.  Next day, the blotting membrane 
was washed 5 times, 5 min at each wash, with TBST solution followed by incubating with a 
proper horseradish peroxidase linked secondary antibody solution for 2 hrs at room 
temperature. Then the blot was washed 5 times with TBST solution followed by bands 
developing using SuperSignal® West Dura kit. Bands were visualized using was the gel imaging 
Syngene® G BOX linked to an automatic control software (GeneSys).   
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Table 4 component of solutions and kits used in protein extraction, protein concertation validation 
and western blotting. 
Reagents or Buffers  Composition  
Lysis Buffer 1.46 g NaCl, 0.91 g KCl, 0.15 g MgCl and 0.93 
EDTA were dissolved firstly with 230 ml 
distilled water DW followed by adding 20 ml 
TBS solution (pH 7.6) plus 625 µl Triton X-100. 
BCA kit  Reagent A: 1 gm sodium bicinchoninate 
(BCA), 2 g sodium carbonate, 0.16 g sodium 
tartrate, 0.4 g NaOH, and 0.95 g sodium 
bicarbonate, brought to 100 ml with distilled 
water (pH to 11.25). 
Reagent B: 0.4 gm cupric sulfate in 10 ml 
distilled water 
Laemmli Lysis-buffer  bromophenol blue, 0.004%, DTT, 400 mM, 
glycerol, 20%, SDS, 4%, TRIS, 0.125 M 
10 % SDS gel  5.27 ml DW, 100 µl of 10% SDS (sodium 
dodecyl sulphate) and 1.25 ml (3 M tris Hcl, 
pH 8.8), 3.33 ml 30% Acrylamide, 50 µl of 
10% APS (Ammonium pre sulfate) and 5µl 
TEMED (tetra methyl etheylen diamine 
Running Buffer  Tris base 3 g, Glycine 14.25 g, SDS 0.5 g, DW 1 
L, pH 8.3.  
Stacking Gel 5.77 ml DW, 1.67 ml 30% Acrylamide, 2.5 ml 
SDS/Tris (0.4% SDS/ 0.5 M Tris.Hcl pH 6.8), 50 
µl of 10% APS, and 5 µl TEMED.  
TBS solution  2.4 g Tris base, 8.7 g NaCl, 1 L DW, pH 7.4  
TBS-tween 20 1 L TBS and 1 ml of 0.1% tween 20 
Semi-dry blotting buffer  5.8 g Tis base, 2.92 g Glycine, 0.38 g SDS, 800 
ml DW, 200 ml Methanol.  
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Table 5 the optimised proportions of tissue samples mixed with the lysis buffer 
Tissue sample Tissue weight/ Lysis buffer 
volume 
Loaded volume in the gel  
Striatum tissue 80 mg/ 160 µl 15 µl 
Substantia Nigra 14 mg/ 100 µl 30 µl 
Frontal Cortex 40 mg/ 250 µl 10 µl 
Hippocampus 90 mg/ 90 µl 10 µl 
Ventral Mesencephalon (6 VM sections) 25 mg/ 160 µl 50 µl 
 
  Cells and Histological determinations  
2.10.1 DAB Immunohistochemistry (DAB-IHC) 
Free floating Immunohistochemistry IHC was used to identify and quantify different protein 
targets of fixed coronal sections of the brains. One or more of a 1:12 series of brain sections 
were washed 3 times with TBS solution (Tris base 12 g, sodium chloride 9 g, D.W. 1L, pH 7.4) 
each wash 5 min. Then the sections were quenched (methanol 10 %, hydrogen peroxide 10 
%, D.W. 80 %) for 15 minutes followed by 3 washes with TBS solution, 10 min each wash. After 
that, they were blocked with an appropriate serum in a concentration of 3% in TBST solution 
(TBS 250 ml, triton 500 µl) solution for 2 hrs. Without washing, the brain sections were 
incubated overnight at room temperature with a primary antibody prepared in an optimised 
concentration in 1% of the block solution. Next day, the tissues were washed 3 times with TBS 
solution before incubating with a proper biotinylated secondary antibody in 1% serum of TBS 
solution at concentration of 1:200 for 2 hrs at room temperature. Afterwards the sections 
were washed 3 times with TBS solution followed by adding Vectastain Elite ABC solution 
(Biotin/ Avidin system linked to the horse peroxidase) in a concentration of 1:200 of 1% serum 
TBS solution and incubated for 2 hrs at room temp. The tissue sections were then washed 3 
times with TBS solution and 2 times with TNS solution (Tris base 9 gm, D.W. 1L, pH at 7.4) 
followed by staining with DAB solution (2 ml of 0.1 % of 3,3’- Diaminobenzidine tetra-
hydrochloride DAB, 40 ml TNS solution, 12 µl of 0.03% hydrogen peroxide) then washed twice 
with TNS solution. Finally, they were mounted on gelatinised slides and left to dry at room 
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temperature. They were then dehydrated by passing the slides through alcohol baths in series 
of increasing concentrations 70%, 95%, 100% and cleared with double xylene solutions (5 
mins in each solution) before cover-slipping with DPX solution (distyrene plasticizer and 
xylene). (see Appendix A for list of antibody details) 
2.10.2 Single or double Fluorescence IHC (F-IHC) 
Similar to DAB-IHC, a free floating IHC process was used. The F-IHC started with washing tissue 
sections with TBS solution 3 times but without quenching step followed by blocking with 3% 
of a serum in TBST solution for 2 hrs. Then without washing, the blocking solution were 
replaced by an optimised concentration of primary antibody in 1% serum TBST solution and 
incubated at room temp overnight. Next, the sections were washed 3 times with TBS solution 
followed by adding a fluorescent secondary antibody using a concentration of 1:500 in 1% 
serum TBS solution (all the process after this step involved covering the tissues with an 
Aluminium foil or placed in a dark area to avoid fluorescence bleaching) then incubated for 2 
hrs at room temp. Afterward the tissue sections were washed 3 times with TBS solution then 
either mounted on slides or processed to add another primary antibody. The process of 
adding a second primary antibody involved repeating the same steps of blocking, adding 
primary antibody, washing and adding secondary antibody but with consideration of choosing 
a secondary antibody with a different florescent dye and not interact with the first antibody. 
Finally, tissue sections were mounted on gelatinised slides followed by dehydration and 
coverslip similar to DAB-IHC (see section  2.10.1) but in a dark place.  (see Appendix A&B for 
list of antibody details) 
2.10.3 Immunocytochemistry ICC 
Fixed cells seeded in PLL coverslips of 24-well plate (see section 2.7) were underwent 
immunocytochemistry ICC. Starting with 3 washes using 0.1M PBS solution (80 g NaCl, 2.0 g 
KCl, 21.7 g Na2HPO4, 2.59 g KH2PO4, prepared in 1 L of distilled water, pH 7.4) it was then 
followed by adding 500 µl of a blocking solution (3% serum, 1% BSA, 0.1% triton X-100, 0.1M 
PBS,) for 30 min. After that, without washing, the blocking solution containing an appropriate 
concentration of a primary antibody was added and incubated overnight at 4 0 C. Next day, 
the cells were washed 3 times with PBS-T (0.1M PBS and 0.1% triton X-100) solution followed 
by adding a fluorescent secondary antibody in a concentration 1:400 with the blocking 
solution and incubated for 2 hrs at room temp (all the processes after adding the secondary 
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antibody was performed with covering the plate with Aluminium foil or in a dark area). 
Afterwards, the cells were washed with PBS 3 times and the processes of adding a second 
primary antibody was started. Similarly, the process involved blocking the cells using similar 
blocking solution but with a suitable serum followed by adding the primary antibody, washing 
and adding the secondary antibody followed by washing. The species of the used second 
primary and secondary antibodies were chosen to be not interact with the first primary and 
secondary antibodies. In addition, the second secondary antibody had fluorescence dye 
different from the first one. At the end, the coverslips were removed from the plate and 
mounted on slides using anti-fade mounting media (VECTASHIELD) with DAPI to stain the 
nuclei. (see Appendix A&B for list of antibody details) 
2.10.4 Optimisation of immunoassays  
IHC, F-IHC and ICC procedures optimised to detect the target and/ or to get the best image. 
The process of optimisation involved using a series of antibody concentrations and comparing 
it with a negative antibody control and/ or incubating the primary antibody for longer period. 
The target signal, for some fluorescence immunoassays, was measured by using biotinylated 
secondary antibodies before adding the fluorescent label or by increasing blocking serum 
concentration or incubation time. In the double immunoassay, each antibody target was 
optimised separately before detecting them together. (Appendix A pointed to the procedures 
that involved an adjustment and optimisation) 
2.10.5 Oil red O staining  
Oil red O staining is a method used to stain lipids in the tissues which depend on the physical 
property of Oil Red O, a diazole dye, being more soluble in lipids than the vehicle solvent. It 
was used to quantify lipids in liver samples used in different experiments in this thesis (see 
section 2.6 for details of liver sample collection). A frozen liver sample was sliced to a 20 µm 
thickness using a cryostat machine set on -32 0 C and then mounted on negatively charged 
slides. The sections were then immediately fixed with 4% PFA solution for 10 min followed by 
washing with a distilled water for 5 min. The slides were dipped in 60% isopropanol solution 
for 5 sec followed by immersing them in a staining jar containing a filtered ORO dyes diluted 
with a distilled water in a ratio of 50:50 for 15 min. After that, the slides were dipped again in 
60 isopropanol solution for 5 sec then passed in a double washing with distilled water for 10 
min. Finally, A Glycerine jelly, an aqueous mounting media, was used to coverslip the slides. 
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This method was optimised after using a range of tissue section thicknesses, a series of ORO 
dilution ratios and different dipping time with isopropanol solution.  
2.10.6 Haematoxylin and Eosin (H and E) staining  
 Fixed liver slices obtained from frozen liver samples (see 2.10.5) underwent Haematoxylin 
and Eosin staining. This method was used to examine the histological and morphological 
appearance of the liver sections. The slides were passed through a series of solutions 
according the following schedule: 2X xylene for 4 min; 2X 100% Alcohol for 4 min; 95% Alcohol 
for 2 min and 70% Alcohol for 2 min. After that, the slides were washed with tap water and 
dipped in Mayer’s Haematoxylin solution for 10 min followed by washing with tap water and 
stain with 1% aqueous Eosin solution for 2 min. Then the slides rinsed with water and passed 
on the following series of alcohol solutions: 70% alcohol for 20 sec; 95% alcohol for 20 sec, 
double 100% alcohol for 3 min and xylene solution for 4 min. At the end, the slides were 
coverslip using DPX as mountant.  
  Microscopy and image analysis  
2.11.1 Graft analysis  
The number of dopaminergic cells in the graft was determined from counting TH labelled cells. 
This were determined by direct counting the cells on 20X or 40X magnification on a bright 
field using Leica light® or Feltiz dilux 22 ® microscope except in chapter 5 where the cells were 
counted using the stereology microscope (Olympus B 50 linked to Visopharm integrator 
system software). The total number of TH cells in the graft was estimated by applying 
Abercrombie equation: N=∑ {n x F x T/(T+H)} where N = Total corrected number, n= number 
of the counted cells, F= frequency of the sections, T= thickness of the sections (30um), and 
H= mean diameter of the cells (Hedreen 1998). The total number of cells in the graft of human 
Embryonic Stem Cells hESC-derived dopaminergic neurons transplantation, in chapter 5 and 
6, was determined by counting HuNu (human nuclei) labelled cells. This was accomplished by 
obtaining several images at 10X magnification for all graft using Leica light® microscope 
followed by image analysis for counting using ImageJ 1.51e software. First, to get a clearer 
image, the images pixel values were inverted followed by background subtraction by 50 pixel-
value before re-invertion. Then, the images converted to 8-bit scale followed by an auto 
threshold determination. After that, a particle analysis function was commanded set up on 
particle size (5 pixel - infinity) and circularity ratio (0.1-1) to count all the particles (HuNu 
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labelled cells). Finally, the images were zoomed and screened to count the undetectable 
particles and adding them to the total number (see Figure 8). The Abercrombie equation was 
then applied to estimate the total HuNu labelled cells in the graft.  
The volume of dopaminergic neurons in the graft was calculated by summation of all the areas 
containing TH+ cells in all the striatal sections in the series multiplied by section thickness (30 
mm) and by series frequency (12). The surface area was measured either by a software 
supplied with the microscope (Olympus B 50 microscope linked to Visopharm integrator 
system software) or by ImageJ software using images captured at 4X magnification. Similarly, 
the volume of all hESC-derived dopaminergic neurons graft was measured by determining the 
surface area of STEM121 stained sections (specifically staining human cells cytoplasm) in one 
1:12 series. 
Dopaminergic graft fibre innervation was evaluated by obtaining images for TH+ labelled 
grafts on using Olympus B 50 or Leica light® microscopes. The image analysis for fibre 
innervation was evaluated by ImageJ 1.51e using two different methods. Both methods 
depended on measuring images threshold surface area limited to the stained TH markers. 
However, in the first method, TH density inside the graft border was evaluated (i.e TH fibres 
and cell bodies, used to evaluate TH density in chapter 4). The TH density was measured by 
dividing the mean of TH innervation area (threshold surface area) over the graft surface area 
(see images A and B of Figure 9). while, in the second method, fibre innervation out of the 
graft border was measured (used to evaluate fibres outgrowth in chapter 5). The section 
located in the middle of the graft was chosen to estimate fibre innervation toward the medial 
or lateral sides at distances of 200, 400 and 600 µm from the graft border. 3 vertical lines of 
squares (200*200 µm2) extended medially and laterally from the graft then the summation of 
threshold surface area (fibres surface area) in the squares of each line was calculated (see 
images C and D of Figure 9).  
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Figure 8 ImageJ software process to count Hunu labelled cell: A, captured image; B, converted image 
to 8-bit scale; C, auto-threshold to determine the HuNu particles; D, zoomed image showing 
detected and counted particles by the software (black arrow) and the undetected manually count 
particles (orange arrow). 
 
 
Figure 9 fibres innervation estimations: images A and B shows first method of evaluation; image C 
and D shows method 2 of evaluation 
2.11.2 SN TH+ lesion analysis 
The percentage of the lesion TH+ labelled cells in the SN were estimated at the level of the 
medial terminal accessory nucleus of the optic tract where the SN is delineated from the VTA. 
This located on the following coordination from the bregma: AP = -5.8; ML = +1; DV = -8.    The 
extent of the lesion was measured by expressing the number of the remaining TH+ cells in the 
right hemisphere (lesioned) as a percentage of the left side (intact). 
2.11.3 Striatal inflammation analysis  
Microglial density and leukocyte infiltration was investigated around the transplanted graft 
in the striatum using CD11b and CD45 markers respectively. CD45 labelled cells were counted 
directly from under Feltiz dilux 22® microscope then the total number corrected using the 
Abercrombie equation. Microglial quantification was evaluated by measuring optical density 
(OD) of CD11b labelled cells in the middle section of the graft. Images were obtained by 
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Olympus B 50 at 4X magnification and analysed by ImageJ 1.51e. Firstly, the ImageJ was 
calibrated for measuring the OD according to ImageJ optical density instructions (ImageJ n.d.). 
The OD was measured around the graft within 40 µm distance of the graft border. Similarly, 
the OD was measured in corresponding places of the intact striatal side in addition to different 
points in the cortex to act as a background control. The OD values of the graft and intact 
striatal sides were subtracted from OD values of the background control. Then evaluation of 
OD around the graft was expressed as a relative percentage to OD of the intact striatum.  
2.11.4 Striatal blood vessels image analysis   
Striatal blood vessels were visualised by Leica light® microscope on 10X magnification after 
labelling with tomato-lectin marker (Lycopersicon esculentum). Then images were obtained 
and analyzed with ImageJ to quantify the blood vessel surface area. The images were 
converted to 8-bit scale followed by determining an image threshold (limited to the labelled 
tomato lectin target) followed by measuring the threshold surface area which was considered 
a measure of the blood vessel surface area per image. The average reading from 3 different 
images obtained from the middle graft section was considered.  
2.11.5 Analysis of co-localised targets  
 Co-localisation of two or more targets was examined either under the LEICA DMIRE2® 
Microscope on 63X objective or using Leica microsystem confocal microscope on 40 
objectives. With LEICA DMIRE2® Microscope, the slide position was fixed prior to capturing 
an image of a certain target followed by switching the laser beam to a proper wave length to 
detect another marker. The localisation of the targets in the two-dimensional image was then 
detected using arrow detecting tools of ImageJ. While with confocal microscope, prior to 
running, the laser bands were adjusted to be within the targets wave length and the Z-width 
was determined from the bottom and upper limit of existence of the focused section. 
Following, the optical sectioning was run to get a 3-dimensional structure of the image then 
the co-localisation of targets was tested at each depth.   
2.11.6 Lipids accumulation in the liver    
The quantity of fat droplets in the liver sections was estimated by capturing images of Oil Red 
O stained sections on 10X objectives of Leica light® microscope and analysed with ImageJ. 
Similar to the method of blood vessels image analysis, 5 images were captured of each liver 
section and converted to 8-bit image scale followed by determination the image threshold 
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surface area which reflecting the fat droplets surface area per image. After that, the liver 
steatosis state was evaluated as a percentage fat surface area per section.  
2.11.7 Stereological cells counting  
Olympus B 50 Stereology microscope linked to Visopharm software was applied to estimate 
the total number of TH+ cell in the graft of chapter 5 using optical fractionator method. This 
method depends on selecting the area of the interest (graft area) then counting the object 
(TH+) located in systematically random samples within the selected area. The sampling 
method depends on counting spaces covering the entire area of interest then unbiasedly the 
sample regions are selected in uniform distances in directions of X and Y within the counted 
spaces. The dimension of the sample box (counting frame) is determined to include an 
average of 2 to 3 objects per frame. To count the object in the samples criteria rules were 
followed including: the object should be either inside the frame or intersect with the top or 
the right vertical line of the frame; while the objects outside the frame or intersect with the 
bottom or the left vertical line of the frame was excluded. In chapter 5, the area of interest 
(graft area) was encircled under 4X object of the microscope while the counting the cells in 
the frames was accomplished under 40X object. The selected dimensions for the frame were 
58.7 µm on X- axis and 73.46 µm On the Y-axis. Number of samples was determined by a 
step length between samples equal to 283.54 µm. Then the total number of cells was 
counted using the following equation:   
N = n * A / (a * S) * F * (T / (T+ D);  
N = total estimated number; n = counted number inside sampling boxes; A = region of 
interest area (graft surface area); a = frame surface area; S = number of samples; F = series 
frequency; T = section thickness; D = cell diameter.  
  Statistical analysis  
The data were analysed using either Prism 5 in chapter 3 or IBM SPSS in the followed chapters 
(chapter 4, 5 and 6). The statistical analysis method explained in details at each experimental 
chapter, in short, the behavioural data was analysed using repeated measure analysis of 
variance ANOVA, except apomorphine test where either one-way or two ANOVA used. In 
histological data either one-way or two-way ANOVA analysis was used unless T- test was used 
when it is appropriate. The analysis test followed by post- hoc test to compare the significance 
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of the difference between the groups and data was considered significant if *p <0.05 and 
highly significant if **p <0.01 or ***p <0.001.   
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3 Chapter 3: Impact of ghrelin and JMV-2894 on the 
survival and efficacy of transplanted allogenic Ventral 
Mesencephalon cells in 6-OHDA rat model of 
Parkinson Disease  
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 Introduction  
Ghrelin is described as an acylated hormone consisting of 28 amino acids, isolated for the 
first time from the rat stomach in 1999 (Kojima et al. 1999). In humans, it is mainly produced 
by X/A like cells of the gastric mucosa, in addition to other sites including the intestine, lung, 
heart, pancreas, kidney, testis, pituitary and hypothalamus (Delporte 2013). In human 
serum, it is present in two main molecular forms: the acyl form, which is responsible for the 
activation of the ghrelin receptors at physiological concentrations; and the des-acyl form 
which represents more than 90% of the total serum ghrelin but cannot interact with the 
receptors at a physiological concentration  (Delporte 2013). Pharmacokinetic studies have 
illustrated that it has a short half-life in the human circulation ranging between 9-11 min in 
the case of the acyl form while the total, for the acyl and des-acyl form, is about 35 min (Tong 
et al. 2013). Moreover, it has been established that its serum level is affected by many factors 
including the circadian cycle, fasting state and exercise (Bertani et al. 2010; Toshinai et al. 
2001; Shiiya et al. 2011). Another important pharmacokinetic aspect is its ability to cross the 
blood brain barrier and interact with the target receptors after a systemic administration 
(Jerlhag et al. 2012) (Kawahara et al. 2009). Physiologically, ghrelin has shown a wide range 
of activities including: stimulation of growth hormone secretion, promotion of appetite and 
food intake, regulation of energy homeostasis , activation of gastric secretion and motility, 
in addition it interferes with many aspects of the reproductive system, the cardiovascular 
system, bone formation, pancreatic secretions and anti-inflammatory function (reviewed in 
(Delporte 2013).  
The role of ghrelin in the protection of neurons first emerged from evidence showing that 
treating cells with a rat serum of hypo-calories (in which ghrelin level increased) leads to 
improving their biogenic characters and decreases reactive oxygen species (ROS) production 
(López-Lluch et al. 2006). Evidence later confirmed this protective role of ghrelin and 
importantly in the dopaminergic neurons of PD models (Andrews et al. 2009). This protection 
for the dopaminergic neurons and possession anti-inflammatory properties (discussed 
below 3.1.23.1.3) would make ghrelin a good candidate for refining VM transplantation.  
3.1.1 Ghrelin receptors: 
Ghrelin receptors or growth hormone secretagogus receptor GHSR-1, which was considered 
as one of the orphan G protein coupled receptors until the discovery of ghrelin. It consists of 
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two types:  GHSR1a is responsible for exerting the functional activity of acylated ghrelin or 
synthetic growth secretagogues hormone and consists of 366 amino acids and holds seven 
transmembrane helix domains (TMD1-7)(Kaiya et al. 2013); The second, GSHR1b, does not 
have a clear functional activity yet and consists of 289 amino acids and has five 
transmembrane domains  (Kaiya et al. 2013). The molecular signalling of GHS-R1a involves 
the activation G protein subtypes and causes a subsequent activation to the phospholipase 
C, inositol triphosphate and intracellular Ca2+ pathways (Smith et al. 1999). The downstream 
signalling is usually affected by the dimerization state which appears between ghrelin 
receptors and other receptors like the somatostatin receptor (Park et al. 2012), 
melanocortin-3 receptor (Rediger et al. 2011) and (D1 and D2) dopaminergic receptors (Jiang 
et al. 2006; Kern et al. 2012). For instance, the heterodimerisation between the D2 receptor 
and GHS-R1a in hypothalamic neurons causes an allosteric modification to the D2 receptor 
intracellular signalling as using GHSR-1a antagonist leads to block D2 agonist effect (Kern et 
al. 2012). Ghrelin receptor distribution in the brain was detected in different regions 
including hypothalamus, substantia nigra and ventral tegmental area (Howard et al. 1996; 
Bennett et al. 1997; Zigman et al. 2006). Importantly, the localisation of ghrelin receptor on 
the dopaminergic neurons of the SNpc (Zigman et al. 2006; Andrews et al. 2009; Jiang et al. 
2008) led to discerning a protective effect of ghrelin on dopaminergic neurons in PD models 
(Moon et al. 2009b; Andrews et al. 2009; Dong et al. 2009a; Jiang et al. 2008).  
3.1.2 Anti-inflammatory effect of ghrelin:  
It has been suggested that striatal inflammation has repercussions on the survival of 
dopaminergic neurons transplanted into the dopamine denervated striatum. Consequently, 
this impairs the motor response achievable by the transplant and in addition may contribute 
to the GID side effect (discussed previously 1.6.1.4 &1.6.4.2). The potential for ghrelin to 
have a positive impact on graft transplantation was illuminated from a series of studies 
coming from both animal and cell line experiments. These have pointed to its capability to 
suppress harmful inflammatory responses. First, on microglia, ghrelin can inhibit microglial 
activation and prevent pro-inflammatory cytokine expression when stimulated by different 
types of microglial activators such as threo-hydroxy-aspartate (THA) and fibrillar β-amyloid 
protein (fAβ), (Lee et al. 2012; Bulgarelli et al. 2009). Similarly, in a mouse Parkinsonian 
model, Moon and colleagues confirmed that ghrelin has been shown to have an inhibitory 
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effect on the microglia of the SNpc and striatum when they are activated by MPTP and this 
effect is mediated indirectly through the inhibition of matrix metalloproteinase-3 (MMP-3) 
expression of the affected DA neurons. They noticed that ghrelin causes a decrease in the 
activation of the inducible nitric oxide synthase and the expression of the pro-inflammatory 
cytokines (TNF-alpha and IL1B) (Moon et al. 2009b). Secondly, on dopaminergic neurons, 
ghrelin can inhibit release of IL6, a pro-inflammatory cytokine, from dopaminergic neurons 
when they are stimulated by lipopolysaccharide (LPS) and mediate this effect through their 
receptors on the DA neurons (Beynon et al. 2013). Thirdly, on leukocytes in the peripheral 
immune system, ghrelin has demonstrated the capability to prevent proliferation of splenic 
T cells when they are stimulated by anti-CD3 and it can diminish Th1 and Th2 cytokine (IL2, 
IFN-γ, IL4, and IL10) mRNA expressions (Xia et al. 2004). Finally, by its anti-apoptotic 
properties, ghrelin may attenuate microglial activation which has been reported to have 
originated from apoptotic caspase 8 and 3/7 signalling (reviewed by (Bayliss & Andrews 
2013). However, the effect of ghrelin on the inflammatory response in the striatum as a 
recipient of an ectopic, allogeneic graft has not been investigated yet. This makes the 
prediction of the beneficial effect of ghrelin on the graft induced inflammation uncertain.  
3.1.3 Protection of dopaminergic neurons: 
Different studies have illustrated that Ghrelin exerts its neuroprotective effect on the 
dopaminergic neurons by different mechanisms including anti-apoptotic, anti-oxidant 
and/or boosting the mitochondrial function. Andrews and colleagues reported that ghrelin 
can protect the nigral dopaminergic neuron when exposed to MPTP toxin in mice model. 
They demonstrated that ghrelin mediates the protective effect through uncoupling molecule 
2 (UCP2), which is a mitochondrial protein responsible for regulating mitochondrial 
biogenesis. They also showed that ghrelin increases the number of mitochondria in the nigral 
dopaminergic neurons and promote mitochondrial respiration and proliferation. This 
protection occurred only when the exogenous ghrelin was given during the ghrelin 
physiological window (i.e. at fasting state and dark phase condition) while the osmotic 
infusion of ghrelin showed no effect. They suggested that ghrelin activates the AMPK-SIRT1-
UCP2 pathway similar to its role in the hypothalamus (Andrews et al. 2008) and they 
attributed the absence of the protection in the normal fed animals to the role of glucose 
which inhibits this pathway (Andrews et al. 2009).  
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Other studies have illustrated the anti-apoptotic effect of ghrelin in neuronal and non-
neuronal cells (Kui et al. 2009; Miao et al. 2007) and importantly on nigro-striatal 
dopaminergic neurons. Dong and colleagues have reported that ghrelin can restore 
mitochondrial membrane potential, reduce reactive oxygen species (ROS) production and 
abolish caspase 3 levels (the key protein in the apoptotic process) which is induced in 
MES23.5 cells by the MPTP neurotoxin (Dong et al. 2009a; Jiang et al. 2008). Jiang and 
colleagues confirmed the anti-apoptotic effect of ghrelin on protecting the dopaminergic 
neurons in MPTP mice model as ghrelin promoted mRNA expression of Bcl-2 with 
attenuating Bax expression and reducing caspase-3 activity in the SN (Jiang et al. 2008). 
Moreover, ghrelin showed an anti-oxidant effect on the dopaminergic neurons. Liu and 
colleagues used MES23.5 dopaminergic cells challenged with MPTP toxin and they illustrated 
that ghrelin inhibit the elevation of the malonaldehyde (MDA) level, which was used as an 
indicator of the extent of the oxidative stress, after exposure to the MPTP. In addition, it 
reversed the reduction in the concentration of anti-oxidant enzymes, Cu–Zn SOD and 
catalase (CAT) enzymes(Liu et al. 2010) which are responsible on converting the ROS to 
hydrogen peroxide then to water (Wang et al. 2007).  
3.1.4 Increasing dopamine secretion  
The other effect for ghrelin may apply on the transplanted dopaminergic neurons is 
increasing the dopaminergic neurons firing rate. A previous study has demonstrated that 
ghrelin propagates the electrical activity of the nigral dopaminergic neurons causing an 
elevation in the tyrosin hydroxylase enzyme expression and an increase in synaptic 
dopamine concentration (Andrews et al., 2009). This study was confirmed later when Shi and 
colleagues showed that ghrelin causes this effect via inhibition of the Kv7/KCNQ/M, voltage-
gated potassium –channels which is mediated by binding to GHSR1a receptor and 
stimulation of the PLC-PKC pathway (Shi et al. 2013). Moreover, apart from its direct action, 
ghrelin can also increase DA secretion in the striatum via the amplification of the nicotine 
inducing dopamine released from the dopaminergic neurons. New evidence has shown that 
ghrelin can exert this role by stimulating the striatum nicotinic acetylcholine receptors 
(nAchR) in the cholinergic neurons which probably express the GHS-R1a receptors (Palotai 
et al. 2013). Such an effect may increase the efficiency of the transplanted dopaminergic 
neurons by providing sufficient synaptic dopamine to stimulate the striatal DA receptors.  
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3.1.5 Long acting ghrelin receptor agonist JMV-2894 
Since ghrelin has short half-life, new GHSR-1a receptor agonist compounds have better 
pharmacokinetic property and lower cost selectivity was produced. JMV-2894 is one of 
these compounds that illustrated high affinity and selectivity for GHSR-1a receptor in vitro 
(Moulin et al. 2007). It also tested in vivo to validate its effectiveness on inducing 
behavioural food intake and releasing growth hormone. The data clarified it has a potent 
effect on increasing growth hormone release with no effect on food intake and this effect 
was abolished in presence of GHSR-1a antagonist (Moulin et al. 2007).  There is no data 
available about the neuroprotection effect of this compound or about its ability to cross 
blood brain barrier.    
3.1.6 Validation of JMV-2894 permeability through the blood brain barrier  
Previously ghrelin showed it can induce neurogenesis in the dentate gyrus of hippocampus 
(Li et al. 2013). In addition, the GHSR-1a receptor has been detected in the dentate gyrus 
(Zigman et al. 2006). Since there is no enough data about the ability of JMV-2894 to cross 
blood brain barrier, this effect of JMV-2894 in the hippocampus was tested in the current 
experiment to validate that JMV-2894 has ability to cross the BBB. In addition, it was used to 
ensure that the used dose of ghrelin in the current experiment has central action.  
3.1.7 Hypothesis, aim and objectives: 
It was clarified in the general introduction (section 1.6.1) that one of the challenges facing 
cell therapy is the low survival rate of the transplanted cells and there are several factors 
that contribute to the death of the transplanted cells like low trophic factor tone, 
inflammatory reaction and oxidative stress. From above, ghrelin showed that it can protect 
the nigral dopaminergic neurons via different mechanisms including anti-apoptotic, anti-
inflammatory and anti-oxidative effects. These observations suggest that ghrelin has the 
potential to support survival of the transplanted dopaminergic neurons. However, the effect 
of ghrelin on the protecting transplanted dopaminergic neurons in the striatum has not been 
explored yet and needs to be investigated. 
I hypothesise that  
•  The above neuroprotective and anti-inflammatory properties of ghrelin may support 
allogenic ventral mesencephalon VM graft survival and efficacy.  
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The aim of this study was 
• Determine whether ghrelin and ghrelin long acting analogue (JMV-2894) 
administration can improve survival and functionality of VM cells transplanted into 
the 6-OHDA lesioned rat model of Parkinson Disease.  
The specific objectives were 
1) confirmation of ghrelin receptor, GSH-R1a, and Ghrelin-O-acyl-transferase (GOAT) 
enzyme expressions in E14 VM and graft 
2) confirmation of GSH-R1a receptor expression in adult rat brain regions 
3) evaluation of therapeutic benefit of administration of acyl ghrelin or JMV-2894 with 
VM graft via  
a. assessment of the motor and behavioural recovery tests and  
b. histological determinations.  
4) Validation of the blood brain barrier permeability of JMV-2894 by determining its 
effect on the hippocampal neurogenesis.   
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 Methodology and Experimental design 
The unilateral nigrostriatal DA neurons of 50 Sprague Dawley rats were lesioned by an 
infusion of 6OHDA into the medial forebrain bundle using stereotaxic surgery (section 2.2.1). 
A successful lesion was evaluated 3 weeks after the surgery using amphetamine-induced 
rotation (rats who rotated 6 or more ipsilateral rotations per minute were expected to have 
more than 90% DA lesion). In the same week, the deficit in motor activity was measured using 
the cylinder, stepping and vibrissae tests. Rats were then allocated into 5 groups (n=10), each 
group has a similar or closer average level of the rotations and the motor tests. A week later, 
four groups underwent allogenic E14 VM cells transplantation and one group remained as a 
lesion control (section 2.2.2). Each group received one of the following treatments: saline; 
acyl ghrelin (10 µg/kg); acyl ghrelin (50 µg/kg) or the ghrelin agonist JMV-2894 (160 µg/kg). 
The treatments were started immediately after the transplantation and continued for 8 
weeks. The recovery of motor tests and amphetamine induced rotations were re-evaluated 
at 3 timepoints after transplantation (4, 6 and 8 weeks). Then, all the rats were perfused and 
the brains were extracted and cut for histological analysis (see Figure 10).  
DAB-IHC were run to label the dopaminergic neurons in the striatum and the SN using TH as 
a marker (section 2.10.1). The survival of the dopaminergic neurons in the graft was 
estimated from direct counting of the TH labelled cells in the transplanted striatum. While 
percentage of the unilateral nigrostriatal dopaminergic lesion was confirmed from counting 
TH+ cells in the right and left side of the SN as defined in sections 2.11.1 and 2.11.2. 
Ghrelin receptor (GSH-R1a) and Ghrelin-O-acyl transferase enzyme (GOAT) expression in E14 
embryonic VM cells of Wistar rats and their co-localisation with markers for ‘stemness’ 
(SOX2), neuronal progenitors (BIII tubulin) and mature dopaminergic neurons (TH) were 
determined using the F-ICC assay and Western blot (sections 2.10.2 and 2.9.3). In addition, 
the presence of GHSR1a in different brain regions of the adult SD rat (striatum, SN, 
hippocampus and frontal cortex) was investigated using Western blot (section 2.9.3). While 
expression of the GHSR1a receptor on the grafted dopaminergic neurons was investigated 
from their co-localisation with TH labelled cells in the graft using double F-IHC (section 
2.10.2).   
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The effect of the peripheral administration of all treatments on hippocampal neurogenesis 
was investigated by labelling the neuronal progenitor with doublecortin (DCX) antibody using 
DAB-IHC. The labelled cells were counted in the sub Granular Zone (SGZ) of the Dentate 
Gyrus (DG) via Olympus B 50 stereology microscope. The granular cell layer (GCL) and (SGZ) 
area in one section of (1:12) series sections were encircled and measured at 4X objective 
then all the labelled DCX cells within this area were counted on 20X objectives. The cell 
density within the counted area was considered to compare between the treatments effect 
on the neurogenesis.  
 
Figure 10 the time line for the in vivo part of the experiment 
 
3.2.1 Treatments 
Acyl Ghrelin (rat) was obtained commercially from TOCRIS bioscience (Cat number 1465) in 
the form of 1 mg reconstituted powder vial and stored at -20 0 C. Each vial was reconstituted 
with 1000 µl of distilled water then diluted with a normal saline to reach the desired 
concentrations and stored in the refrigerator at 4 0 C for a maximum of 4 days. JMV-2894 was 
obtained from Aeterna Zentaris company in the form of 10.25 mg powder which was stored 
at 4 0 C then reconstituted with distilled water and diluted with normal saline to the desired 
concentration and then stored at 4 0 c for 14 days. 
Doses and schedules were determined by previous work reported in the literature. The effect 
of ghrelin at a low dose 10 µg/kg and enhanced dose 50 µg/kg once daily was tested in this 
experiment. Both doses were given intraperitoneally informed by previous work showing that 
ghrelin can protect the nigrostriatal dopaminergic neurons in an MPTP mice model via 
peripheral administration (Moon et al. 2009a). While administration of JMV-2894, a long 
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acting ghrelin agonist (Leyris et al. 2011), at a dose of 160 µg/kg (i.p.) once daily was shown 
to stimulate growth hormone secretion in rodents (Moulin et al. 2007). Treatments were 
started at 16:00 every day. All the rats had restricted access to food for the 3 hours after drug 
administration, aiming to decrease the serum glucose levels which may potentiate the 
protective effect of the ghrelin (Andrews et al. 2009).  
3.2.2 Statistical analysis  
The data from the rats who had unsuccessful cell transplantation were excluded (number of 
excluded rats = 15) therefore the final number of rats in each transplanted group that 
underwent statistical analysis was between 5 to 7 as the following: graft plus saline (n = 5); 
graft plus ghrelin 50 (n=6); graft plus ghrelin 10 (n = 7); graft plus JMV-2894 (n = 7). 
Behavioural data was analysed using IBM SPSS while histological data was analysed using 
Prism 5. Repeated measure analysis ANOVA was performed to analyse behavioural data 
followed by Bonferroni post hoc test; time considered as within subject factor while the 
groups (lesion; graft + saline; graft +ghrelin 10; graft+ ghrelin 50; graft+JMV-2894) considered 
as between subject factor. The histological data was analysed using one-way ANOVA followed 
with Dunnett post-hoc test.  
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 Results  
3.3.1 Ghrelin receptor GHS-R1a and related enzymes investigations  
As expected, F-ICC for the E14 VM cells illustrated the presence of SOX2, BIII tubulin and TH 
labelled cells in the mix of cells used for transplantation. GHSR1a co-localised with SOX2 and 
BIII tubulin demonstrating that it is present in stem cells and differentiated neurons at the 
time of transplantation (Figure 11). GHSR1a was also co-expressed with TH showing that 
transplanted dopaminergic neurons are expressing the receptor (Figure 11). Similarly, GOAT 
was expressed in the differentiated and undifferentiated neurons in addition to co-existence 
with dopaminergic neurons (Figure 11). Western blot results identified the GHSR1a in samples 
extracted from 7 different pieces of E14 VM obtained from 2 different mothers. GHSR1a was 
detected in the SN, striatum, hippocampus and frontal cortex of two adult SD rats (Figure 12). 
Post mortem double F-IHC analysis illustrated the presence of GHSR1a on the TH labelled cells 
in the grafted striatum demonstrating that the target was present throughout the 
transplantation to graft maturity (Figure 13). 
76 
 
 
Figure 11 GHSR1a and GOAT expression on VM cells: F-ICC on E14 VM cells showed expression of 
GHSR (red) with TH, sox2 and BIII tubulin labelled cells (green). Similarly, Ghrelin O Acyl transferase 
enzyme GOAT (red) expressed on TH, SOX2 and BIII tubulin labelled cells (green). 
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Figure 12 Western Blot analysis: WB showed 
detection of GHSR1a protein (size 41Kda) in 
tissue samples dissected VM sections and from 
the following brain regions of adults female SD 
rats: SN; hippocampus; striatum; and frontal 
cortex. The GAPDH protein was used as a 
house-keeping and detected at size 37 Kda. 
 
 
Figure 13 GHSR1a expression in the graft: double F-IHC illustrating co-localisation of the TH and 
GHSR1a markers on the graft. The images were captured using 5x and 63X microscope objectives. 
 
3.3.2 Motor and behavioural results  
In amphetamine-induced rotation task, lesion only control rats showed a sustained rotational 
bias to the ipsilateral side after amphetamine administration. Data analysis showed a 
significant difference between the groups (F (4,29) = 15.4, p<0.001) and significant interaction 
with the time (F (4,29) = 7.8, p< 0.001) (repeated measure analysis, groups = between subject 
factor; time = within subject factor). The group * time analysis showed significant difference 
between the groups on week 4, 6 and 12 (min: week 6: F (4,29) = 16.4, p<0.001). The pairwise 
comparison adjusted with Bonferroni post hoc test at each time point showed that the graft 
plus saline group has a high significant a reduction in number of ipsilateral rotations compared 
to lesion control group (p<0.001); and there was no difference between the transplanted 
groups treated with ghrelin (both doses) or JMV-2894 compared to graft plus saline group 
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(Figure 14). In vibrissae and stepping motor tasks, the data analysis showed there is no 
significant difference between the groups (max: vibrissae test: F (4,29) = 1.8, n.s). In cylinder 
test, the data analysis showed significant difference between the groups (F (4,29) =3.2, p<0.05), 
However, the pairwise comparison adjusted with Bonferroni post hoc test showed that there 
was no significant difference between lesion group and graft plus saline group; and there was 
no difference between the transplanted groups treated with ghrelin (both doses) or JMV-
2894 compared to graft plus saline group. The only difference was between the lesion group 
and graft plus ghrelin 50 µg group (p<0.05), which is not relevant comparison in this 
experiment.   
 
Figure 14 Motor and behavioural outcomes: (figure A) Amphetamine induced rotation test showed 
that the graft plus saline group ameliorated ipsilateral rotations significantly compared to lesion 
control (repeated measure analysis one-way ANOVA, ***P< 0.001).  (figures B, C & D) cylinder, 
vibrissae and stepping test illustrated on effect for the graft plus saline to improve rats’ 
performances compared to lesion group and no effect for the ghrelin either dose and JMV-2894 on 
these tests compared to the graft plus saline control group (repeated measure analysis).   
3.3.3 Dopaminergic neuronal survival in the graft and lesion in the SN: 
The percentage loss of TH+ cells in the right side of the SN compared to the intact side 
exceeded 97% in all groups suggesting nearly a complete degeneration of the endogenous 
nigrostriatal dopaminergic neurons of the right hemisphere. Counting the TH labelled cells in 
the grafted striatum revealed that TH positive graft were present with average size: graft with 
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saline group = 891.4±398; graft with JMV= 597±226; graft with ghrelin 50ug/kg= 375±153; 
graft with ghrelin 10ug/kg= 434±164. There was no effect of drug treatment on graft size, 
reflecting the lack of difference in behavioural outcomes.  
 
Figure 15 TH cell counting in the graft and SN: (A) mean number of the TH in graft showed there was 
no significant difference between number of cells that survived in groups treated with ghrelin  or 
JMV 2894 comparing to saline control group (one-way ANOVA analysis). (B) percentage of the 
degenerated TH labelled cells in the lesioned side compared to the intact side was more than 97% in 
all groups. 
  
3.3.4 Effects of ghrelin and JMV 2894 on the hippocampal neurogenesis 
The DCX labelled cells in the dentate gyrus of the right hemisphere (lesioned or transplanted) 
and the left side (intact) was compared separately in all groups. On the left hemisphere, 
ghrelin showed a tendency to increase DCX density at a dose of 50 µg/kg while the lower dose 
10 µg/kg exerted a significant increase (one-way ANOVA p < 0.05) compared to saline and 
lesion controls. While, JMV-2894 showed it had no effect on the DCX cells in the dentate gyrus 
of the intact side (left side). On the right hemisphere, ghrelin showed a tendency to increase 
the neurogenesis only at the lower dose but without significance. While neither ghrelin 50 
µg/kg nor JMV-2894 showed any effect on the DCX cell density of dentate gyrus (Figure 16). 
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Figure 16: effect of treatments on hippocampal neurogenesis: DCX labelled cell density in the DG of 
the left (intact) and right (lesion & transplanted) hemisphere was compared between the different 
groups. In the intact side, the enhanced dose of ghrelin showed a tendency to increase DCX density 
while the lower does made a significant increase comparing to the control groups (one-way ANOVA, 
P< 0.05) while JMV-2894 didn’t show a difference. In the lesion side, only the lower dose-ghrelin 
group showed a tendency to increase DCX density without significant difference. 
 Discussion 
This data confirmed the presence of GHSR1a and GOAT on the mature and immature E14 VM 
cells and importantly on the dopaminergic precursors. This displayed availability of the basic 
component for transduction of the ghrelin signal into the neurons. GHSR1a is the receptor 
responsible for the biological function of ghrelin and GOAT is the enzyme responsible for 
converting the ghrelin to its active form (acylation of the the third serine residue) (Gutierrez 
et al. 2008). Furthermore, co-expression of GHSR1a with TH in the graft confirmed 
maintaining the receptor after 8 weeks of transplantation in the host striatum. This would 
suggest presence of appropriate machinery that ghrelin maintained functional activity on the 
transplanted cells throughout the experiment. The current data consolidate previous reports 
that showed expression of GHSR1a in different brain regions SN, hippocampus, cortex 
(Zigman et al. 2006) and striatum (Kern et al. 2012). 
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Amelioration of rotation deficit in the amphetamine test implied that the transplanted 
allogeneic VM cells were functional in all transplanted groups. Amphetamine administration 
induces release of dopamine into the synapse leading to a difference in dopamine levels 
between the intact striatum and lesion side and creating asymmetrical rotations (Hefti et al. 
1980; Torres & Dunnett 2007). The grafts were capable of compensating for the 
amphetamine-induced ipsilateral dopamine drive indicating release of dopamine in the lesion 
side. However, these grafts were inadequate to improve motor performances in stepping and 
whisker tests and only showed a tendency to improve the response in the cylinder test. This 
is likely to be due to the graft size being relatively small. Previous studies illustrated that there 
may be a threshold level required for the size of the graft needed to improve the motor 
deficits (Hagell & Brundin 2001). Nevertheless, this small graft would give ground for better 
evaluation of whether ghrelin and JMV-2894 have the potential to increase graft size. 
Despite the presence of the appropriate machinery, the behavioural results showed no 
additional improvement in functional benefit of the graft plus treatments with ghrelin at 
either dose or with JMV-2894. The behavioural data reflected the histological analysis of the 
grafts which illustrated no significant difference in the number of surviving TH+ cells in all 
groups. These observations lead to the conclusion that peripheral administration of ghrelin 
and JMV-2894 at the doses used does not have a supportive effect on the survival and efficacy 
of transplanted VM cells. VM dopaminergic neurons are precursors for the developed 
endogenous nigrostriatal dopaminergic neurons. Ghrelin in previous experiments was 
protective for these neurons and exerted its protective effect through GHSR1a receptors 
which was confirmed by either knocking out the receptor (Andrews et al. 2009) or blocking it 
with D-Lys-3- GHRP-6 (Moon et al. 2009a). This experiment is the first to explore the potential 
protective effect of ghrelin on E14 VM cells transplanted ectopically in the striatum which 
could involve factors which halt the protective effect. Moreover, ghrelin has a short half-life, 
9-11 min, and was administered as a single daily dose. This was consistent with previous work 
in a mouse model of PD showing that single daily dosing was effective in protecting 
dopaminergic neurons from MPTP toxin challenge (Moon et al. 2009). It is reasonable to think 
that this dose frequency, even if it was protective for the nigral dopaminergic neurons, may 
not be capable of supporting the survival of dopaminergic neurons in an ectopic environment. 
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Alternatively, it could be that this would be sufficient in the mouse but it may not sufficient 
for rat model to achieve the require action. 
JMV-2894 is a long acting GHSR1a agonist and didn’t show any preferential effect on 
transplanted cell survival or efficacy. JMV-2894 is a ghrelin receptor agonist product and there 
is no information about its ability to cross the BBB. However, Moullin and colleagues (Moulin 
et al. 2007) demonstrated that JMV-2894 (compound number 41 in the paper) was not 
capable of increasing food intake in rats through peripheral administration, although it was 
able to increase growth hormone levels. One possible explanation is that it may have poor 
bioavailability at receptor sites in the pituitary gland to stimulate food intake while it 
provoked growth hormone levels peripherally via vagus nerve by increasing GHRH and 
neuropeptide Y release. It has been confirmed that ghrelin can stimulate GHRH release 
peripherally via the vagus nerve and centrally at the hypothalamus level (Wagner et al. 2009).  
To determine whether there was a functional effect of either, and to confirm that they can 
passed the BBB, I explored the effect of the ghrelin and ghrelin mimetic on inducing the 
hippocampal neurogenesis. Previous work indicated that ghrelin has a significant effect on 
increasing the number of DCX labelled neuroblast cells in dentate gyrus from peripheral 
administration of 80 µg/kg once daily for 8 days in SD rats (Li et al. 2013). My data confirmed 
this positive effect of ghrelin in both left and right hippocampi while JMV-2894 had no effect 
on the DCX cells compared to the control groups in both sides. This support to the idea that 
JMV-2894 was not capable to cross the BBB while ghrelin was available at the hippocampus 
and induced the neurogenic effect in both low and high doses over 8 weeks.  
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 Conclusion   
Despite the accumulating evidence that supports the protective effect of ghrelin on the 
dopaminergic neurons in different PD models, this study clarified that peripheral 
administration of ghrelin and JMV-2894 were not able to support the survival or the efficacy 
of VM dopaminergic neuron transplantation. The results confirmed expression of the ghrelin 
receptor GHSR1a and GOAT enzyme on the VM cells at the point of transplantation in addition 
to maintaining receptors expression on grafted dopaminergic neurons through maturation 
and innervation of the striatum. However, inadequate dose or administration frequency of 
ghrelin and the possibility of poor penetration of JMV-2894 through the BBB were suggested 
to be the reason for halting their effect in supporting the graft. To this end, the next chapter 
will explore another potential neuro-protective agent that may support graft survival and 
efficacy from peripheral administration.  
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4 Chapter 4: Impact of glucagon Like peptide-1 
agonists on support survival and efficacy of allogenic 
ventral mesencephalon transplantation in rats’ 
model of Parkinson Disease  
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 Introduction  
Effect of glucagon like peptide-1 receptor GLP-1R agonists on the neurodegenerative disease 
started from evidence showed that Type 2 diabetes mellitus T2DM is one of many etiological 
factors in Alzheimer Disease (AD) (Luchsinger et al. 2007; Ristow 2004; Strachan 2005). So, 
some hypotheses suggest that brain insulin resistance contributes to the pathology of the 
disease (Talbot & Wang 2014). For this reason, some trials have investigated normalisation of 
insulin signalling in the brain using anti-diabetic drugs, including GLP-1 agonists, in an AD 
model. GLP-1 can cross the blood brain barrier and its receptors are expressed in many 
regions of the brain, however it has a short half-life and is rapidly degraded by the DDP-4 
enzyme which limits its exploration in AD models. Instead exendin-4 and liraglutide, GLP-1 
analogues, dominated the studies in the AD and other neurodegenerative diseases because 
they mediate the same GLP-1 physiological effect when bound to the GLP-1 receptor and they 
are relatively stable in blood circulation with the capability of crossing the blood brain barrier 
(Kastin & Akerstrom 2003; Hunter & Hölscher 2012). In an APP/PS1 mouse model of AD, 
peripheral administration of liraglutide reverses the main neurodegenerative signs of the AD 
model including preventing synapse loss in the hippocampus, reducing β-amyloid plaque 
count (pathological mark of the disease) in the cortex, reducing microglia inflammation, 
increasing neurogenesis in the dentate gyrus and preventing memory impairment in object 
recognition and water maze tasks (McClean et al. 2011). The neuroprotection effect of GLP-1 
agonists in AD models motivated exploration of their effects on other neurodegenerative 
disease including multiple sclerosis, stroke, amyotrophic lateral sclerosis, peripheral 
neuropathy (reviewed in (Hölscher 2014)) and importantly in models of PD (next section).  
4.1.1 Exendin-4 effects on models of Parkinson’s disease 
Several studies have tried to characterise the protective effect of exenidin-4 on the 
dopaminergic neurons and models of PD. Li and colleagues elucidated that exendin-4 has a 
protective effect on VM dopaminergic neurons in cell culture. The cells were exposed to 6-
OHDA which caused a significant reduction in number of TH+ cells by 30%, while the addition 
of exendin-4 completely preserved the cells. Furthermore, it caused an elevation in the yield 
of TH+ cells by 60% in the absence of 6-OHDA. The same group explored the mechanisms by 
which exendin-4 protected the cells in the SH-SY5Y cell line and they found that exendin-4 
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inhibits levels of pro-apoptotic proteins, caspase-3 and BAX and elevates levels of anti-
apoptotic proteins Bcl2 after exposure to 6-OHDA (Li et al. 2009).  
In the MPTP treated mouse model of PD, peripheral administration of exendin-4 caused a 
significant reduction in the loss of SN neurons and striatal fibres (Kim et al. 2009b; Li et al. 
2009). The same study showed a parallel reversal of motor deficits in rotarod, pole test, beam 
walk, and open-field activity tests (Li et al. 2009). Exendin-4 is also involved in reduction of 
microgliosis in the SN and the striatum of the mice after MPTP challenge. In addition, it caused 
a reduction of the matrix metalloproteinase-3 (MMP-3) expression on the SN dopaminergic 
neurons, which is involved in microglial activation, and reduced levels of microglial derived 
pro-inflammatory mediators (TNF-α and IL-1β) after MPTP exposure (Kim et al. 2009b). 
Similarly in 6-OHDA and LPS rat models of PD, exendin-4 protected  nigral dopaminergic 
neurons, increased levels of striatal dopamine and reversed the deficit in the behavioural test 
(apomorphine-induced rotation test) (Harkavyi et al. 2008). 
Exendin-4 efficacy on the progression PD was assessed in a single blind clinical trial of 45 
patients. Twice daily Exenatide (exendin-4) for 12 months improved scores in the Movement 
Disorders Society Unified Parkinson’s Rating Scale (MDS-UPDRS) by 2.7 points in the treated 
group while the control group declined by 2.2 points (Iciar Aviles-Olmos et al. 2013). Those 
patients had been followed up in an open labelled randomised control trial after 12 months 
of cessation of the exenatide treatment. The results showed that the patients who were 
previously treated with exenatide maintained improved MDS-UPDRS scores compared to the 
control group by 5.6 points (Aviles-Olmos et al. 2014). These data illustrate a potential 
advantage of using exenatide in modulating PD progression which may be mediated through 
neuroprotective effects on the nigral dopaminergic neurons.  
4.1.2 GLP-1R agonists effects on other neurodegenerative disease models 
From cell culture models, cumulative evidence has demonstrated that GLP-1 agonists have 
neuroprotective properties on different types of neurons. Perry and colleagues explored the 
effect of GLP-1 and exendin-4 on pheochromocytoma (PC12) cell line (mostly used for 
studying neuronal differentiation) which expressed GLP1 receptors. Both treatments induced 
neurite outgrowth similar to the effect of nerve growth factor NGF. Exendin-4 potentiated 
the effect of NGF on inducing neuronal differentiation, in addition it inhibited neuronal 
degeneration in NGF deprived media (Perry et al. 2002). Exendin-4 may also be able to protect 
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cultured hippocampal neurons against cell death when exposed to beta amyloid peptide 
(neurotoxic molecule played a role in pathogenesis of AD) and oxidative insults (Perry et al. 
2003). In human neuroblastoma cell line SH-SY5Y, Sharma and colleagues found that 
liraglutide can improve cell viability and reduce cytotoxicity and apoptosis when stressed with 
methyl glyoxal (stressor attenuated energy metabolism in the cells). They also reported an 
increase in the expression of anti-apoptotic protein Mcl-1 and reduce the pro-apoptotic 
proteins Bax and Bik (Sharma et al. 2014).  
Other studies suggested that GLP-1 agonists could have modulatory effects on 
neuroinflammation. In cell culture, Iwai et al. identified the presence of GLP-1 receptor on 
microglia and astrocytes and they reported that GLP-1 prevented release of IL-1β (pro-
inflammatory cytokines) from the microglia after lipopolysaccharide LPS (endotoxin) 
induction (Iwai et al. 2006). In APP/PS mice (AD model), liraglutide reduced levels of activated 
microglia associated with amyloid-β plaque pathology of the disease (McClean et al. 2011; 
Long-Smith et al. 2013). Other studies exposed mouse brain to x- ray irradiation to induce 
chronic inflammation characterised by increasing levels of activated microglia and 
concentration of pro-inflammatory cytokines IL-6 and IL-2 in the dentate gyrus and cortex 
while pre-treatment with liraglutide illustrated high significance on reducing the 
inflammation (Parthsarathy & Hölscher 2013).  
4.1.3 Glucagon like peptide-1 
Glucagon like peptide-1 (GLP-1)  is an incretin hormone secreted from L-cells in the distal 
ileum (Eissele et al. 1992). It is responsible for the augmentation of insulin secretion under 
high glucose conditions (Kreymann et al. 1987; Gromada et al. 1998). It also induces B cell 
proliferation and increase resistance to apoptosis (Drucker & Nauck 2006; Li et al. 2003). It 
has a role in maintaining a variety of haemostatic functions like feeding behaviour, gastric 
motility, glucose regulation and cardio-vascular function via its receptors in the peripheral 
and central nervous system (Baggio & Drucker 2007). Human plasma levels of GLP-1 are 5 to 
10 pmol/L in fasting conditions which increase 2 to 3 fold after meals (Orskov et al. 1994). 
This level is affected by food intake which causes an increase in GLP-1 level after 10-15 min 
of the meal followed by a second increase after 30-60 min (Herrmann et al. 1995). GLP-1 levels 
are increased by leptin release (Anini & Brubaker 2003) while its release is decreased by 
insulin, insulin resistance, somatostatin and neuropeptide galanin (Baggio & Drucker 2007). 
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Exercise is another factor which has been reported to have effects on GLP-1 levels as acute to 
moderate exercise boosts GLP-1 secretion after food intake (Martins et al. 2007; Ueda et al. 
2009; Martins et al. 2010). GLP-1 is rapidly deactivated in the circulation by ubiquitous 
proteolytic enzyme dipeptidyl peptidase-4 (DDP-4) to its N- terminal metabolite(Deacon et al. 
1995) with a short half-life about 5-6 min (Ørskov et al. 1993) while the intact GLP-1 is cleared 
via kidney with half-life of 2 minutes (Ruiz-Grande et al. 1993). 
The GLP-1 receptor is related to the B-family of 7- transmembrane spanning, heterotrimeric 
G- protein coupled receptors GPCR (Mayo et al. 2003). Binding of the ligand to the GPCR 
causes dissociation the heterotrimeric G-protein to Gα and Gβλ  subunits which each may link 
to effector molecules (Wess 1997). GLP-1 receptor is similar to other GPCR, the binding of the 
ligand to the receptor leads to activate the Gα subunit. The GLP-1R ligands mostly activate 
Gαs which is associated with activation of adenylate cyclase, however it is also able to activate 
Gαq, associated with activation phospholipase C, and Gαi, associated with inhibition to the 
cAMP (Fletcher et al. 2016). These causes that GLP-1 agonists have more than one 
downstream signalling pathways. Different agents of GLP-1R agonists have different bias in 
selecting the signalling pathway which results in some differences in clinical effects of the 
GLP-1 agonists (Pabreja et al. 2014).  Extended exposure of the GLP-1 receptor to the ligand 
is terminated by a regulatory mechanism via two methods: 1. Desensitisation, which involves 
direct cessation of the signalling cascade by uncoupling with G protein or indirectly via 
phosphorylation of one type of the receptor and desensitise other type; 2. Internalisation, 
which involves endocytosis of the receptor-ligand complex, followed by recycling the receptor 
to the cell surface (Fletcher et al. 2016). GLP-1 receptor is located at several tissues including 
pancreatic cells, lung, heart, kidney, stomach, intestine, pituitary, skin and ganglion neurons 
of the vagus nerve (reviewed in (Baggio & Drucker 2007). It is also located in different CNS 
sites like the hippocampus, cerebellum, neocortex (Hamilton & Hölscher 2009) and 
hypothalamus (Acuna-Goycolea & van den Pol 2004). Moreover, Yazhou and colleagues 
identified expression and functionality of GLP1 receptors on the embryonic ventral 
mesencephalon and cerebrocortical cells (Li et al. 2009).  
4.1.4 Exendin-4 (exenatide): 
Exendin-4 is a GLP-1 receptor agonist consisting of 39 amino acids terminated with an amino 
group histidine residue, isolated for the first time  from Glia lizard venom Heloderma 
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suspectum in 1992 (Eng et al. 1992). The amino acid sequence of exendin-4 is identical to 53% 
of the amino acid sequence of endogenous GLP1 (Blonde & Montanya 2012). The presence 
of a glycine at position 2 makes it resistant to degradation by the DDP-4 enzyme and circulates 
in blood vessels for a longer time compared to the endogenous GLP1 with a half-life range 
between 60-90 minutes (Kolterman et al. 2005) and its biological action on lowering glucose 
levels extends for 4 hrs after a single dose (Young et al. 1999). The downstream signalling of 
exendin-4 results from activation of Gαi and Gαs protein subtype in the GLP-1 receptor with 
bias toward the inhibitory subtype Gαi (Weston et al. 2014), while the receptor-ligand 
complex termination is regulated via internalisation (Gao & Jusko 2012; Gao & Jusko 2011). 
Clearance of exendin-4 from the body is achieved by degradation to peptide fragments in 
kidney membranes and eliminated either intact or as fragmented peptide via glomerular 
filtration and tubular secretion (Copley et al. 2006). Some of these fragmented peptides have 
been reported to have low to moderate antagonism potency on GLP1 receptors like exenatide 
(15-39) and exenatide (16-39) (Copley et al. 2006).  
Exendin-4 was registered as a treatment for T2DM patients by the Food and Drug 
administration in the United States in 2005. Clinical trials revealed that exendin-4 is effective 
in the treatment of T2DM patients whose glucose levels are not controlled by metformin 
and/or sulfonylurea treatments. Twice daily sub-cutaneous injection of exendin-4 is effective 
in controlling fast and postprandial glucose levels, reducing HbA1c levels and improving B cells 
function markers (Fineman et al. 2003; DeFronzo et al. 2005). The most common side effects 
reported in clinical trials were nausea, usually happening in the first week of the therapy, and 
mild to moderate hypoglycaemia when its used at therapeutic doses higher than 10 µg twice 
daily (Kendall et al. 2005; Buse et al. 2004).  
4.1.5 Liraglutide: 
Liraglutide is another GLP1 agonist anti-diabetic drug that has been approved for clinical use. 
It has a longer half-life (12.53hr) than exendin-4 and longer control on glycaemia which can 
be maintained by a single daily dose (Campbell 2011; Han et al. 2013). Liraglutide has 97%  
amino acid sequence homology with GLP-1 but it differs in that it includes a palmitic acid 
moiety linked to the lysine at position 26 via glutamic acid spacer (Madsen et al. 2007) (Figure 
17). It has a delayed absorption after subcutaneous injection and lower affinity for 
degradation by PPD4 enzyme which leads to a prolonged half-life and efficacy (Malm-erjefält 
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et al. 2010; Blonde & Montanya 2012). Dissimilar to exendin-4, the downstream signalling of 
liraglutide results from activation of both Gαi and Gαs subtypes without bias (Weston et al. 
2014) and it has 10 times higher affinity to undergo receptor complex internalisation (Roed 
et al. 2014) which may be the reasons for some differences between their effects.  
Liraglutide has the same action as exendin-4 on alleviating hyperglycaemia via insulintropic 
effects and suppression of glucagon release (Blonde & Montanya 2012). However, liraglutide 
showed it has a more significant effect on reducing fast plasma glucose levels and HbA1c than 
exendin-4 while exendin-4 it is more effective in reducing postprandial glucose level (Buse et 
al. 2009). The main side effects of liraglutide are mild nausea, vomiting and diarrhoea with a 
lower incidence of hypoglycaemia compared to exendin-4 (Campbell 2011).  
 
Figure 17 amino acid sequences of GLP-1, exendin-4 and liraglutide. The highlighted amino acid 
block represents the change from GLP-1 structure (modified from (Pabreja et al. 2014)). 
 
4.1.6 Aims and objectives of this chapter  
Exendin-4 has shown that it can protect the dopaminergic neurons in cell culture and animal 
models. In addition, another GLP-1 agonist, liraglutide demonstrated advantages on 
protecting the neurons and reducing brain inflammation in different models. This raised a 
question about the capablity of GLP-1 agonists on supporting survival and efficacy of cell 
therapy in PD which illustrated incosistencey in efficacy and low rate of cell survival in animal 
models and clinical trials. Specifically, exendin-4 and liraglutide hold the advantages of 
crossing the blood brain barrier and their safety is already approved for clinical use which 
would make them ideal agents for supporting cell transplantation. It was hypothesised that 
both exendin-4 and liraglutide can support survival and efficacy of allogenic VM cell 
transplantation in a 6-OHDA rat model. This needs to be tested in a clinically relevant animal 
model by exposure to a chronic anti-PD medication, like L-dopa, before and after cell 
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transplantation and using allograft transplantation to add a level of immunolgical reaction. So 
the aims of this chapter are to determine whether: 
1. GLP-1 agonists (exendin-4 and liaglutide) can be effective in improving the survival and 
efficacy of transplanted VM dopaminergic neurons in a 6-OHDA parkinsonian rat 
model.  
2. L-dopa has additional impact on the neuroprotective effect of the GLP-1 agonists 
(exendin-4 and liraglutide) on the graft. 
The following objectives were followed to test the hypothesis of that exendin-4 and liraglutide 
are able to support survival and efficacy of allogneic VM graft in presence and abscnese of L-
dopa:  
1. Detection expression of GLP-1 receptors on the transplanted cells at the 
transplantation time and on the graft during the post-mortem analysis. 
2. Assessment of exendin-4 and liraglutide influence on the motor and behavioural 
recovery in the presence and absence of L-dopa treatment in 6-OHDA lesioned rats.  
3. Determination the effect exendin-4 and liraglutide on post-mortem histological 
measurments of the graft in presence of absence of L-dopa.   
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 Methodology and Experimental design: 
 
 
Figure 18 the experiment groups and time line  
Nigrostriatal dopaminergic neurons were degenerated unilaterally by infusion of 6OHDA into 
the right medial forebrain bundle of 70 female Sprague Dawley rats (section 2.2.1). The 
lesions were assessed 2 weeks later by performance in the amphetamine-induced rotation 
(ipsilateral rotations ≥ 6 times/ min, was considered to be successful, ie a loss of more than 
90% of the dopaminergic neurons). 9 rats were excluded due to incomplete lesion and 5 rats 
excluded due to unsuccessful transplantation because of technical issue (number of rat per 
group in figure 18). The rats were then allocated into 7 groups; one group was the lesion 
control and 6 groups were transplanted with Wister E14 VM cells into the striatum of the right 
hemisphere (section 2.2.2). The grafted groups were subdivided into two sets each containing 
3 groups: the first set received L-dopa and pair of them treated with either exendin-4 or 
liraglutide; the second set was without L-dopa and received either exendin-4, liraglutide or 
saline (see Figure 18). L-dopa treatment was started on week 3 after the lesion surgery and 
continued for 5 weeks before transplantation surgery. The amphetamine-induced rotations 
and simple hand motor tests were carried out before starting the L-dopa treatment, one week 
before cell transplantation and three times after the transplantation. While the Abnormal 
Involuntary Movements (AIMs) and L-dopa-induced rotations tests were recorded once 
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weekly before and after cell transplantation (section 2.4). L-dopa and GLP-1 agonists were 
stopped 2 days before each behavioural and motor test to wash out any acute effect. Blood 
sampling and perfusion were carried out at week 13 post transplantation. The rats were on 
food restriction for 9 hrs before blood sample collections and they received their appropriate 
treatment 80 min before blood sampling. This was followed by perfusion of the rats and 
collection of the brains for histological analysis. The cellular and histological determinations 
included: IHC to detect TH, CD11b, CD45, 5HT and IRS-1 pS1011 markers (section 2.10.1); F-IHC 
to detect striatal blood vessels using the marker tomato lectin (section 2.10.2); double F-IHC 
to detect co-localisation of TH with Girk2 and TH with GLP1R (section 2.10.2); double F-ICC to 
detect co-localisation of GLP1R with TH, GLP1R with SOX2 and GLP1R with BIII tubulin (section 
2.10.3); Oil Red-O staining to stain fat in the liver (section 2.10.5); Eosin and Haematoxylin to 
stain liver sections (section 2.10.6). Western blot analysis was used to determine GLP1R in 
the substantia nigra, striatum, hippocampus, frontal cortex (section 2.9.3). Plasma analysis 
was used to determine insulin, glucose and GLP1 levels (section 2.8).  
4.2.1 Treatments 
L-dopa was combined with benserazide (section 2.4.1) at a dose of 12 mg/kg (s.c.). The L-
dopa/ benseraside treatment commenced 3 weeks after lesion surgery for 5 weeks before 
transplantation surgery with a single daily dose for the first week then with a single dose each 
alternative day. L-dopa treatment continued after transplantation surgery until the end of the 
experiment on week 12 using the same dose each alternate day. This dose combination was 
used and obtimised previously in our lab (Breger 2013).   
Exendin-4 was given (i.p.) at a dose of 0.5 µg/ kg twice daily. This was consistent with a 
previous study illustrating that 0.5 µg/kg tiwce daily of exendin-4 was effective on protecting 
the dopaminergic neurons in a 6-OHDA rat model (Harkavyi et al. 2008). The treatments 
started immediately after transplatation of the VM cells in the depleted striatum and 
continued until week 12 post transplantation. Exendin-4 (1 mg vial, Tocris Bioscience) was 
dissolved in 1 ml of 0.9% sterlized normal saline then aliquoted into 30 aliquots and stored on 
-20 0C for a maximum of 30 days. 
Liraglutide was administered to the rats (i.p.) at a dose of 100ug/kg. This dose was selected 
based on a previous study in an AD rat model (McClean et al. 2010). Pre-filled pen liraglutide 
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(Victoza(R)) at concentration 6 mg/ml then 83 µl of the drug solution withdrawn from the pen 
and diluted with 5 ml of 0.9% saline to get a concentration 100ug/ml prior to injection.    
4.2.2 Statistical analysis  
The data analysis was performed using IBM SPSS while Prism 5 software was used to create 
the figures. For the assessment of graft effect compare to lesion control in behavioural tests, 
the graft plus saline group and lesion only group were analysed separately. 
Repeated measure ANOVA (time was the within subject factor; treatment group was the 
between subject factor) was performed for the behavioural data. Two-way ANOVA was 
applied for the histological and blood analysis data (between subject factor include L-dopa, 
exendin-4 and liraglutide). Bonferroni’s post hoc test was used for pairwise comparisons and 
statistical adjustment. Two tailed t-test was used to compare between lesion control and graft 
plus exendin-4 group in oil liver test.  
All the data sets have been checked for the normality distribution test. In amphetamine 
rotation test, (graft+ exendin-4) and (graft+ L-dopa+ liraglutide) groups had significant 
abnormality distribution (Shapiro-Wilk test, p<0.001). Two outliers, one in each group, were 
detected and excluded from the analysis. The outlier was considered if it has a value lower or 
higher than the double standard deviation distance from the data mean.    
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 Results  
4.3.1 GLP1 receptor expression in the VM cells and the graft:   
Investigation of the GLP1 receptor on E14 VM cell populations identified its co-expression on 
the neurons marked with BIII tubulin and importantly on the dopaminergic neurons (TH+). 
The GLP-1R was not present on immature stem cells marked as SOX2 expressing cells (Figure 
19). This demonstrates that it appears in the relevant grafted population of cells at maturity. 
Western blot analysis detected the GLP1 receptor proteins in the E14 VM sections obtained 
from 7 embryos collected from two Wistar rats which is representative of the tissue that was 
transplanted. The post-mortem analysis of the brains of transplanted rats, showed co-
expression of the GLP-1 receptor on the grafted dopaminergic neurons TH+ after 13 weeks of 
the transplantation (Figure 21). In adult SD rats, the western blot analysis identified the GLP-
1 receptor in different brain regions including striatum, substantia nigra, hippocampus and 
frontal cortex which are representative of the host brain (Figure 20).   
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Figure 19 GLP1R expression in E14 VM cells: F-ICC showed expression of GLP1R (red labelled cells) 
with BIII tubulin and TH cells but it is not present with SOX2 (green labelled cells). 
 
 
 
Figure 20 Western Blot of GLP1R protein (size 53 kDa) in E14 VM sections of Wistar rats. It was 
also detected in different brain regions Substantia nigra (SN), striatum (str), frontal cortex (ctx) 
and hippocampus (Hipp). GAPDH was used as a house keeper, size 37 kDa.  
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Figure 21 GLP1R expression in the grafted neurons: double F-IHC showed co-localisation of the TH 
cells (green) and GLP1R (red) in the striatum 13 weeks of transplantation (The arrow points to the 
co-localised cells). 
4.3.2 Behavioural assessment of the graft 
The control graft (saline group) showed a highly significant overall effect on reducing the 
number of amphetamine rotations toward the ipsilateral side compared to the lesion control 
group (repeated measure ANOVA, group was between subject factor, time was within subject 
factor) (F (1,16) = 12.6, **p< 0.01). The interaction with time showed the significant 
amelioration was on week 4, 8, and 12 (Min: week4 F (1,16) = 10.5, P< 0.01). The graft also had 
an overall significant effect on amelioration of the motor deficit in the cylinder test (repeated 
measure ANOVA, group was between subject factor, time was within subject factor) (F (1,16) = 
12.4, **p< 0.01). The interaction with the time showed the graft group has significant effect 
on week 12 (F (1,16) = 19, P<0.001). It had no overall effect in the other sensorimotor tests, 
stepping and vibrissae (max: vibrissae: F (1,16) = 3, n.s). 
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Figure 22 graft effect on the motor and behavioural tests: (A) the graft plus saline had overall 
significant effect on ameliorating behavioural deficits in amphetamine rotation test compared to 
lesion group (***P< 0.001), (B) the graft had overall significant effect on cylinder test ( ***p<0.001) 
but it had no effect on the stepping (C) and vibrissae (D) tests. 
 
4.3.3 GLP-1 agonist Effect on behavioural results of the grafted groups in 
presence and absence of L-dopa treatment  
Amphetamine rotation test: over all there is significant effect of Exendin-4 and liraglutide on 
amelioration of amphetamine rotations while L-dopa has no significant effect (F (1,37) min 
exendin-4 = 4.1, *P<0.05) (repeated measure ANOVA, between subject factors include: 
exendin-4, liraglutide and L-dopa; within subject factor include the time). There is a significant 
interaction between L-dopa treatment and liraglutide (L-dopa x liraglutide, F (1,37) = 6, 
*p<0.05); liraglutide illustrated significant effect on reducing amphetamine rotations in 
presence of L-dopa treatment (F (1,37) =14.3, ***p< 0.001) but it has no effect in saline treated 
group (F (1,37) = 1.3, n.s). There is also    a significant interaction between exendin-4, L-dopa and 
the time (L-dopa x exendin-4 x time, F =5, p<0.01); exendin-4 ameliorate rotations significantly 
in saline groups on weeks 4, 8 and 12 (min: week 12; F (1,37)  = 8, **p<0.01) but it has no effect 
in presence of L-dopa (max: F (1, 37) = 1.3, n,s).  
Vibrissae test: only liraglutide showed an overall significant effect on improving rats’ 
performance in vibrissae test (F (1,37) = 6.4, p<0.05) and there is no effect for exendin-4 and L-
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dopa (max: exendin-4: F (1,37) = 2, n.s) (repeated measure ANOVA, between subject factors 
include: exendin-4, liraglutide and L-dopa; within subject factor include the time). The 
interaction with the time shows that liraglutide produced the significant effect on week 4 in 
presence of L-dopa (F (1,37) = 6.3, p<0.05) and on week 8 in saline group (F (1,37) = 4.3 p<0.05). 
Stepping test: overall only liraglutide significantly improved rats’ performance in stepping test 
(F (1,37) = 8.4, p<0.01). exendin-4 illustrated tendency to improve but didn’t reach significant 
difference and L-dopa has no effect (exendin-4: F (1,37) = 3.7, p = 0.06) (repeated measure 
ANOVA, between subject factors include: exendin-4, liraglutide and L-dopa; within subject 
factor include the time). The interaction between liraglutide, L-dopa and time shows that 
liraglutide has the significance effect on week 12 in L-dopa group.  
Cylinder test: overall, exendin-4 has significant effect on improving rats’ performance in 
cylinder test (F (1,35) = 4.7, p<0.05); L-dopa illustrated overall significant effect on reducing rats’ 
performance (L-dopa, F (1,35) = 10, P< 0.01); liraglutide has no effect (F (1,35) = 1.7, n.s) (repeated 
measure ANOVA, between subject factors include: exendin-4, liraglutide and L-dopa; within 
subject factor include the time). There is a significant interaction between L-dopa and 
exendin-4 (F (1,35) = 4.2, p<0.05); exendin-4 has significant effect in saline treated group on 
week 12 (F (1,35) = 7.7, p<0.01) but it has no effect in L-dopa treated group (F (1,35) = 0.6, n.s); L-
dopa has significant effect on reducing rats’ performance only in exendin-4 treated group (F 
(1,36) =12.5, p<0.001) and no effect in non-exendin-4 group (F (1, 36) = 2.6, n.s). 
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Figure 23 behavioural results: (A) exendin-4 ameliorate rotations in saline treated group only on 
week 4, 8 and 12 (**P<0.01), liraglutide ameliorate rotations in L-dopa treated group only 
(**P<0.01). (B) exendin-4 improved rats’ performance in stepping test only in saline treated group 
(**p<0.01). (C) liraglutide has overall effect on improving rats’ performance in stepping test (C) and 
vibrissae test (D) (*p< 0.05, **p<0.01)  
4.3.4 L-dopa induced abnormal involuntary movements (AIMs) and rotations: 
Total AIMs score, pre-transplantation, increased gradually over 5 weeks to achieve the higher 
point prior to transplantation. Then, post-transplantation, AIMs declined over 10 weeks to 
reach the lower point on week 10 followed by a brief increase on week 11. The time factor 
has significant effect on the AIMs score (F (12,240) = 22.6, p<0.001). The pairwise comparison 
adjusted with Bonferroni post hoc test showed that the reduction in AIMs score was 
significant since week 4 compared to base line time point week 1 pre-transplantation 
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(**p<0.01, ***p<0.001). No significant difference was recorded between GLP-1 agonist 
treated groups and graft control group (repeated measure ANOVA, time = within subject 
factor; groups= between subject factor).  
 L-dopa induced rotations towards the contralateral side, pre-transplantation increased 
gradually from the initiation of L-dopa treatment to reach a higher level prior to 
transplantation in all groups. Then, post-transplantation, the level of the contralateral 
rotations was ameliorated throughout the experimental time to reach the lower level at week 
11. Data analysis showed a significant effect of the time of number of rotations (F (12,240) = 8.6, 
p<0.001). Pairwise comparison adjusted with Bonferroni post hoc test showed that the slope 
of the reduction reached a significant difference on weeks 10 and 11 compared to the 
baseline time point week 1 pre-transplantation (*p<0.05). The data demonstrated that there 
was no significant difference between the groups treated with either exendin-4 or liraglutide 
compared with the graft control group (repeated measure ANOVA, n.s.).  
 
Figure 24 L-dopa induced rotation and Abnormal Involuntary Movements AIMs: (A) L-dopa induced 
contralateral rotations reduced gradually post-grafting reaching a significant difference on weeks 10 
and 11 compared to week -1 (repeated measure analysis, *p<0.05). (B) total AIMs score reduced 
gradually post grafting with significant difference since week 4 compared to week -1 (pre-graft) 
(repeated measure analysis, **p<0.01, ***p<0.001). There were no differences between the graft 
control and treated groups with either exendin-4 or liraglutide in both L-dopa induced rotations (A) 
and AIMs score (B) (repeated measure ANOVA). 
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4.3.5 Dopaminergic neurons loss in the substantia nigra  
The TH+ cells counted in the right (lesioned) and left (intact) sides of the substantia nigra 
demonstrated that the percentage of TH+ loss in the lesioned side compared to the intact 
side was higher than 97% in all groups. This confirmed that the recovery in behavioural tests 
resulted from the transplanted cells and not from endogenous nigral dopaminergic neurons.   
 
Figure 25 TH+ count in the substantia nigral: the percentage of the TH loss in the lesioned side (right 
side) of the SN was more than 97% compared to the intact side in all groups. 
 
4.3.6 Graft TH+ count, volume and density  
TH+ count: overall, there is no significant effect of L-dopa, exendin-4 and liraglutide on 
increase total TH+ count with a tendency of exendin-4 to increase the total number (F (1,39) 
max exendin-4 = 3.55, p = 0.06, n.s) (two-way ANOVA, between subject factor include: L-dopa, 
exendin-4 and liraglutide). There is a significant interaction between L-dopa and exendin-4 (L-
dopa x exendin-4, F (1,39) = 6.64, p<0.05). Exendin-4 increase TH+ count significantly in graft 
plus saline group (F (1,39) = 11.7, p<0.001) but it has no effect in the presence of L-dopa (F 
(1,39) = 2.8, n.s).  
TH+ volume: overall there is no effect no effect for L-dopa, exendin-4, and liraglutide (F (1,39) 
max liraglutide = 3.5, n.s) (two-way ANOVA, between subject factor include: L-dopa, exendin-4 
and liraglutide). However, there is tendency to improve the total volume by liraglutide and 
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there is a tendency for interaction between L-dopa and liraglutide (liraglutide x L-dopa, F (1, 39) 
= 3, n.s). 
TH+ fibres density: liraglutide has a significant overall effect on increasing TH+ fibres density 
in the graft core (F (1,39) = 8.3, p<0.01), exendin-4 and L-dopa has no effect on the TH+ density 
(max: exendin-4: F (1,39) = 0.39) (two-way ANOVA, between subject factor include: L-dopa, 
exendin-4 and liraglutide). There is a significant interaction between L-dopa and exendin-4 (F 
(1,39) = 10, p< 0.01); exendin-4 increase fibres density significantly in saline treated group (F 
(1,39) = 4.4, p<0.05) while it reduced fibres density significantly in L-dopa treated group (F (1,39) 
= 12.7, p<0.001). 
 
Figure 26 histological characterisation of the graft: (A) exendin-4 had a significant effect on 
increasing TH+ count in saline group but no effect in L-dopa group (***p< 0.001), (B) no effect for 
exendin-4 and liraglutide on graft volume, (C) liraglutide has significant overall effect on increasing 
TH+ fibres density while exendin-4 increase fibres density in saline group and reduced the density in 
L-dopa group (*p<0.05, **p<0.01, ***p<0.001) (two-way  ANOVA).   
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4.3.7 Effect of GLP1 agonists on dopaminergic cells subtypes and serotonergic 
neurons in the graft 
The double labelling of the TH and Girk2 in the graft illustrated that there was no effect of 
exendin-4, liraglutide and L-dopa on the ratio of A9 (Girk2+ cells) dopaminergic neuron 
subtype to the total dopaminergic neurons (TH+ cells) (two-way ANOVA, n.s.). The data also 
demonstrated that there was no effect of exendin-4, liraglutide and L-dopa on the number of 
serotonergic neurons labelled 5-HT in the graft (two-way ANOVA, F (1, 39) max L-dopa = 2.4, n.s.).  
 
 
Figure 27 Subpopulations of dopaminergic neurons and serotonergic neurons in the graft: figure A 
shows co-localisation of TH (green) representing the dopaminergic neuron and Girk2 (red) 
representing the A9 subtype of the dopaminergic neuron in the graft (blue arrow pointed to some of 
co-localised targets while yellow arrow pointed to some of non-co-localised targets). (B) both 
exendn-4 and liraglutide had no effect on the A9/TH proportions (two-way ANOVA). (C) exendin-4 
and liraglutide show no effect on the total number of the serotonergic neurons in the graft (two-way 
ANOVA). 
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4.3.8 Microglial stained CD11b analysis  
The level of the microglial reaction around the graft was expressed as a ratio between the 
optical densities of the activated microglia around the graft to the optical density of the 
microglia at corresponding places in the intact side. The data showed that L-dopa has overall 
effect to increase the level of microglia labelled CD11b around the graft significantly (F (1,39) = 
16.8, p<0.001), and there is no overall effect of exendin-4 or liraglutide on the level of CD11b 
(max: liraglutide: F (1,39) = 1.9, n.s) (two-way ANOVA, between subject factor include: L-dopa, 
exendin-4 and liraglutide). There is a significant interaction between L-dopa and exendin-4 (F 
(1,39) = 4.9, p<0.05); L-dopa increase level of CD11b significantly in in exendin-4 treated rats (F 
(1,39) = 14, p<0.001), but it has high tendency but not significant effect in non-exendin-4 treated 
rats (F (1,39) =3.9, n.s).  
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Figure 28 microglial stained (CD11b) density around the graft: L-dopa has overall significant effect on 
increase level of CD11b labelled cells around the graft and no effect for exendin-4 or liraglutide 
(*p<0.05), there is an interaction between L-dopa and exendin-4 shows that L-dopa increase CD11b 
cells in presence of exendin-4 (***p<0.001).  
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4.3.9 Leukocyte stained CD45 analysis  
The data showed that there are only few infiltrated leucocytes labelled CD45 detected in the 
striatum of the lesion control group. In grafted groups, liraglutide has overall effect to 
increase number of infiltered CD45 cells (F (1,39) = 4.8, p<0.05) and there is no effect of L-dopa 
and exendin-4 (F (1,39) max L-dopa = 3.3, n.s) (two-way ANOVA, between subject factor include: 
L-dopa, exendin-4 and liraglutide). There is a significant interaction between L-dopa and 
liraglutide (F (1,39) = 7, p<0.01); liraglutide increase CD45+ cells in L-dopa treated group (F (1,39) 
= 13, p<0.001) but it has no effect in saline treated rats (F (1,39) =0.4, n.s). 
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Figure 29 leucocyte staining (CD45) count in the grafted striatum: liraglutide has a significant overall 
effect on increasing the number of infiltrated leukocytes to the grafted striatum (p<0.05); liraglutide 
has significant interaction with L-dopa illustrated it significantly increase CD45 level in L-dopa group 
and no effect in saline group (***p<0.001).    
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4.3.10 Striatal blood vesseles length and diameter 
Blood vessel surface area analysis, stained with tomato lectin, in the right hemisphere of the 
striatum (grafted side) illustrated there was no effect of L-dopa, exendin-4 and liraglutide in 
the average blood vessel surface area in grafted rats (F (1,36) max L-dopa = 2.25, n.s). The blood 
vessels diameter analysis showed that liraglutide has overall effect on increase diameter of 
the blood vessels in the grafted stratum (F (1,36) = 9.1, p< 0.01) and there was no effect of L-
dopa and exendin-4 on the blood vessels diameter (F (1,36) max = 0.5, n.s) (two-way ANOVA, 
between subject factor include: L-dopa, exendin-4 and liraglutide). 
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Figure 30 blood vessels staining (tomato lectin) in the grafted striatum: L-dopa, exendin-4 and 
liraglutide had no effect on the striatal blood vessels surface area; while liraglutide shows overall 
significant effect on increase the diameter of the blood vessels at the grafted side (two-way ANOVA, 
**p<0.01). The images were taken on 10x magnification from the striatum of the right hemisphere 
of each group (G= graft; LD= L-dopa; Ex= exendin-4; Li= Liraglutide). 
 
4.3.11 The plasma level of insulin and glucose investigations  
The GLP-1 agonists exendin-4 and liraglutide produced different actions on graft function and 
histological charachteristics in the presence and absence of L-dopa. To explore the reasons 
for this difference, the plasma level of insluin and glucose was investigated to understand 
whether these differences are related to changes in glucose and insulin hemostasis or not.  
The analysis of insulin level in the plasma of the graft groups illustrated that exendin-4 has 
overall significant effect on increasing insluin level (F (2, 45) = 7.78, p<0.001) while liraglutide 
and L-dopa have no effect (F (1,45) max L-dopa = 3, n.s) (two-way ANOVA, between subject factor 
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include: L-dopa, exendin-4 and liraglutide). There is a significant interaction between L-dopa 
and exendin-4 (F = 6.1, p< 0.05); exendin-4 increase insuline level significantly in L-dopa  
treated group (F (1,45) = 10.2, p< 0.001) and it has no effect in the saline treated group (F (1,45) 
= 0.5, n.s). The average of insulin level in group treated with exendin-4 and L-dopa equal to 
(718 ± 209 pg/ ml). 
The analysis of glucose level in the plasma of the grafted groups illustrated that exendin-4 has 
high significant overall effect on increaing glucose level (F (1,45) = 24,7, p<0.001), liraglutide 
also has significant overall effect on increasing glucose level (F (1,45) = 4.3, p<0.05) (two-way 
ANOVA, between subject factor include: L-dopa, exendin-4 and liraglutide). The average of te 
glucose level in group treated with exendin-4 and L-dopa equal to (10 ± 0.68 mmol/ liter) 
 
Figure 31 plasma level of insulin and glucose: exendin-4 increased the level plasma insulin level 
significantly in L-dopa treated group (two way ANOVA, ***p<0.001) and it has overall effect to 
increase the glucose level (two-way ANOVA, p<0.001); liraglutide has no effect on insulin level but it 
has overall effect to increase glucose level (two-way ANOVA, p<0.05).   
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4.3.12 Phosphorylated insulin receptors in the graft  
The phosphorylation of insulin receptors investigated by IRS-1 pS1011 immunohistochemistry 
was used to identify the insulin receptor resistance on the grafted cells. One subject of each 
group was investigated in this test.  A positive staining of IRS-1 pS1011 confined to the nuclei 
was detected in the graft of all groups. However only the group treated with in exendin-4 and 
L-dopa showed a high density of cytoplasmic IRS-1 pS1011 positive staining while it was not 
detected in the graft of any other group.  
 
Figure 32 phosphorylated insulin receptors labelled with (IRS-1 pS1011) in the graft: IRS-1 pS1011 
identified confined to the nuclei of grafted cells in one rat of all groups. However, the cytoplasmic 
detection was only in exendin-4 plus L-dopa treated group. The images were captured on 4X and 10X 
magnification. (G= graft, LD= L-dopa Ex = exendin-4, Lir= liraglutide). 
 
4.3.13 Fat accumulation analysis in the liver 
Fat accumulation in the liver was explored as a further investigation to explore the signs of 
abnormal insulin and glucose levels recorded in the group treated with exnendin-4 and L-
dopa.  
The Oli Red-O (ORO) staining for liver sections illustrated that the lesion only control group 
had a high percentage of fat accumulated in the liver representing 17.33 ± 6.5 % of liver 
surface area.  
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In the grafted groups: L-dopa, exendin-4 and liraglutide have no effect on the level of 
accumulated fat level in the liver (max: L-dopa: F (1,45)  = 1.3, n.s) (two-way ANOVA, between 
subject factor include: L-dopa, exendin-4 and liraglutide).  A direct comparison between the 
lesion group and graft group which received exendin-4 showed that the later had a 
significantly lower percentage of accumulated fat in the liver compared to lesion control (t-
test, two tailed, *p<0.05).  
Haematoxylin and Eosin staining was used as another method to visualise fat accumulation 
in the liver. The test confirmed the ORO staining results as high accumulation of fat droplets 
was seen in the cytoplasm of cells that had a high percentage of ORO staining while few or 
no fat droplets were detected in the liver sections that had a low percentage of ORO (image 
B and D in Figure 33). 
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Figure 33 Percentage of fat accumulation in the liver: high percentage of fat accumulated in the liver 
of the lesion group representing 17.33% of liver surface area. There is overall effect of L-dopa, 
exendin-4 and liraglutide on the level of the accumulated fat in the grafted groups (two-way 
ANOVA). Image (A) shows a high level of Fat droplets in the liver of a rat of the lesion group stained 
by Oil Red-O and confirmed by H & E staining, image (B). Image (C) shows a low percentage of fat 
droplets in the liver of grafted rats treated with exendin-4 and confirmed by H & E staining, image 
(D). (ORO = Oil Red-O)  
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Table 6 summary for the results of exendin-4 and liraglutide compared to the graft control either in 
L-dopa or non-L-dopa treated groups. 
test Exendin-4 Liraglutide  
saline L-dopa  saline L-dopa  
Behavioural 
tasks 
Amphetamine  Improved No No Improved 
Cylinder Improved No No effect 
 
Stepping No effect (tendency) 
 
Improve 
Vibrissae No effect  
 
Improve  
 
L-dopa 
rotations 
- No effect - No 
L-dopa 
induced AIMs 
- No effect - No 
Histological 
characteristics 
TH count Increase No effect No effect  
 
TH volume No effect No effect (tendency) 
 
TH fibres 
density 
Increase Reduce  Increase 
Plasma 
analysis 
Insulin level No effect Increase   No effect 
Glucose level Increase 
 
Increase 
 
Insulin 
resistance  
IRS-1 pS1011 Not 
detected  
Detected  Not detected 
Inflammatory 
markers 
Microglia 
CD11b 
No effect Increase  No effect  
 
Leukocyte 
CD45 
No effect 
 
No effect Increased 
Blood vessels Surface area No effect  
 
No effect  
 
Diameter  No effect  Increase 
A9 / TH+ ratio  
- 
No effect  
 
No effect 
 
Serotonergic 
neurons 
count 5-HT 
 
- 
No effect  
 
No effect 
 
percentage of 
fat 
accumulation 
in the liver 
 
- 
*Reduced 
compared 
to lesion 
group 
No effect No effect 
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 Discussion  
The survival rate of the transplanted E14 VM cells in the current experiment was consistent 
with its survival in previous experiments in chapter 3. The data illustrated that only around 
190 cells of the dopaminergic neurons (TH+) had survived in the graft of control group 
(received saline only) after transplanting of two thirds of VM cells. By assuming that number 
of dopaminergic neuron precursors in each rat embryo’s VM section is between 30,000 – 
40,000 cells (Brundin et al. 2000), then the survival rate in this group was less than 1%. The 
graft was functional and present efficiency on reducing rats’ asymmetric rotations after 
amphetamine administration. This indicates releasing the dopamine by the graft in the 
depleted side to counterbalance the dopamine level in the intact side, the data confirmed a 
complete degeneration for the endogenous nigral dopaminergic neurons to conclude this 
recovery is from the graft. The graft also ameliorated the motor deficit in the cylinder test but 
it was not effective in reversing deficits in stepping and vibrissae tests. This limitation was 
mainly attributed to the small size of the graft, as previous works clarified that wider 
innervation to the striatum and a certain threshold of graft size are required for better motor 
recovery (Hagell & Brundin 2001; Falkenstein et al. 2009).  
The overall effect of L-dopa treatment on the grafted groups showed it has no influence on 
either graft function or survival unless it interacted with GLP-1R agonists. The only effect of 
L-dopa recorded in this experiment is increasing level of microglia and reducing rats’ 
performance in cylinder test. The data showed that the effect on cylinder test was only in 
presence of exendin-4 treatment which it has been suggested that the latter in presence of L-
dopa may deteriorate the effect of the graft (discussed below). L-dopa effect on microglia was 
also affected by exendin-4 treatment as higher level of microglia was recorded in presence of 
exendin-4 and no effect in absence of exendin-4. The effect of L-dopa on the graft in this study 
is consistent with previous studies which clarified that L-dopa has no effect on the survival or 
function of the VM cell transplantation but it has interference with the microglial 
inflammatory reaction toward the graft (xenograft) (Breger et al. 2016). in the current study, 
the data revealed that the presence of L-dopa treatment influenced GLP-1 agonist effects on 
graft survival and function (discussed below).   
Exendin has neuroprotective effects in PD but the mechanism through which this may occur 
is unclear. Given that the same neurochemical processes are present in the striatum at the 
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time of transplantation, it was relevant to consider whether the same degree of protection 
might be afforded to the transplanted neurons. This study confirmed the presence of GLP1 
receptors on VM dopaminergic neurons (E14) at the time of transplantation suggesting 
availability of the mechanical components for the GLP1 agonist to produce their effect to 
support graft survival. Post-mortem analysis 13 weeks after transplantation also confirmed 
the persistence of this receptor on the transplanted dopaminergic neuron which lead to 
conclude the receptor were present in the graft throughout the experiment. The GLP1 
agonists exendin-4 and liraglutide showed they have the supporting effect on the survival and 
functionality of the transplanted VM dopaminergic neurons. However, the presence of L-dopa 
interfered with their effects. As exendin-4 was successful in supporting the graft only in the 
non-L-dopa treated group, while liraglutide was supportive to the graft only in rats who 
received L-dopa.  
The current data illustrated nearly a complete lesion of the nigrostriatal dopaminergic 
neurons exceeding 97% in all groups including GLP-1 agonists treated rats with or without L-
dopa. This indicated that GLP-1R agonists did not reverse the complete nigral dopaminergic 
neurons lesion induced by 6-OHDA, consequently it has no effect on the behavioural recovery 
results due to interference with the endogenous nigrostriatal dopaminergic neurons. In 
addition, in chapter 6, the data illustrated that exendin-4 has no effect on behavioural results 
(drug-induced rotation test, stepping test, vibrissae test and cylinder test) of a completed 
nigral dopaminergic lesion 6-OHDA rat model. Concluding that the behavioural tests in this 
experiment is evaluating the effect GLP-1R agonists on the graft rather than other targets.  
Impact of exndin-4 on the graft survival and functional capacity: 
Exendin-4 illustrated capability on supporting survival of transplanted cells but this effect was 
determined by presence of L-dopa treatment. It caused significantly increasing total number 
of dopaminergic neurons labelled TH+ in the graft in absence of L-dopa treatment while it has 
no effect in presence of L-dopa. In absence of L-dopa, exendin-4 caused an increase in the 
mean number of transplanted cells significantly by 6 times more compared to the graft 
control. This increment ratio is competitive to other trial attempt to improve the survival rate 
of grafted cells. For instance, intra-striatal injection of neurotrophic factors GDNF or FGF with 
VM tissue increased the number of TH cells that survived to 2.6 and 10 fold respectively in a 
rodent model (Rosenblad et al. 1996; Takayama et al. 1995). Moreover, treating the VM cell 
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suspension with caspase inhibitor or lazaroid prior to transplantation enhanced cell survival 
by almost two-fold (Schierle, Hansson, et al. 1999b; Karlsson et al. 1999). The consequence of 
using younger VM cells (E12 in rats) lead to a 6 fold improvement in TH cell survival (Torres et 
al. 2008). Besides increasing cell survival, the TH density in the core of the graft (TH fibres and 
cell body) was also significantly higher with exendin-4 treatment. This suggested that more 
fibres innervated by the dopaminergic neurons in the core of the graft which increase chance 
of fibres integration with the host cells. Importantly, this effect in absence of L-dopa was 
reflected in the better motor and behavioural recovery which included significant reduction 
in amphetamine-induced rotations and significant recovery in cylinder test. This is consistent 
with previous studies which showed recovery in the motor and behavioural tests is correlated 
with improvement in the graft dopaminergic neurons survival and fibre density (Hagell & 
Brundin 2001) . Taken together, the initial hypothesis that exendin-4 in the absence of L-dopa 
treatment influences the support of VM transplantation therapy is valid via increasing cell 
survival, fibre density, and improving motor performances in amphetamine rotation test and 
cylinder test.  
The emphasis in this thesis is on evaluating the cell therapy in an animal model including L-
dopa treatment to mimic the real clinical condition of patients who received L-dopa before 
and after cell transplantation. Exendin-4 effectiveness on graft survival and function was 
abolished in presence of L-dopa, even more it was responsible on reducing TH+ (TH fibres and 
cell body) density in the graft. Moreover, it participated on enhancing the effect of L-dopa on 
increase microglial level around the graft. Clinical trial had suggested a relationship between 
the deficiency of motor recovery and the accumulation of microglia around and inside the 
graft of patients who had short term immunosuppression (Olanow et al. 2003). Previous work 
on animal models has shown that induction of systemic inflammation leads to an 
inflammatory response against allogenic VM transplantation in a PD model which affects graft 
survival and function negatively (Shinoda et al. 1995; Hudson et al. 1994). Similarly xenograft 
transplantation caused a strong immunological reaction leading to  graft rejection (Duan et 
al. 1995). Surprisingly, administration of exendin-4 with L-dopa caused elevation in the 
plasma levels of the insulin and glucose suggesting the development of insulin resistance in 
this group of rats. Thus, the data illustrated that L-dopa may contradict the protective effect 
of exendin-4 (discussed below).  
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Impact of liraglutide on cell survival and functional capacity: 
Liraglutide showed it had no effect on increasing the number of dopaminergic neurons. This 
may suggest that liraglutide was not able to protect the dopaminergic neurons. Recently,  a 
published study revealed that liraglutide has a limitation on protecting the nigral 
dopaminergic neurons or recovering amphetamine rotation test in partial and complete 6-
OHDA unilateral nigral lesions in the rat model (Hansen et al. 2016). However, liraglutide in 
the current study improved rats’ performances in the vibrissae test, stepping test and 
amphetamine rotation test significantly which may suggest it has the therapeutic potential to 
improve the motor performance even with a smaller graft. Liraglutide illustrated a significant 
effect to increase the graft TH+ density (TH fibres and cell body). In addition, it had tendency 
to increase graft volume which may reach the significant difference if larger rat number was 
used to reduce variability. These could be the reason for supporting graft function by 
liraglutide. Previous study illustrated that the increment in fibres density and the graft volume 
has a positive influence to improve graft function (Hagell & Brundin 2001). 
The effect of liraglutide on amphetamine rotation test interacted with L-dopa treatment, as 
better graft function was in presence of L-dopa and no effect in absence of L-dopa. This 
suggested that L-dopa may potentiate the effect of liraglutide on supporting the graft function 
without interference on the graft survival, volume or fibres density. The data revealed that 
liraglutide increase infiltration of leukocytes around the graft in presence of L-dopa. Although 
this infiltered leukocyte had no detrimental effect on graft survival but it may have a role on 
this improvement in graft function (discussed below).  
Liraglutide showed it has an effect on increasing the diameter of the blood vessels in the 
grafted striatum. A study has shown that liraglutide has an effect on increasing blood flow 
and it has vasodilation effect on peripherally blood vessels in adult patients with T2DM 
(Nandy et al. 2014). In cerebral blood vessels, recent study showed that liraglutide has the 
ability to reinstate the integrity of cerebral blood vessels and decrease the degree of cerebral 
microanuerysms and leakage in the APP/PS1 mice model which characterised by 
microangiopathies (Kelly et al. 2015). This dilation of the striatal blood vessels in the current 
study possibly participate in infiltration of Leukocyte in L-dopa treated rats. Especially, 
Previous work showed that L-dopa caused a significant increase in the length of the blood 
vessels of the dyskinetic rats in the substantia nigra with reporting of dysfunctional signs of 
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the blood brain barrier (Westin et al. 2006). Taken together, could L-dopa and lirglutide 
affecting permeability of blood vessels and infiltration of leukocytes.   
 The data clarified that co-administration of liraglutide with L-dopa did not induce abnormal 
changes in plasma insulin level suggesting these changes may be specific to exendin-4. 
Although liraglutide treatment causes increase level of plasma glucose significantly but the 
average glucose level in these rats (7.2 ± 0.6 mmol/liter) was within normal range of glucose 
level in Sprague Dawley rats (7 – 9 mmol/ liter) (Havel et al. 2000; Buchanan et al. 1991). 
Did L-dopa treatment halt the protection effect of exendin-4?  
 The histological and behavioural data showed that L-dopa may influence the neuroprotective 
capability of exendin-4.  Analysis of plasma samples illustrated that exendin-4 + L-dopa 
suffered from hyperinsulinemia and hyperglycaemia. This suggested a possibility of 
developing insulin resistance in these rats. The preliminary data from staining one rat’s brain 
sections of each group with phosphorylated insulin receptor IRS-1 pS1011 showed a distinctive 
high level of the phosphorylated insulin receptor in the nuclei and cytoplasm of the cells in 
the graft of exendin-4 + L-dopa compared to others which only confined to the nuclei (Figure 
32). Previous work studied insulin resistance in Alzheimer disease showing that detection of 
phosphorylated insulin receptors in the cytoplasm is expressed with insulin resistant cells in 
the hippocampus of AD while the receptors which are located at the nuclei are expressed in 
the normal cells (Talbot et al. 2012; Talbot & Wang 2014). A recent study showed that 
knocking out insulin receptors specifically in the brain using NIRKO mice caused mitochondrial 
dysfunction with increasing level of reactive oxygen species and increased lipid oxidation in 
the striatum. In addition, it caused a reduction in the level of dopamine in the striatum and 
nucleus accumbens by increasing activity of mono-amino-oxidase enzyme (MAO) which was 
reversed by MAO inhibitors (Kleinridders et al. 2015). Moreover, Wang and colleagues 
illustrated that the nigral dopaminergic neurons in a ob/ob and db/db mice model (a well-
accepted T2DM model) are more vulnerable to degeneration by MPTP toxin compared to wild 
type mice. They also showed that insulin signalling is not only impaired in the pancreas and 
liver in this model but also in the midbrain (Wang et al. 2014). Furthermore, Saller et al. 
showed intravenous glucose dose (15 mg/kg) which elevated blood glucose levels by 30% in 
SD rats produced a reduction of dopaminergic neuron activity in SN and reduce dopamine 
release by 60-80% during the period of glucose elevation while administration of glucose at 
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250 mg/kg dose IV caused a complete cessation of dopamine release (Saller & Chiodo 1980). 
In clinical trials, several studies suggested that there is an association between Parkinson 
disease and T2DA (reviewed in (Santiago & Potashkin 2013)). Taken together, developing the 
insulin resistance in the host environment may potentiate several factors leading to the 
promotion of death of the transplanted cells or a reduction in their function. So, it has been 
hypothesised that hyperinsulinemia and hyperglycaemia may participate in suppression of 
the protective effect of exendin-4 on transplanted dopaminergic neurons.  
Another possible reason for the halt in the protective effect of exendin-4 in presence of L-
dopa is the reversing of the suppressive effect on the microglia levels. High plasma levels of 
insulin and glucose may have contributed to the increase in the host immunological response. 
Previous work illustrated that high glucose levels can stimulate glial activation via increasing 
oxidative stress leading to increased secretion of TNFα and monocyte chemotactic protein-1 
(MCP-1) in rat microglia culture and elevation of IL-6 and IL-8 expression and secretion by 
astrocyte (Quan et al. 2011; Bahniwal et al. 2017). In addition, peripheral insulin resistance 
has been linked with inflammation including release of pro-inflammatory cytokines like TNF-
α, IL-6, IL-1β that can cross blood brain barrier (De Felice & Ferreira 2014). L-dopa may also 
have a direct effect on driving more activated microglia around the graft. Breger and 
colleagues showed that there was  a significantly higher number of microglia and leukocytes 
around the xenograft (but not allograft) in a similar model exploring the role of L-dopa in cell 
transplantation (Breger et al. 2016). However, this higher inflammatory response by L-dopa 
did not affect graft survival or function, a closer analysis suggested that microglial or leukocyte 
phenotypes were affected by L-dopa.   
The possible interpretation for this paradoxical effect of exendin-4 in the presence of L-dopa 
treatment is that there may be an interaction between these treatments which leads to 
accumulation of the exendin-4 metabolite that has mild to moderate GLP-1 receptor 
antagonism (exendin (15-39) and exendin (16-39)). These metabolites are normally cleared 
by the kidney via glomerular filtration (GFR) and tubules secretion (Baggio & Drucker 2007). 
A previous study showed that benserazide, administered in combination with L-dopa, 
interferes with GFR as it is used to reduce the increase in GFR in case of  infusion of amino 
acid solution or in case of diabetic inducing GFR when infused at rate of 30µg/min/kg (Pfeil et 
al. 2006; Miihlbauer et al. 1994). In this experiment, benserazide was given subcutaneously 
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in a ratio of 1:1 with L-dopa at a dose of (12 mg/kg) once daily or each alternate day. This dose 
is higher than the total infused benserazide dose over 4 hrs to reduce the GFR (7.2 mg/kg), in 
addition it is given at the same time as exendin-4 which has a half-life of 60-90 min and 
biological action for 4 hrs. Moreover, the used L-dopa/ Benserazide dose in this experiment 
was also higher than patient’s maintenance regular dose which is in the range of 400-800 mg 
daily of L-dopa and in a ratio of 4:1 with benserazide (i.e benserazide dose range 1.4 - 5.7 
mg/kg/day, assuming adult weight is 70kg). So, it was assumed that the relatively high dose 
of benserazide may have reduced excretion of the exndin-4 metabolite leading to their 
accumulation in the blood. These metabolites may halt the protective effect of the exendin-
4 on the graft either directly by blocking the GLP1 receptor or indirectly through inducing 
pathophysiological changes. 
Did L-dopa support the liraglutide effect on graft function? 
Previous work showed that L-dopa treatment does not affect graft survival or functioning. 
However, a recent study did reveal that L-dopa contributed to increased infiltration of 
leukocytes around the xenograft with proliferation of more CD4 subtype (T helper 
lymphocyte) than CD8 (cytotoxic lymphocyte) (Breger et al. 2016). Similarly, the group treated 
with liraglutide and L-dopa here had a high leukocyte infiltration around the graft. Other 
experiments suggested that L-dopa is responsible for promoting the differentiation of a more 
T helper subtype 2 (Th2) cells which cause release of the anti-inflammatory cytokines rather 
than T-helper subtype 1 (Th1) which cause release pro-inflammatory cytokines. Furthermore, 
L-dopa induce Th2 cells to release neurotrophic factors like BDNF and IGF-1 and polarise the 
microglia toward the M2 phenotype which has neuroprotective effects and releases anti-
inflammatory cytokines (Carr et al. 2003; Mori et al. 2013; Nakano et al. 2009). CD4 
lymphocyte and anti-inflammatory cytokines like IL-4 could cause conversion of microglia 
from M1 state to M2 phenotype (Ziv et al. 2006; Butovsky et al. 2006). Interestingly, GLP1 
agonists have been reported to have the ability to polarise macrophages from M1 state to M2 
via stimulation of STAT-3 pathway (Shiraishi et al. 2012). A possible interpretation of the graft 
function support of liraglutide in the presence of L-dopa could be that a synergistic effect 
between the two therapies leads to a predominance of the anti-inflammatory markers. This 
may explain the beneficial effect of L-dopa plus liraglutide on improving graft function with 
effect on graft size. In previous study comparing motor functions of small dose graft and large 
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dose graft, the data suggested that less inflammatory reaction around the graft was one of 
the factors that may enable small graft to have the same large graft functional performance 
(Bartlett et al. 2004). However, future studies are needed to characterise the type of 
inflammatory cells and kind of predominant cytokines around the graft in the presence of L-
dopa and liraglutide.  
Effect of the graft and GLP-1 agonist on L-dopa induced dyskinesia and L-dopa induced 
rotations. 
Development of dyskinesia following chronic L-dopa administration occurs through the lack 
of dopaminergic neuronal control of dopamine release and turn over in the synapse, leading 
to accumulation of dopamine post-synaptically and causing an excessive stimulation of 
dopamine receptors. The long-term consequence is the development of dyskinesia. The 
replaced dopaminergic neurons of all graft groups successfully reduced LID from week 4 and 
L-dopa-induced rotations on week 10 and 11 of transplantation compared to pre-
transplantation level. The reduction in LID is depended on the graft size where a large graft 
(graft volume = 3.16 mm3  ; TH count = 17,400) caused a higher reduction in LID compared to 
a smaller graft (graft volume = 0.11 mm3 ; TH count = 280) (Lane et al. 2006). In the current 
study, exendin-4 showed a limitation to support survival of dopaminergic neurons in presence 
of L-dopa treatment while liraglutide even it showed ability to improve fibres density but it 
also didn’t have significant effect to improve cell survive. This limitation in improving graft 
size may the reason for ineffectiveness of GLP-1 agonists to reduce L-dopa induced AIMs and 
rotations. However, exendin-4 and liraglutide illustrated a tendency on getting a better 
reduction on the AIMs slope at the first two weeks of transplantation compared to the graft 
control (AIMs reduction slope: graft (-0.4); exendi-4 (- 7.7) and liraglutide (- 9.1)). This may 
suggest that GLP-1 agonist may accelerate the maturation of the graft and its ability to handle 
exogenous L-dopa.  
Effect of the GLP-1R agonists on DA subtype and serotonergic neurons survival in the graft 
The other factors investigated in this experiment are the effect of GLP-1R agonists on the ratio 
of A9 subtype-dopaminergic neuron and survival of the serotonergic neurons in the graft 
because they are important in determining the graft functionality and side effects. Studies 
clarified that A9 subtype is the phenotype responsible for the motor recovery in the graft 
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(Grealish et al. 2010) and the presence of serotonergic cells in the  graft are suggested to have 
an important role in developing GID (Politis et al. 2011). The results demonstrated that both 
exendin-4 and liraglutide had no effect either on A9 proportions or on serotonergic neuron 
survival in the graft, either in presence or absence of L-dopa. Thus, the effect of these 
parameters on the graft outcome were less likely to be changed by administration of GLP-1R 
agonists.  
Dose the liver status has interference with Parkinson Disease and cell transplantation efficacy?  
The fatty status of the liver was explored in this experiment because of the evidence of 
abnormal metabolic changes which were recorded with insulin and glucose. This experiment 
was not designed to evaluate the changes in the liver in PD model in presence the graft or the 
treatments.  There is a lack for normal rats’ liver control and normal liver exposed to all the 
used treatment in this experiment and lesion control group exposed to these treatments. 
However, Interestingly, the current liver data may give insight into the possible involvement 
of the liver in Parkinson Disease and/or cell transplantation. Surprisingly, in the 6-OHDA lesion 
control group a high accumulation of fat droplets in liver sections was recorded while the 
graft with exendin-4 reduced this condition. From previous work the percentage of fat in the 
liver of the normal rat was in the range between 0-2% (Kho et al. 2016; Bang et al. 2017; Gu 
et al. 2017) while the mean fat accumulation in the lesion control was higher than 17%, which 
could suggest the abnormal fat accumulation in the Parkinson’s liver. Consistent with this is 
the finding that exendin-4 is effective at reducing fat accumulation and steatosis condition in 
the liver of Non-Alcoholic Fatty Liver Disease (NAFLD) (Eguchi et al. 2015; Lee & Jun 2016; Liu 
et al. 2014). So, this may give some support to the hypothesis that the liver is affected in this 
particular model of PD. However, this needs to be clarified in a study designed for this purpose 
in future and exploring the clinical liver data base in PD to determine whether there is a 
clinically relevant effect. 
 Conclusions  
GLP-1R agonists were effective in supporting survival and function of the VM graft in 6-OHDA 
rat model. However, their supportive effect was determined by adding L-dopa treatment to 
the model. Exendin-4 increased graft size and enhanced graft function, however this effect 
was halted by L-dopa treatment. Plasma investigations showed that the interaction between 
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L-dopa and exendin-4 caused elevation in insulin and glucose levels. Further analysis 
identified signs of insulin resistance in the graft. It was hypothesised that insulin resistance 
which was developed from interaction between L-dopa and exendin-4 hindered the 
protective effect of the later. On the other hand, liraglutide illustrated no effect on the graft 
survival, instead it increased TH+ density of the graft (cell body and fibres). However, 
liraglutide illustrated ability to support graft function. Liraglutide effect on graft function is 
also interacted with L-dopa treatment, in contrast to exendin-4, it supports graft function in 
presence of L-dopa. Histological investigation showed that the interaction between L-dopa 
and liraglutide caused a significant increase in leukocyte infiltration around the graft. This 
data suggests the drug combination may induce inflammatory modulation leading to 
supporting graft function.  
Thus, this chapter has helped to identify neuroprotective agents that can support survival and 
efficacy of primary VM cell transplantation. In addition, the impact of L-dopa on determining 
the supportive effect of the neuroprotective agents on the graft, highlighted the importance 
of considering L-dopa in cell therapy evaluation in animal models. The next chapters will 
address another issue of cell therapy in PD which is understanding the effect of L-dopa 
treatment on the development and function of human embryonic stem cell derived 
dopaminergic neuron hESC-DA transplantation in same model. In addition, it will explore the 
effect of exendin-4 as a neuroprotective agent to support these grafts.  
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5 Chapter 5: characterisation of (H9) human Embryonic 
Stem Cells (hESC)-derived dopaminergic neuron 
transplantation in a 6-OHDA rat model of PD in the 
presence of L-dopa treatment and neuroprotective 
agent  
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 Introduction  
Recently studies have successfully generated dopaminergic neurons that have the substantia 
nigra/A9 specific markers using stem cells derived through different lines and with varying 
protocols. In some cases, transplantation of these cells typically into the 6-OHDA lesioned rats 
produced successful cell survival and some evidence of graft function. hESC-DA derived from 
H9 cell line showed successful survival, functional and safe transplantation in animal models. 
H9 (WA09) cell line is a clinical grade line and banked under GMP conditions (Wi Cell® labs). 
Kirkeby and colleagues treated these cells with dual SMAD inhibitors and glycogen synthase 
kinase 3 (GSK3) inhibitors followed by adding SHH-C2411 to get region specific neurons 
(Kirkeby et al. 2012). They successfully yielded cells expressing the specific VM cells markers 
(FOXA2 and LMX1A) and generated a high number of TH expressing dopaminergic neurons in 
vitro. These cells were transplanted into the 6-OHDA rat and compared with human VM cells 
for 6 weeks. The TH count in the graft of hESC-DA was 15 times higher than the hVM graft; 
and 81% of the hESC-DA expressed LMX1A and FOXA2 compared to 21% of the hVM. The 
morphology of the neurons was bipolar and angular cell bodies with elongated axons and the 
pattern of innervation was identical to hVM. Then, they evaluated the graft for 18 weeks’ 
post-transplantation, they found that 54% of the hESC cell in the graft was TH labelled 
(TH/HuNu) with a large proportion of Girk2 labelled neurons indicative of the A9 phenotype. 
In addition, they found that the graft can release dopamine, reverse amphetamine-induced 
rotations and improve performance in the cylinder test (Kirkeby et al. 2012). A follow up study 
illustrated the successful synaptic integration of these cells with the host striatal neurons and 
the making of rapid and extensive connections with afferent and efferent neurons (Grealish, 
Heuer, et al. 2014). So, these cells showed remarkable success in animal models which make 
it a potential candidate for clinical trials. 
 However, to transfer stem cell-based transplantation therapy into clinical studies, it should 
be validated in an animal model that mimics the real conditions as closely as possible. One of 
the clinical factors which has never been considered in hESC-DA experiments is: first, that the 
patients typically receive a variety of anti-Parkinsonian medications, commonly L-dopa; 
second, mostly those patients have developed LID, the most common side effect of these 
medications. In addition, patients continue to use these medications after transplantation for 
a while till get a mature and functional graft (the table below (Table 7) shows the range of 
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medications used by patients prior to and following human VM cell transplantation in the 
TransEuro clinical trial). It is plausible that the presence of L-dopa following transplantation 
may have a direct effect on the programming, differentiation and development of these cells. 
A recent paper published by Belinsky and colleagues showed that dopamine receptors (D1-
D5) are expressed at different stages of differentiation of DA neurons from hESC; they found 
that treating these cell with L-dopa during the early and later stages of differentiation had 
effects including more neuroepithelial colonies, more neuronal clusters and more TH clusters 
(Belinsky et al. 2013). The interaction between these medications and stem cell- based 
transplantation needs to be tested to validate the safety, survival and functionality of these 
cells.  Previous works in animal models of PD illustrates that L-dopa causes changes in blood 
brain permeability  (Westin et al. 2006) and induces an enhanced  inflammatory reaction 
around striatal xenografts (Breger et al. 2016) such things could change the host environment 
around the graft.  
The other important point that needs to be highlighted in stem cell derived dopaminergic 
neuron transplantation is understanding the capability of these cells to ameliorate LID and 
the possibility of these cells to generate GID. To test the dyskinesia profile in an animal model 
of PD, animals should be exposed to a chronic L-dopa treatment prior to transplantation to 
establish LID. This because L-dopa makes conformational changes in the striatal cells leads to 
the induction of LID, then the efficiency of the graft to alleviate LID can be evaluated. 
Considering all of this together, it is important to characterise stem cell transplantation in 
animal models treated with anti- parkinsonian medication to be able to evaluate the safety, 
survival, functional and dyskinesia profile of stem cell grafts before moving to clinical trials.  
This study aims to: 
Firstly, understand the effect of L-dopa on hESC-DA graft using the cells developed by Kirkeby 
and colleagues and resolve key questions before clinical trials: 
• Does L-dopa affect graft maturation and development?  
• Does L-dopa affect the functional efficacy of the graft?   
• Are hESC-DA able to reduce LID? 
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Secondly, based on the findings of the neuroprotection produced by exendin-4 on the VM 
cells in chapter 4, it also appears relevant to determine whether exendin-4 could support 
hESC-DA graft survival and function.  
The objectives of this study therefore are:  
1. Assessment the motor and behavioural recovery of the graft in the presence and 
absence of L-dopa. 
2. Characterisation the histological features of the graft in the presence and absence of 
L-dopa.  
3. Post-mortem detection of GLP-1 receptors expression in the graft of H9 hESC-derived 
dopaminergic neurons at the analysis. 
4. Determination of the effect of exendin-4 on the behavioural and the histological 
measurments of the graft matured in the presence or absence of L-dopa.  
 
Table 7 Parkinson Disease medications used by 12 patients at the time of VM cell transplantation 
(obtained from prof. Roger Barker, transEuro coordinator, personal communication) (abbreviations:  
AADC = aromatic amino-acid decarboxylase; COMT = catechol O methyl transferase). 
Treatment class number of patients out 
of 12 
average daily dose 
L-dopa + AADC Inhibitors 
(Stalevo, Madopar, Sinemet, Co-
Beneldopa) 
11 667 mg 
D2 agonist (Ropinirole, 
Pramipexole) 
9 ropinirole (15mg), 
Pramipexole (1.5 mg) 
Monoaminoxidase inhibitors 
(Selegiline and Rasagiline) 
10 Selegiline 10 mg; Rasagiline 
1mg) 
COMT inhibitor (Entacapone) 6 775 mg 
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 experimental design and methods 
 
 
Figure 34 experimental time line and grouping 
 
6-OHDA was infused unilaterally into the medial forebrain bundle in the right hemisphere 
(2.2.1) of 45 female Sprague Dawley rats. Two weeks later, amphetamine-induced rotations 
were assessed to determine the nigral dopaminergic lesion (rats who performed ipsilateral 
rotations ≥ 6 times/ min, were considered to have more than 90% lesioned of the right SN). 
Then the rats were divided into 5 groups (n=9): one group was lesion only control; four groups 
were transplanted with the ESC-DA into the depleted striatum (section 2.2.2.2.1). Groups 
were then allocated to a treatment group (two groups treated with saline ± exendin-4 and 
two groups with L-dopa ± exendin-4) (see Figure 34). The treatment with L-dopa started 5 
weeks before cell transplantation surgery and continued for 15 weeks after transplantation. 
All the transplanted groups received immunosuppression using cyclosporine-A (10 mg/kg) 24 
hrs before cell transplantation and continued daily i.p. until the end of the experiment (16 
weeks). Exendin-4 treatment started 24 hrs before transplantation surgery and continued 
until week 15 post-surgery. The motor and behaviour tests including amphetamine-induced 
rotations, adjusting step test, vibrissae test, cylinder test and apomorphine-induced rotations 
were carried out throughout the experiment. These tests were applied on the following time 
points: prior to starting of L-dopa treatment; prior to transplantation surgery and every 4 
weeks after graft surgery up to 16 weeks. The cylinder test was carried out only at the pre-L-
dopa time point and at week 16, while the apomorphine test was carried out only at week 16. 
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Abnormal Involuntary Movements (AIMs) and L-dopa-induced rotation tests were recorded 
weekly before and after cell transplantation from the start of L-dopa treatment (section 2.4). 
L-dopa and exendin-4 treatments were stopped 2 days before each behavioural and motor 
test in order to wash out any functional effect. On week 17 of transplantation, all rats were 
perfused and the brains were collected for histological analysis. DAB-IHC was used to identify: 
TH to label dopaminergic neurons in the graft and the SN; HuNu to label human nuclei, Stem-
121 to label human cytoplasm (ie incorporating projections); and CD11b to label the activated 
microglia around the graft (section 2.10.1). Double F-IHC was used to stain TH and GLP-1R 
(section 2.10.2).  
5.2.1 Treatments  
L-dopa in combination with benseraside was given to the rats 5 weeks before the 
transplantation surgery. It was started with a dose of 12 mg/ kg of each of L-dopa and 
benserazide and given as single s.c. injection every day for 3 week then reduced for 6 mg/kg 
of L-dopa + 12 mg/kg of benserazide for two weeks. The latter dose was continued in use 
after transplantation surgery every day for 16 weeks. L-dopa treatment was stopped 2 days 
before graft surgery and 2 days before each behavioural and motor tests.  
Cyclosporine treament commenced 24 hrs before graft surgery and continued every 24±1 hrs 
until killing the rats. It was used at a dose of 10 mg/kg intraperotineally. Cyclosporine was 
obtained from Heath hospital pharmacy manufactured by Novartis in 50 mg/ 1ml ampoules. 
The ampoules were diluted with 0.9% normal saline and used immediately or kept  
refridgorated for no longer than 3 days.  
Exendin-4 was given (i.p.) a dose of 0.5 µg/ kg twice daily for the first two weeks after cell 
transplantaton. Then because of poor rodent health (significant weight loss), it was stopped 
for 5 days and then commenced with single daily doses untill week 15. Exendin-4 was ordered 
from Tocris Bioscince  as a 1mg reconstituted powder.  It was dissolved in 1 ml of 0.9% normal 
saline and aliquoted (stored on -20 C0 for a maximum 30 days). 
5.2.2 Statistical analysis  
The statistical analysis of the data was preformed using IBM SPSS. The behavioural data 
analysis was separated into two sets. First was between graft alone (in the absence of 
exendin-4 and L-dopa) and lesion groups to characterise the effect of the graft without 
treatments using repeated measure analysis (time as within subject factor; group (graft or 
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lesion) as between subject factor). The second set was between the grafted groups to 
evaluate the effect of exendin-4, L-dopa and their interaction on the graft throughout the 
experimental time using repeated measure analysis (time as within subject factor; exendin-4 
treatment factor and L-dopa treatment factor as between subject factors). Repeated measure 
analysis was also performed on L-dopa rotation and AIMs score data (time as within subject 
factor, exendin-4 as between subject factor). Histological data was analysed using two-way 
ANOVA to find the effect of L-dopa, exendin-4 or their interaction on the graft (between 
subject factor included exendin-4 treatment factor; and L-dopa treatment factor). Fibre 
outgrowth medially or laterally was analysed using repeated measure analysis (distance from 
the graft as within subject analysis; exendin-4 factor and L-dopa treatment factor was 
between subject factor). Bonferroni was used for multiple pairwise comparison. Two tailed t-
test was used to analysis the difference between the graft and the lesion at week 16 in 
apomorphine results and it is also used to analyse the difference between the medial and 
lateral fibre innervation in the graft alone (without treatment). The data was considered 
significant if P value < 0.05.  
 Results  
5.3.1 Percentage of the nigro-striatal dopaminergic neurons lesion  
TH cells counted in the SN showed that the percentage of dopaminergic neuronal loss on the 
lesioned side was more than 98% compared to the intact side in all experimental groups. This 
indicated an almost complete lesion of nigral dopaminergic neurons. It was therefore 
interpreted that any change in performance was due to the graft, not the treatment.  
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Figure 35 percentage of the lost dopaminergic neuron in the lesioned hemisphere compare to the 
intact side: more than 98% of the nigral dopaminergic neurons were lost in all groups. 
5.3.2 Motor and behavioural results  
5.3.2.1 The effect of the graft alone 
The graft of H9 hESC-DA produced a significant overall recovery in amphetamine-induced 
ipsilateral rotation and this effect has significant interaction with the time (graft F (1,15) = 7.4, 
**p<0.01; time*graft, F (5,75) = 16, p<0.001); the significant difference was in week 12 and 16 
(F (1,15) min week 12 = 7, p<0.01) (repeated measure ANOVA). it also has significant effect on 
apomorphine-induced contralateral rotations (week 16) (t-test, two tailed **p<0.01) 
compared to the lesion only control group. In the sensorimotor tests, the graft only group 
produced a high overall significant recovery in vibrissae tests and this effect has significant 
interaction with the time (graft, F (1,15) =11, p<0.01); graft*time F (5,75) = 5.4, p< 0.001); it 
produced this significant difference only on week 16 (F (1,15) = 17.8, p<0.001) (repeated 
measure ANOVA). Graft showed it has no significant effect in the stepping and cylinder test 
(max: cylinder test, F (1,15) max = 1.3, n.s).  
5.3.2.2 Effect of L-dopa and exendin-4 treatments on the graft  
L-dopa treatment had no overall effect on amphetamine induced-rotations (repeated 
measure ANOVA, F (1,30) = 0.1, n.s) and apomorphine-induced rotations, (two-way ANOVA, F 
(1,30) = 0.04, n.s.). Exendin-4 also had no effect on graft function in either the amphetamine-
induced rotations, (repeated measure ANOVA, F (1,30) = 0.58, n.s;) or apomorphine-induced 
rotations (two-way ANOVA, F (1,30) = 1.6, n.s.).  
In the vibrissae test, the effect of both L-dopa treatment and exendin-4 had an overall 
significant effect to improve responses and there is a significant interaction between the 
treatments (repeated measure ANOVA: L-dopa, F (1,30) = 5.6, +p< 0.05; exendin-4, F (1,30) = 9.4, 
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**p< 0.01; L-dopa x Exendin-4 F (1,30) = 5.6, p< 0.05). This interaction showed that L-dopa effect 
was significant in absence of exendin-4 (F (1,30) = 9.8, p<0.01) and had no effect in presence of 
exendin-4 (F (1,30) = 0); similarly, exendin-4 was effective in absence of L-dopa (F (1,30) = 14, 
p<0.001) and had no effect in presence of L-dopa treatment (F (1,30) = 03, n.s). This interaction 
between L-dopa and exendin-4 was also interacted with the time (time x L-dopa x exendin-4: 
F (5,150) = 4.1, p<0.001); on week 4, exendin-4 was effective in presence of L-dopa (F (1,30) = 
5,p<0.05) and not effective in saline group (F (1,30) = 1.7, n.s), while on weeks 8, 12 and 16, 
exendin-4 was effective in saline groups (min: week 16: F (1,30) = 7.8, p<0.01) and not effective 
in L-dopa group (max: week 16: F (1,30) = 2.4, n.s). 
In addition, in vibrissae test, there was a significant interaction between exendin-4 and the 
time (exendin-4 x time: F (5,150) = 3.8, p<0.01); further analysis showed that exendin-4 was 
effective in weeks 4, 8 and 12 (min: week 4: F (1,30) = 6.5, p<0.05) but it had no effect on week 
16 (F (1,30) = 0.7, n.s). There was a high tendency for interaction between L-dopa and the time 
but it was not significant (L-dopa x time: F (5,150) = 1.9, p=0.09); the close analysis showed that 
L-dopa was effective on week 8, 12 (min: week 8: F (1,30) = 4.5 p<0.05) but no effect on week 
16 (F (1,30) = 0.7, n.s) 
In cylinder tests, L-dopa and exendin-4 had no overall effect on the test (max: exendin-4 F (1,30) 
= 2.5, n.s). However, there is a significant interaction between the time, L-dopa and exendin-
4 (time x L-dopa x exendin-4: F (1,30) = 7.8, p<0.01), on week 16, L-dopa had significant 
improving effect in absence of exendin-4 (F (1,30) = 15.8, p<0.001) and had no effect in presence 
of exendin-4 (F (1,30) = 0.01, n.s); while exendin-4 had significant reducing effect in L-dopa 
group (F (1,30) =5.5, p<0.05) and had no effect in absence of L-dopa (F (1,30) = 2.9, n.s). 
In stepping test, there was no significant effect for L-dopa, exendin-4 or their interaction 
(max: exendin-4: F (1,30) = 0.4, n.s). 
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Figure 36 The effect of H9 hESC derived dopaminergic neurons graft on behavioural results: the graft 
effect was significant on reducing number of amphetamine rotations (repeated measure, ** p<0.01); 
on reducing number of apo-morphine rotations (univariant analysis, **p<0.01); on increasing rats’ 
response in vibrissae test (repeated measure, **p<0.01). the graft had no effect on the stepping and 
cylinder tests. 
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Figure 37 effect of L-dopa and exendin-4 on the motor and behavioural results: L-dopa and exendin-
4 showed they had no effect on the amphetamine rotation tests, stepping test (repeated measure 
ANOVA) and apomorphine test (two-way ANOVA). In vibrissae test, both treatment had overall 
significant effect with significant interaction between them (L-dopa, +p< 0.05, ++p< 0.01; exendin-4, 
*p< 0.05, **p< 0.01). In cylinder test, L-dopa has improving effect on week 16 only in non-exendin-4 
group (+++p<0.001). 
5.3.3 L-dopa induced dyskinesia and rotations  
Before transplantation, the dose of 12 mg/kg of L-dopa induced a fast upregulation in the 
level of contralateral rotations and total AIMs score through the 3 weeks of the treatment, as 
a result dosing was reduced and maintained for two weeks at a dose of 6 mg/kg.  
After transplantation, total AIMs scores steadily reduced through the 15 weeks following 
transplantation and the pairwise comparison with time showed that the highly significant 
reductions started from week 4 compared to the base line time point one week before 
transplantation (repeated measure analysis, **p<0.01, ***p<0.001). Exendin-4 had no effect 
on the total AIMs score (repeated measure analysis, F (1,12) = 0.003, n.s.). Similarly, L-dopa 
induced contralateral rotations reduced significantly and the pairwise comparison within the 
time showed that the significant difference started from week 5 compared to one week prior 
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to transplantation (repeated measure analysis, *p<0.05). Exendin-4 had no effect on L-dopa-
induced rotations (repeated measure, F (1,13) = 1.1, n.s).  
 
Figure 38 L-dopa induced rotation and Abnormal Involuntary Movements AIMs: (A) L-dopa induced 
contralateral rotations reduced significantly after transplantation since week 5 of the graft 
compared to baseline time point week -1(repeated measure analysis, *p<0.05); (B) total AIMs score 
reduced in high significance since week 4 of transplantation compared to week -1 (repeated 
measure analysis, **p<0.01, ***p<0.001). exendin-4 had no interference on number of L-dopa 
rotations or AIMs score. 
5.3.4 Expression of GLP-1R on the dopaminergic neurons at the graft  
Post-mortem analysis of the transplanted H9 hESC derived dopaminergic neurons in the 
lesioned striatum showed co-expression of the GLP-1 receptor with the dopaminergic 
neurons 17 weeks following transplantation.  
 
Figure 39 expression of GLP-1R in the graft: double fluorescent IHC illustrated co-expression of TH 
markers (green) with GLP-1R marker (red) in the 17 weeks graft of H9 hESC derived dopaminergic 
neurons graft. 
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5.3.5 Graft cells survival and volume  
In the graft only group (absence of L-dopa and exendin-4), total graft cell survival identified 
by HuNu was 72,300 ± 5500 cells representing 24% of the transplanted cells (300,000) and 
the graft volume identified with stem-121 was 1.3± 0.18 mm3.  The dopaminergic neurons 
identified with TH immunohistochemistry showed a robust survival, the mean of the total 
dopaminergic neurons was (16118 ± 5370 cells), the volume of the dopaminergic neurons 
graft occupied an average of 1.27 ± 0.42 mm3 of the striatum, and the dopaminergic neuron 
density was 13,461± 4,400 cells per mm3. Compared to the total graft, the dopaminergic 
neurons represented around one fifth (22.2% ± 7 %) of total cell population and 86%± 28% of 
the total graft volume. 
The adding of L-dopa and/or exendin-4 treatment to the graft had no effect on the grafts’ 
characteristic features in terms of dopaminergic cell survival, dopaminergic graft (TH) volume, 
total cell population in the graft count, total cell graft volume, proportion of the dopaminergic 
neuron count to the total cells count and the dopaminergic graft volume to the total graft 
volume (two-way ANOVA analysis).  
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Figure 40 graft analysis: the graft in all groups labelled with TH to mark the dopaminergic neurons, 
HuNu to label the nuclei of all human cells in the graft and stem-121 to label all the cytoplasm of all 
human cells in the graft. There was significant effect for the exendin-4 and L-dopa on the graft and 
there was interaction between the groups on the following measurements (dopaminergic neurons 
count, dopaminergic neurons volume, total cells population count, total graft volume, the 
proportions of dopaminergic neurons count or volume to the total graft cells count or volume) (two- 
way ANOVA). 
5.3.6 Pattern of fibres outgrowth  
In the graft group (in the absence of L-dopa and exendin-4), within 600 µm distance of graft 
centre medially and laterally, the percentage of the striatum covered by the graft fibres was 
49.6 % toward the medial side and 30.7 % at extending from the lateral side. This bias in 
sending fibres towards the medial side was significantly different from the lateral side (t- test, 
two tailed, * p< 0.05).  
The effect of L-dopa and exendin-4 on graft innervation, A relative surface area of the fibres 
at distances of 200, 400, and 600 µm medially and laterally of the graft core showed a clear 
tendency of the graft to send more fibres toward the medial side compared to the lateral side. 
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The results showed that L-dopa and exendin-4 had no effect on fibre innervation on the 
medial and lateral side and there was no interaction between the treatments (F (1,28) max 
exendin-4, medially = 2.6, n.s) (repeated measure ANOVA, distance was the between subject 
factor). However, the data analysis at only 600 µm distance point showed that exendin-4 has 
a significant effect on increasing the percentage of striatal area covered by the graft fibres 
(two-way ANOVA: exendin-4, F (1,30) = 4.9, p<0.05).  
 
Figure 41 fibres outgrowth pattern: (A) in graft without treatments, the mean percentage of fibres 
covered the striatum throughout 600 µm of graft centre was 49.6 % medially and 30.7 % laterally 
with significant difference (t-test, p <0.05; (B) image for the graft showing pattern of TH innervation 
in the striatum; (C) effect of treatments on fibres surface area at distances of 200, 400, 600 µm of 
the graft centre medially and laterally showed there is no overall significant effect of the L-dopa and 
exendin-4 on fibres outgrowth and no interaction between the treatments (repeated measure 
analysis). However, at 600 µm distance point, exendin increase fibres surface area significantly (two-
way ANOVA analysis, exendin-4, p<0.05, L-dopa, n.s.)   G= graft, LD = L-dopa, Ex = exendin-4 
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5.3.7 Microglial density around the graft  
The ratio of microglia stained with CD11b around the graft relative to the intact side was not 
significantly difference between the grafted groups, either in the presence or absence of L-
dopa. Similarly, the addition of exendin-4 did not affect the level of activated microglia around 
the graft (two-way ANOVA, F (1,27) max L-dopa = 0.7, n.s).   
 
Figure 42 microglia labelled CD11b density around the graft: the measurement of the optical density 
of CD11b stain around the graft compared to the intact side of the striatum showed there was no 
significand difference in microglia density around the graft between all the transplanted groups 
(two-way ANOVA, n.s).  
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 Discussion 
H9 hESC derived dopaminergic neurons graft (without treatments) characterisation: 
The histological features of the graft illustrate a robust survival of total cells in the graft 
(HuNu) at a rate exceeding 23% of the cells prepared for transplantation and the 
dopaminergic neurons (TH+) constituted about 22% of the cells in the graft (around 15,000 
cells). These histological features were consistent with Kirkeby and colleagues, which used 
the same cell source and they even reported a greater yield of dopaminergic neurons from 
transplanted cells compare to the present study (around  18,000 per each 100,000 
transplanted cells) (Kirkeby et al. 2012). The current histological findings were consistent with 
the functional efficacy of the graft which was evaluated using different behavioural and 
sensorimotor tests throughout this study. The confirmation that there was almost complete 
depletion of endogenous dopaminergic neurons demonstrated that the graft alone produced 
all motor function improvement. In the amphetamine-induced rotation test, which is used to 
assess the functional ability of the graft to release dopamine, a clear decline in the number of 
rotations since week 12 reflected the high dopaminergic population in the graft at post 
mortem. This is consistent with Kirkeby and colleagues who similarly reported the 
functionality of the same hESC-DA graft from week 12 of transplantation (Kirkeby et al. 2012) 
in the same assay.  In a more detailed behavioural analysis the apomorphine test clarified 
whether the graft could normalise the sensitivity of the striatum created by the dopaminergic 
depleting lesion. Apomorphine is a non-selective dopamine receptor agonist which induces 
contralateral rotations in the unilaterally 6-OHDA rats due to super-sensitivity of the 
dopamine receptors on the lesioned side due to the lack of dopamine. So, the data confirmed 
that the pooled dopamine by the graft was efficient to partially reverse this sensitivity. So, 
both amphetamine rotation and apomorphine rotation data demonstrated the functionality 
of the H9 hESC graft.  
Despite a robust survival of the dopaminergic cells in the graft and functionality of the graft 
to release dopamine, of all the sensorimotor tests, only the vibrissae test showed an 
improvement in motor function while deficits failed to recover in any of other tests (cylinder 
or adjusting step) recovered. This may suggest that 16 weeks was not long enough for the 
graft to have developed full functional therapeutic value. However, the Kirkeby study, which 
used the same cell source for transplantation, showed that the graft can alleviate number of 
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touches in the cylinder test significantly on week 14 of transplantation (Kirkeby et al. 2012). 
The limited functional recovery could be attributed to the low tendency of the graft to send 
fibres toward lateral side of the striatum while spreading the fibres favourably toward the 
medial side. Previous work clarified that better recovery for the sensorimotor tests is achieved 
from wider spread of the graft in the striatum (Falkenstein et al. 2009).  In particular, the 
motor parts of the cortex send projections primarily to the dorsal and lateral portion of the 
striatum (Haber 2014), of which the latter had the lower innervation in the present study. 
Kriks et al transplanted H9 hESC-DA into the 6-OHDA-lesioned rat, which produced a graft 
that had histological features similar to the present study in terms of cell survival and volume. 
A published image (figure 4e in the paper) in this study shows an extensive graft innervation 
at the lateral side of the striatum suggested that this graft may have a preferable innervation 
toward lateral side. The grafts in this study reportedly alleviated stepping and cylinder tests 
significantly from week 12 following transplantation (Kriks et al. 2011) which is contrary to 
the present study. The developed dopaminergic neurons in both the Kriks et al study and the 
current study started from the same cell line (H9 hESC) and carry the essential protein 
expressions of midbrain dopaminergic neurons, but they were developed using different 
differentiation protocols (Kriks et al. 2011; Kirkeby et al. 2012). So, the difference in the motor 
recovery between current study and Kirks et al study could be related to the pattern of 
innervation in the lateral side of the striatum or possible a difference between the 
transplanted dopaminergic neurons due to the difference in the generating protocols. 
Effect of graft on alleviation of L-dopa induced dyskinesia and rotations  
The current study shows, for the first time, that hESC derived grafts can ameliorate L-dopa 
induced dyskinesia. The graft reduced AIMs scores at early post transplantation stages, even 
earlier than relieving motor and behavioural complications. The capability of the graft to 
alleviate LID in rodent model has previously been shown with foetal cells but has not been 
attempted with hESC-DA until now. Clinical cases report that VM cell transplantation can 
increase “on” time  without dyskinesia (Kordower et al. 1998). In animal models, several 
studies from this lab have confirmed the capability of a VM graft to reduce AIMs scores 
(Breger et al. 2016; Lane et al. 2006). Different mechanisms have been suggested for the 
development of LID (reviewed in section 1.5.2), the most common theory is the dysregulation 
of synaptic dopamine levels after administration of exogenous L-dopa causing excessive and 
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pulsatile stimulation to the striatal dopamine receptors. Chronic L-dopa administration leads 
to long term plasticity in the dopamine receptors which increases sensitivity to dopaminergic 
stimulation. Uncontrolled synaptic dopamine levels are mostly due to the lack or reduction of 
the dopamine transporter DAT, a compensatory mechanism due to the degeneration of 
dopaminergic neurons. Recently the action of DAT on reducing LID was confirmed by a study 
showed that transplantation of non-dopaminergic cells (C17.2 cells) expressing DAT can 
reduce the dyskinesia score (Tomas et al. 2016). So, it is expected that stem cells controlled 
the LID dyskinesia via controlling the dopamine in the synapse via DAT or probably via 
reducing the striatum sensitivity by reversing the abnormal cell signalling and the genomic 
change that leads the dyskinesia, however the full mechanism remains to be elucidated. 
Similarly, L-dopa-induced rotations were reduced by the stem cell grafts in time parallel to 
the reduction in AIMs score where the rats reached a static state of locomotion by week 4. 
The mechanism by which the graft reduced the L-dopa rotations is also dependent on 
termination of the dopamine action in the synapse by DAT. Without DAT, the stimulation of 
the dopamine at the DA receptors on the lesioned side is higher than the intact side causing 
the contralateral rotations. The ability of the hESC-DA to ameliorate L-dopa induce dyskinesia 
and rotations confirmed the functionality of these cells and relatively at early stages.   
Effect of L-dopa treatment on the graft function, efficacy and histological characteristics: 
Importantly, this data indicated for the first time that a graft transplanted into an 
environment receiving regular L-DOPA is not impaired in terms of survival or functionality. L-
DOPA had no effect on the amphetamine-induced rotation test, the pattern of reduced 
rotations was identical in the presence or absence of L-dopa throughout the experimental 
time. This indicated that L-dopa did not affect the pattern of graft releasing dopamine 
throughout the graft maturation over 16 weeks.  It also did not change the effectiveness of 
the graft on reversing dopamine receptor sensitivity as the apomorphine test showed no 
difference in the action of the graft in the presence or absence of L-dopa treatment.  
The histological data clarified that L-dopa had no effect on the dopaminergic neurons survival, 
volume and fibres outgrowth. However, Interestingly, L-dopa had an overall supportive effect 
on improving the efficacy of the graft in the vibrissae test, which is the only parameter that 
recovered by H9 hESC-DA graft in this study. In addition it has improvement effect in cylinder 
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test in absence of exendin-4 treatment.  A possible reason for this improvement could be 
related to improve graft maturation or accelerate graft maturation. The data showed there 
was a tendency for interaction of L-dopa effect with the time (p = 0.09). A close analysis 
illustrated that L-dopa effect reduced with the time, it has a significant effect on week 8 and 
12 but no effect on week 16. This interaction tendency could be significant if longer 
experimental time was run, as further graft maturation may end with no more difference of 
L-dopa effect on the graft function.  
The other interesting finding of L-dopa effectiveness on behavioural tests is it has interaction 
with exendin-4. The data showed that L-dopa was non-effective in vibrissae test in presence 
of exendin-4 at weeks 8, 12 and 16 and in cylinder test in week 16. This interaction is 
consistent with the interaction of exendin-4 and L-dopa in chapter 4, which involved 
developing insulin resistance leads to reduce exendin-4 effect of graft survival and function 
(discussed in chapter 4). Similar changes in the glucose and insulin homeostasis could be 
happened from this interaction in this chapter lead to reduce the effect of L-dopa. However, 
further histological and plasma analysis needs to support this hypothesis.  
The effect of exendin-4 on the functionality and histological characteristics of the graft  
Exendin-4 has neuroprotective effects in VM dopaminergic neurons transplanted in the 
depleted striatum of 6-OHDA rat model (chapter 5). Given that the H9 hESC-DA has the same 
midbrain dopaminergic neurons criteria, it was relevant to investigate whether the same 
degree of protection can be applied on H9 hESC-DA transplantation. The histological results 
indicate expression of the GLP-1 receptors on the dopaminergic neurons of the graft, thus the 
molecular machinery for exendin-4 to produce an effect was also available. However, 
exendin-4 did not have an effect on graft survival or volume neither in dopaminergic neurons 
nor on other cells in the graft indicating it has no protective effect on the transplanted cells. 
it also showed it has no effect on the graft fibres outgrowth. This was reflected in the 
behavioural data which showed no impact of exendin-4 on any of the drug-induced motor 
tests.  
However, exendin-4 may have therapeutic value in the support of graft function as it did have 
a significant effect on recovering graft function in the vibrissae test. This improvement could 
be a result of improving or accelerating graft maturation. The data showed a significant 
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interaction between exendin-4 and the time and lost its effectiveness in the last time point 
(week 16).  
Similar to L-dopa, the effectiveness of exendin-4 on behavioural tests was also affected by 
interaction with L-dopa. In vibrissae test, at early time point (week 4) the presence of L-dopa 
was supportive to the exendin-4 action as the latter produced better effect in presence of L-
dopa. However, in the later time points (weeks 8, 12 and 16), L-dopa reduced the action of 
exendin-4. Furthermore, in week 16, exendin-4 had deteriorating effect in the cylinder test in 
presence of L-dopa. This may suggest that the L-dopa has potentiate the effectiveness of 
exendin-4 on graft at early time point but then possible physiological changes in insulin 
haemostasis resulted from both drugs interaction may lead reduce the effect of exendin-4. 
This adds further weight to evidence that exendin-4 may have a beneficial effect on graft 
function but that this is negated by the presence of L-DOPA. 
The possible reasons why exendin-4 did not illustrate those same robust effects on graft 
function and survival as shown on the primary cell transplantation (chapter 4) include: 1) the 
lower dose used in this experiment, as exendin-4 used here was lower in dose frequency (0.5 
µg/kg) once daily instead of twice daily due to the poor health of the animals (rapid weight 
loss was observed in treated animals requiring us to alter the protocol for animal health 
reasons); 2) A possible interaction between cyclosporine and exendin-4 could lead to the 
former counteracting the action of the later. It has been explained in chapter 4 that exendin-
4 metabolism in the kidney produces metabolites that have mild to moderate antagonistic 
effects on the GLP1 receptors and both exendin-4 and its metabolites are excreted via the 
kidney. Studies showed that cyclosporine at a dose of 5mg/kg for a long period  (9 weeks) 
caused nephrotoxicity characterised by tubulointerstitial  lesion and reduction in the 
glomerular filtration rate GFR (Sereno et al. 2015; Sereno et al. 2014).  
The present study reports a severe reduction in the weight of the rats who were treated with 
exendin-4 after 2 weeks of starting the exndin-4 treatment, especially in group with L-dopa. 
This reduction in weight is believed to be related to the exendin-4 treatment rather than the 
graft as it was only present in groups treated with exendin-4 and all rats improved after 
reducing the dose of exendin-4. In particular, it is well recognised from pre-clinical and clinical 
studies that GLP-1 and GLP-1 receptor agonists promote satiety and weight loss (Baggio & 
Drucker 2007). A possible interaction between exendin-4 and cyclosporine-A could also be 
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the cause of the rats’ weight reduction by exendin-4. In chapter 4 cyclosporine treatment was 
not necessary and none of the grafted rats treated with exendin-4 had weight loss.  In chapter 
6 with the same protocol, a severe weight loss was similarly observed in the exendin plus 
cyclosporine treated animals. This consolidates a possible interaction between exendin-4 and 
cyclosporine-A. This is important for clinical translation because patients will be receiving 
both L-dopa and cyclosporine for the first few months’ post-transplantation at a minimum.  
Impact of exendin-4 and L-dopa on the microglia reaction around the graft 
Exendin-4 and L-dopa had no effect on the levels of microglia around the graft. In contrast, L-
dopa had a notable effect on increasing the level of microglia around allogenic VM grafts and 
this effect was exaggerated in the presence of exendin-4 chapter 4 (section 4.3.8). It has been 
suggested that developed insulin resistance in rats treated with exendin-4 and L-dopa leads 
to induce level of microglia around the graft (discussed in chapter 4). Possible reasons for the 
absence of this effect of L-dopa could be related to the presence of the immunosuppressant 
agent cyclosporine or to the reduced dose of exendin-4. 
Safety, stability and graft side effect 
The current study showed that the transplantation of dopaminergic neurons derived from H9 
hESC utilising the Kirkeby protocol produced no evidence of any tumour over 17 weeks of 
transplantation neither in the presence nor absence of L-dopa. Importantly, this is the first 
study to have attempted to determine whether GID could be induced by hESC derived grafts. 
No evidence of GID was observed either in the presence of L-DOPA, amphetamine or in their 
spontaneous behaviours. Amphetamine stimulation is needed to evaluate GID risk in animal 
models (Lane et al. 2006). At week 16 none of the rats showed any signs of GID when tested 
under the influence of amphetamine. So, the present data suggests that the grafts either with 
or without L-dopa are safe, stable and without GID throughout the 16 weeks of the 
experiment.   
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 Conclusion  
This chapter demonstrates that the H9 hESC- derived dopaminergic neurons can survive and 
function in an animal model exposed to the chronic administration of L-dopa treatment in the 
same manner as a non-L-dopa exposed model. Furthermore, L-dopa has supportive effects 
on some of the motor tests performed and this effect could be a result from either supporting 
graft function at early stages post-transplantation or due to acceleration of graft maturation. 
H9 hESC-DA also ameliorated LID and L-dopa-induced rotations at early stages post-
transplantation, earlier than relieving other motor deficits. This chapter also demonstrated 
that exendin-4, the neuroprotective agent, has no effect on protecting or improving survival 
of the H9 hESC-DA cells. However, it demonstrated the ability to improve some motor tasks, 
this effect may be due to improve or accelerate graft maturation. The current chapter 
answered important questions about the effect of L-dopa and exendin-4 on hESC-DA. 
However, other questions are raised about if this result is unique to this cell line or could be 
applied to another hESC line; given that some of this data is consistent with foetal cell studies 
in chapter 4 but some elements are different. So, the next chapter will explore the effect of 
L-dopa and exendin-4 in grafts derived from an alternate hESC line.  
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6 Chapter 6: the impact of L-dopa and exendin-4 on 
transplanted RC17 human embryonic stem cell 
(hESC)- derived dopaminergic neurons   
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 Introduction  
The translation of stem cell therapy from animal models through to clinical trials requires the 
use of dopaminergic neurons generated from clinical grade and genetically stable stem cell 
lines. These directed lines then require differentiation with clinical grade materials to 
generate dopaminergic neurons prior to transplantation into people with Parkinson’s disease. 
The genetic stability of the cell line is an essential factor to be consider in stem cell therapy to 
avoid the possibility of these cells developing a carcinogenic phenotype – continuous, 
unchecked proliferation. Some pluripotent stem cell lines have multipotency and self-renewal 
characteristics similar to cancer cells and some others gain chromosomes when cultured for 
a long time (Stephenson et al. 2010; Baker et al. 2007; Draper et al. 2004). Recently, Canham 
and colleagues screened the genetic stability of 25 hESC lines which they are established 
under clinical grade Good Manufacturing Practice (GMP) conditions in the UK (the genetic 
stability of the H9 cell line used in chapter 5 has not been explored yet). They used a whole-
genome single nucleotide polymorphism (SNP) array analysis to determine copy number 
variation (CNV) and copy-neutral loss of heterozygosity (CN-LOH) in isolated genome of the 
cell lines. They found 9 of these cell lines have structural genomic variance identical to the 
health cells while 15 cell lines have CNV greater than 100 kb, however most of these variations 
were found to be commonly occurring in health individual when checked in the genomic 
variant database (Canham et al. 2015). RC17 cell line was one of the hESC lines which was 
screened by Canham and colleagues and they reported that RC17 cell line have CNV equal to 
144 kb which is commonly occurring in healthy cells in a ratio of 1:25. 
Tilo Kunath at Edinburg University has generated dopaminergic neurons carrying midbrain 
markers from RC17 hESCs. They adapted a protocol modified from Kirkeby and colleagues 
which depends on dual SMAD inhibition to direct cells towards a neural fate, followed by 
adding SHH and activation of WNT signal to yield the midbrain criteria dopaminergic neurons. 
Clinical grade materials are used to direct the RC17 stem cells to create the dopaminergic 
neurons which made these cells clinically applicable (Tilo Kunath, Personal Communication, 
NECTAR 2014). These cells were recently transplanted into the 6-OHDA lesioned rat by the 
Brain Repair Group at Cardiff University. These cells were capable of surviving and functioning 
in the dopamine depleted striatum. Interestingly, the size of this graft was relatively small and 
characterised by long fibre projections within the striatum which may make them efficient to 
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cover the striatum with less dopaminergic neurons (Mariah Lelos, Personal communication, 
NECTAR 2016).  
In chapter 5, I clarified the importance of testing cell transplantation in an animal model 
exposed to anti-parkinsonian medication and for that purpose H9 hESC derived dopaminergic 
neurons were evaluated in the 6-OHDA lesioned rat model exposed to regular L-dopa 
treatment.  In addition, in chapter 4, I also demonstrated that exendin-4 behaves as a 
neuroprotective agent that supported the survival and efficacy of primary cells 
transplantation in the 6-OHDA lesioned rat. It is important to determine whether these 
findings translate to other dopaminergic neurons derived from other hES cell lines and 
therefore can be more generalizable. Given that RC17 grafts appear to have a different 
histological phenotype after transplantation and are generated via different a protocol. I 
decided to use this line, in collaboration with Kunath and colleagues, which also has the added 
advantage of matching the clinical grade criteria. So, I hypothesised that L-dopa and exendin-
4 can change the efficacy and histological features of the RC17 hESC-derived dopaminergic 
neurons graft in unilateral 6-OHDA lesioned rat model of Parkinson’s disease. 
Aims: 
• Determine the efficacy and survival of RC17 hESC-derived dopaminergic neurons graft 
in 6-OHDA rat model. 
• Understand the potential of exendin-4 to protect late stage degeneration and/or 
transplanted dopaminergic neurons to increase survival. 
• Understand the extent and pattern of L-dopa effect on the efficacy and survival of the 
graft. 
The objectives of the study are to use the unilateral 6-OHDA lesioned rat model to determine: 
1. whether exendin-4 has neuroprotective effects at prolonged post lesion intervals.  
2. the ability of transplanted RC17 hESC- derived dopaminergic neurons to ameliorate 
motor and behavioural deficits followed by characterisation of the histological 
features of the graft. 
3. the effect of L-dopa on the survival and function of the hESC derived graft. 
4. the ability of the graft to ameliorate L-dopa induced dyskinesia. 
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5. the presence of GLP-1 receptors on the RC17 hESCs- derived dopaminergic neuronal 
graft. 
6. the therapeutic value of adding exendin-4 to the grafted groups on supporting the 
behavioural results and its effect on the histological features of the graft.  
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 Experimental design and methodology 
 
 
Figure 43 experimental time line and the grouping  
57 female Sprague Dawley rats underwent 6-OHDA unilateral lesion surgery to the right 
medial forebrain bundle (section 2.2.1). Three weeks later, the extent of the nigral 
dopaminergic lesion was evaluated by amphetamine rotation, the successfully lesioned rats 
were selected based on more than 6 ipsilateral rotations per min. The lesioned rats were then 
divided into 6 groups: lesion only control group; lesion plus exendin-4; and four groups were 
transplanted with the RC17 hESC derived dopaminergic neurons into the depleted striatum 
(section 2.2.2.2.2) and divided into the following: graft only; graft plus exendin-4; graft plus 
L-dopa; graft plus L-dopa and exendin-4 (see grouping in Figure 43). A range of motor and 
behaviour tests, including amphetamine rotations, adjusting step and vibrissae tests were 
conducted one week before transplantation and at 4 time points (every 4 weeks) after 
transplantation surgery, the cylinder test was performed prior to transplantation and at week 
16 while apomorphine rotations were carried out only at week 16. Abnormal Involuntary 
Movements (AIMs) and L-dopa-induced rotations were tested once a week before and after 
cell transplantation from the initiation of L-dopa treatment (section 2.4). Both L-dopa and 
exendin-4 treatments were stopped 2 days before each behavioural and motor test to wash 
out their pharmacological effects. On week 17 of transplantation, all rats were perfused and 
the brains were collected for histological analysis. DAB-IHC was used to determine: the 
number of dopaminergic neurons in the graft and confirm the degree of loss in the SN (TH); 
the number of human cells surviving (HuNu staining human nuclei) and Stem-121 to label 
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human cytoplasm; and density of microglia around the graft (CD11b) (section 2.10.1). Double 
F-IHC was used to co-localise TH and GLP-1R (section 2.10.2).  
6.2.1 Treatments  
L-dopa was started 4 weeks before cell transplantation surgery and continued for 15 weeks 
after transplantation. Rats were immunosuppressed with Cyclosporine-A (10 mg/kg), and was 
started one day before cell transplantation and continued every 24 hrs until the end of the 
experiment. Exendin-4 treatment was started immediately after transplantation surgery and 
continued until week 15 post-transplantation.  
L-dopa was used at a dose of 6 mg/kg/ day in combination with a double proportion of 
benserazide and administered daily, s.c.. Exendin-4 was given at dose of 0.5 µg/kg (i.p.) twice 
daily for the first two weeks after cell transplantaton. Severe weight loss in some animals led 
to a reduction in frequency to once daily administration. L-dopa and exendin-4 treatment 
were stopped 2 days before each behavioural and motor test.  
6.2.2 TH fibre outgrowth measurement 
Fibre outgrowth was analysed in this chapter by two different methods. The first method 
aimed to compare the fibre measurement between the groups. The images of the grafts were 
captured at 10X magnification using an Olympus B 50 microscope, the images were then 
inverted to the dark field using ImageJ to allow easy recognition of the stained TH fibres from 
the background. A grid was applied across the image on dimensions of 100*100 µm. Then the 
number of fibres intersecting with the vertical line of the grid at distances of 200, 400 and 600 
µm were counted manually across the medial and lateral side of graft borders (Figure 44). The 
second method aimed to measure the percentage of the striatum that was covered by the 
graft fibres medially and laterally within 600 µm distance of the graft centre in the graft only 
group. ImageJ software was used to adjust the image threshold selectively to the fibres area 
then the proportion of area that was covered in the striatum expressed as a percentage of 
the striatal area was calculated. The process included reducing the image background and 
enhance the threshold selectivity to the fibres by using the following steps (Second method, 
Figure 44): inverting the image to dark field then enhancing the image contrast (image B); re-
inverting the image to the brightfield (image C); using IHC tool to select DAB colour and 
remove other colours (image D); inverting image to dark field again (image E) and applying 
the image filter process using Gaussian blur option (image F); re-inverting the image to white 
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field and converting the image to the grey scale (8 bit) then the image threshold selection was 
applied (image G) followed by calculating the percentage of the threshold surface area in the 
selected image.  
 
Figure 44 fibre outgrowth analysis methods using ImageJ software: first method included inverting 
the image to dark field followed applying 100*100 grid then the fibres intersected with vertical line 
of grid counted at distances 200, 400, 600 µm; second method included a process of reducing image 
background (A to G) then the percentage of threshold surface area in the selected image was 
counted. 
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6.2.3 Statistical analysis  
The data was analysed using SPSS. Repeated measure analysis was performed in the 
behavioural results to determine the effect of time, graft, and drug treatments (L-dopa, 
exendin-4 and their interaction). Two-way ANOVA was used to analyse the effect of L-dopa, 
exendin-4 and their interaction on the graft in the apomorphine-induced rotation results and 
the histological analysis of the graft. AIMs score and L-dopa rotation were analysed using 
repeated measure analysis. Bonferroni post hoc was selected for pairwise comparison. 
Selected T-test analysis was used to analyse the apomorphine results comparing graft and 
lesion or comparing lesion to lesion plus exendin-4.  
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 Results 
6.3.1 Nigrostriatal dopaminergic lesion 
The initial amphetamine-induced rotation test showed that all lesioned rats rotated ipsilateral 
more than 6 rotations per minute indicating that more than 90% of the nigral dopaminergic 
neurons were degenerated. The histological data confirmed this and showed that more than 
97% of the nigral dopaminergic neuron were depleted in the right hemisphere (Figure 45). 
This confirms that the behavioural tests were evaluating the graft effect on the behavioural 
recovery outcomes and nigrostriatal dopaminergic neurons were not affected by the use of 
the different agents. 
 
Figure 45 nigrostriatal dopaminergic lesion:  percentage of the lost nigrostriatal dopaminergic 
neurons in the right hemisphere compared to the intact side was more than 97% in all groups  
  
6.3.2 Behavioural results  
6.3.2.1 Effect of exendin-4 on the lesion group 
 The purpose of testing effect of exendin-4 to lesion control group is to confirm that exendin-
4 alone has no effect on this late post lesion interval. The behavioural tests (amphetamine-
induced rotation test, apomorphine-induced rotation test, stepping, vibrissae, and cylinder 
tests) confirmed that exendin-4 had no effect on the behavioural outcomes of the lesion 
group throughout the 16 weeks of treatments (repeated measure ANOVA).  
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6.3.2.2 The effect of graft alone (absence of L-dopa and exendin-4) 
 The presence of the RC17 hESC derived graft had no significant effect on any of the motor 
and behavioural results (amphetamine rotation, apomorphine rotation, stepping, vibrissae 
and cylinder tests) over the 16 weeks following transplantation; However, there was a trend 
for a reduction in the amphetamine-induced rotations but without statistical difference 
(repeated measure ANOVA, max: amphetamine test, F (1,16) = 2.98, p = 0.1, n.s; apomorphine: 
t-test, 2-tailed, n.s). A more detailed look at the pattern of amphetamine-induced rotations 
on pre-transplantation and week 16 showed that the grafted rats started rotation at a lower 
level than the lesion group in week 16. Analysis of the rotation through-out first 40 min of 
amphetamine injection at both time points showed that the overall effect of the graft was 
not significant (F (1,16) =1.9, n.s) but it has interaction with time (time*graft, F (1,16) = 8.2, 
p<0.01); the graft has significant reducing effect on week 16 (F (1,16) = 5.14), p<0.05) (repeated 
measure ANOVA, group was between subject factor; time was within subject factor).   
6.3.2.3 Effect of L-dopa and exendin-4 treatments on the graft:  
There was no significant effect of L-dopa, exendin-4 or their combination on amphetamine 
rotations throughout the 16 weeks on the graft, However, there was a tendency for 
amelioration in the number of rotations in response to L-DOPA (repeated measure ANOVA: 
L-dopa effect, F (1,33) = 3.1, p = 0.08; exendin-4 effect, F (1,33) = 0.06, n.s; exendin-4 and L-dopa 
interaction, F (1,33) = 0.152, n.s). In the apomorphine rotation test, there was no significant 
effect of treatment, however there was a tendency for exendin-4 to reduce the number of 
rotations (two-way ANOVA: exendin-4 effect, F (1,33) = 4, p =0.052; L-dopa effect, F (1,33) = 1, p 
= 0.3; interaction, F (1,33) = 0.02, n.s). Similarly, treatments had no significant effect on 
stepping, vibrissae and cylinder tests (repeated measure analysis).  
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Figure 46 effect of exendin-4 on behavioural outcomes of 6-OHDA lesion rat model: exendin-4 had 
no significant effect on the lesion control group in any of behavioural results amphetamine-induced 
rotation test (A), vibrissae test (B), (cylinder test), stepping test (D), and apomorphine-induced 
rotation test (E) (repeated measure analysis).  
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Figure 47 effect of RC17 hESC-derived dopaminergic neurons graft (without treatments) on 
behavioural and motor results: RC17 hESC-DA graft had no significant effect on the lesion control 
group in any of behavioural results amphetamine-induced rotation test (A), vibrissae test (B), 
(cylinder test), stepping test (D), and apomorphine-induced rotation test (E) (repeated measure 
analysis). 
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Figure 48 pattern of amphetamine-induced rotations of the graft (without treatment) throughout 90 
min pre-transplantation (A) and on week 16 post- transplantation (B). figure (C) showed significant 
reduction in the ipsilateral rotation through-out first 40 of amphetamine injection (repeated 
measure analysis, *p<0.05).  
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Figure 49 effect of L-dopa and exendin-4 of the behavioural results of the graft: L-dopa showed a 
tendency to ameliorate amphetamine induced rotations without significant difference (figure A) 
(repeated measure analysis); neither L-dopa nor exendin-4 had effect on the vibrissae (B), cylinder 
(C), stepping (D) (repeated measure analysis) and apomorphine rotation tests (E) (two-way ANOVA). 
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6.3.3 L-dopa induced Abnormal Involuntary Movements (AIMs) and rotations 
L-dopa-induced dyskinesia, reflected in the total AIMs score gradually reduced throughout 
the 16 weeks following transplantation. The overall effect of the graft to reduce the AIMs 
score was highly significant and pairwise comparison to the base line time point (week -1) 
showed a significant reduction from week 3 post transplantation (repeated measure ANOVA, 
***p< 0.001). Exendin-4 has no effect on AIMs score post transplantation (repeated measure 
ANOVA, F (1,18) = 0.185, P = 0.696).  
The number of L-dopa-induced contralateral rotations was significantly reduced in both graft 
and graft plus exendin-4 groups. The overall effect of the graft, throughout the experimental 
time, on reducing the number of contralateral rotations was significant; the pairwise 
comparison with base line time point before transplantation (week -1) showed a significant 
difference from week 7 following transplantation (repeated measure ANOVA, *P< 0.05). 
There was no additional effect of exendin (repeated measure ANOVA, F (1,18) = 1.55, P = 0.229).  
 
Figure 50 L-dopa- induced rotation and AIMs: figure (A) the overall effect of graft on reducing 
number of contralateral rotations was significant throughout 16 weeks of transplantation and 
without statistical difference between the graft and graft plus exendin-4 groups (repeated measure 
analysis, *p<0.05). Figure (B) the overall effect of graft on reducing AIMs score was highly significant 
throughout 16 weeks of transplantation without statistical effect for the exendin-4 treatment 
(repeated measure analysis, ***p<0.001).  
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6.3.4 Expression of GLP-1 receptor on the graft  
GLP-1 receptors were colocalised with on TH labelled cells in the graft of RC17 hESC derived 
dopaminergic neurons after 17 weeks of transplantation.  
 
 
Figure 51 expression of GLP-1R in RC17 hESC graft: double fluorescent IHC showed co-localisation of 
TH markers (green) with GLP-1R marker (red) in 17 weeks’ graft. 
 
6.3.5 Histological analysis of the graft  
The histological characteristics of the graft alone (absence of L-dopa and exendin-4): The 
average number of dopaminergic neurons in the graft, identified by TH 
immunohistochemistry was 532 ± 88 cells; the average volume of the TH positive graft was 
0.066 mm3; with a density of 8000 cells per mm3. To examine the total grafted cell population, 
we labelled all the grafted human cells with HuNu. The average graft size with human cells 
was 2004± 88 cells; the average of the total graft volume labelled with stem121 was 0.08 ± 
0.016 mm3. This gave an average number of dopaminergic neurons as a proportion of the 
total cell population in the graft as 46% with an average proportion of TH volume to the total 
graft volume of about 88%. The percentage of the yielded dopaminergic neurons in the graft 
was about 0.1% of the number of the cells transplanted in this experiment (500,000 cells).  
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L-dopa, exendin-4 and their combination had no effect on the number and the volume of 
the dopaminergic neurons TH+ in the graft (two-way ANOVA). They also had no effect on the 
total grafted cells population number labelled HuNu or volume labelled stem121 (two-way 
ANOVA, L-dopa, F (1,29) = 0.2; exendin-4, F (1,29) = 0.12, n.s.). The proportions of dopaminergic 
neurons count TH+ to the total number of cell populations in the graft HuNu (TH count/ 
HuNu count) was not changed significantly by either L-dopa or exendin-4 and without 
significant interaction between both treatments; however, exendin-4 illustrated a trend to 
reduce TH/HuNu ratio (two-way ANOVA, exendin-4, F (1,29) = 1.8, n.s.). While, the 
proportions of dopaminergic neurons volume TH+ to the total cell populations graft volume 
stem121 (TH volume/ stem121 volume) was reduced significantly by exendin-4 (two-way 
ANOVA, F (1,29) = 4.212, p < 0.05).    
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Figure 52 histological analysis of the graft: two-way ANOVA analysis used to determine the effect of 
L-dopa, exendin-4 and their interaction on the: both treatments and their interaction had no effect 
on  (A) TH count; (B) HuNu count; (D) TH volume; (C) stem121 volume; (E) TH count/TH volume; (F) 
TH count/HuNu count; while exendin-4  showed a significant overall effect on reducing the 
Proportion of TH volume to the total graft volume stem121 (TH volume/ stem121 volume) (G) (two-
way ANOVA analysis, *p<0.05). 
 
6.3.6 Fibres outgrowth pattern of the graft  
In the grafted group (absence of L-dopa and exendin-4), the percentage of fibres covering the 
striatum at a distance 600 µm distance from the graft centre was about 5 % towards the 
medial side and 1.84% toward the lateral side of the striatum. The tendency of sending fibres 
medially was significantly different from the lateral side (t- test, two tailed, * p< 0.05). 
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 We evaluated the effect of the treatments on the graft innervation, counting the number of 
fibres at the distances of 200, 400, and 600 µm from the graft centre medially and laterally. 
This showed that the bias for medial project was unchanged by the addition of L-dopa and / 
or exendin-4. The statistical analysis showed that both treatments and their interactions has 
no significant effect on fibre projections at either of the 3 distance points from the graft centre 
medially and laterally (Repeated Measures ANOVA).  
 
Figure 53 fibres outgrowth measurement: (A) number of counted fibres at distances of 200, 400, 600 
µm of the graft centre medially and laterally showed there is no significant effect of the L-dopa and 
exendin-4 on fibres outgrowth (repeated measure analysis). (B) in graft only group, the mean 
percentage of fibres covering the striatum was 5% medially and 1.8 % laterally within 600 µm 
distance from the graft core; there is significant bias toward medial projections (t-test, p <0.05). (G= 
graft, LD = L-dopa, Ex = exendin-4) 
168 
 
6.3.7 Microglial level around the graft  
Measuring the optical density of microglia stained CD11b around the graft relative to the 
intact side illustrated that the graft and the lesion control group have similar levels of 
inflammation. There was no effect of L-dopa, exendin-4 and their combination on the level of 
microglia around the graft. However, L-dopa induced a trend to increase the level of microglia 
around the graft without statistical difference (two-way ANOVA: L-dopa, F (1,31) = 4.09, P= 
0.052; exendin-4, n.s.; interaction, n.s.).  
 
Figure 54 relative optical density of activated microglia labelled CD11b around the graft compared to 
the intact side of the striatum: L-dopa and exendin-4 or their interactions had no effect on the level 
activated microglia around the graft.   
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 Discussion  
Therapeutic value and histological characterisation of RC17 hESC – derived dopaminergic 
neurons graft (in absence of L-dopa and exendin-4): 
The behavioural data illustrated that the graft has only a trend to recover amphetamine-
induced rotations without an effect on other behavioural tests up to 16 weeks of 
transplantation. However, the data from analysing the pattern of amphetamine rotations on 
week 16 illustrated that the graft was functional at the early phase of the amphetamine 
response and the graft reduced the number of rotations significantly over the first 50 min of 
the assessment. This early phase rotation reduction is likely to be the most relevant to the 
initial burst of dopamine release (Lane et al. 2006). This may suggest that the graft is 
functional but not mature enough at this stage to release sufficient dopamine in response to 
amphetamine effect. The pattern of rotations showed that the difference in number of 
rotations between the groups was narrowed at the second hour of the test and consequently 
the difference in the net rotation between the groups was insignificant. The response to 
apomorphine confirmed that dopamine receptor super-sensitivity was not affected by the 
graft, also indicative that this was too immature to release sufficient dopamine to normalise 
striatal receptor dysregulation. Previous experiments conducted by the Brain Repair Group at 
Cardiff University (unpublished work) using the same cell source (RC17 – derived 
dopaminergic neurons) transplanted into the 6-OHDA rat model showed that the graft was 
functional and able to ameliorate deficits in motor tests at week 20 following transplantation. 
This would appear to confirm that 16 weeks post transplantation was not a sufficient duration 
for the graft to be significantly functional. Due to the combined administration of 
immunosuppression and pharmacological agents, animal welfare was adversely affected and 
whilst normally studies can continue to 20-24 weeks, this study had to be terminated at week 
16.  Future studies, using the neonatal desensitisation model (Heuer et al. 2016; Kelly et al. 
2009) would allow longer experiments to be conducted without the need for 
immunosuppression.  
The histological data confirmed the behavioural data that a low number of dopaminergic 
neurons survived and their fibres covered only a small area of the striatum which may 
represent the main reason for the limitation in the graft functionality at 16 weeks post 
transplantation. In comparison to the H9 hESC- DA grafts in chapter 5 (see  
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Table 8) which were also terminated at week 16 post transplantation, H9 hESC- DA graft 
produced effectiveness in recovery of motor function from week 12 following 
transplantation. However, histological comparisons showed that the RC17 graft had 30 times 
fewer dopaminergic neurons, 19 times smaller volume and its fibre coverage of the striatum 
was less medially by 10 times and laterally by 15 times than H9 hESC- DA graft. On the other 
hand, to compare the efficiency of the graft on covering the striatum regardless its graft size, 
the ratio between the percentage of the striatum covered by the fibres and graft volume was 
calculated. The comparison showed that RC17 projected fibres had the relative ability to cover 
striatal area two times more than H9. This infers that RC17 hESC derived neurons are more 
powerful in term of fibres outgrowth than H9 hESC graft. The current histological data is 
consistent with the data presented by the Brain Repair Group who showed a small graft and 
relatively long fibres with a functional graft at week 20 (unpublished work).   
The histological analysis of the graft demonstrated that the dopaminergic neurons 
constituted about 46 % of the total number of cell populations in the graft labelled with HuNu. 
This is considered relatively large proportion of the total surviving cells compared to the same 
ratio in H9 hESC graft which represented about 22% of the total cells population. Although 
the graft was smaller, this suggests that neurons derived from the RC17 cell line are more 
likely to retain their dopaminergic phenotype compared to the H9 cell line under the used 
protocols. This would be considered an advantage for RC17 graft as one of the aims in stem 
cells transplantation is getting more purified dopaminergic neurons graft with less cells 
heterogeneity. The identity of other cells in the graft of these stem cells is unknown and their 
presence could have an impact on graft functionality, safety or existence of graft side effects. 
Previous experiments in which human-induced pluripotent stem (hiPS) cell derived 
dopaminergic neurons were transplanted into a rat model demonstrated the presence of 
undifferentiated cells (positive for the marker Nestin) within the grafted cell population which 
may carry the possibility of continuous cell division and the possibility of tumour formation 
(Cai et al. 2010). On the other hand, from primary cell transplantation, it has been clarified 
that the heterogeneity of transplanted cells in clinical trial, like presence of serotonergic 
neurons, is one of the factors that could drive the emergence of GID (Politis 2010). So, it is 
important for future studies to identify the other type of cells in stem cells graft and to 
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understand what possible effect they can have in term of graft development, function and 
safety.  
The current data also showed that the graft had no effect on inducing microglial reaction and 
the level of microglia around the graft was identical to its level in the lesion control. In the 
large graft of the H9 hESC-DA (Chapter 5), the graft was surrounded by a higher level of the 
microglia compared to the RC17 hESC-DA graft in the current experiment. This difference in 
microglial reaction between the two grafts is possibly to be related to the difference in the 
graft size as the smaller size of RC17 hESC-DA graft has a low tendency to induce microglial 
reaction. This could be another advantage of getting a small and effective (well innervating) 
graft as inflammation may interfere with graft survival, function and the development of graft 
induced dyskinesia.  
The comparison between the small and large graft of hESC-DA in this thesis is comparable to 
previous comparisons between the small graft and large graft of VM cells transplantation. 
Bartlett and colleagues demonstrated that smaller graft (TH+ count around 600 cells) induces 
less inflammatory reaction and has longer fibre outgrowth compared to a graft the 4 times 
larger. They also showed that the small graft can produce the same function as larger graft 
but it is time dependent, as longer periods of time are required by small grafts to reach the 
same effect of larger graft  (Bartlett et al. 2004).  
Effect of the graft on L-dopa-induced dyskinesia and rotations  
Importantly, even with a small graft with limited functional efficiency there was a clear 
efficiency in amelioration of LID. The graft reduced both the number of contralateral rotations 
induced by L-dopa and the expression of AIMS. This suggests that the presence of the graft 
establishing dopamine responsive negative feedback system that control the L-dopa-derived 
dopamine levels and therefore reducing AIMs and rotations because the level of dopamine in 
the striatum can be reduced.  This data not only confirmed that the stem cells transplantation 
can reduce L-dopa induced dyskinesia but also this amelioration can be achieved by small 
grafts and at early stages of transplantation. Taken together with amphetamine-induced 
rotation results (some recovery) and apomorphine-induced rotations (no effect), the graft 
was able to release the dopamine and establish a dopamine responsive negative feedback 
system without normalising the super-sensitivity of the dopamine receptors. 
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The effect of L-dopa on graft survival and function: 
As with the previous chapter, this work for the first time examines the effect of L-dopa 
administration on the development of the graft. Determining the effect of L-dopa on the 
functionality of the graft was not fully tested in this experiment because of the limited size of 
the graft. However, L-dopa tends to ameliorate the amphetamine-induced rotation response 
at a faster rate than in the absence of L-dopa (without reaching statistical difference, 
probability for the null hypothesis P = 0.08). This effect is likely to be from the effect of L-dopa 
on the graft rather than the host brain as previous studies confirmed that L-dopa has no effect 
on the amphetamine-induced rotation test of 6-OHDA lesioned rat models (Steece-Collier et 
al. 2009; Breger 2013). So, this data could suggest that L-dopa is unlikely to be toxic to the 
grafts and in fact may support graft functionality or accelerate graft maturation. Rats treated 
with L-dopa alongside the graft did also appear to begin to show a reduction in rotations in 
response to apomorphine which may also indicate that the L-dopa increases the ability of the 
graft to normalise striatal sensitivity. However, no data is available to confirm that this change 
in apomorphine-induced rotations does not result from the impact of L-dopa on the 6-OHDA 
lesion rather than the graft. This make the interpretation of the apomorphine response of the 
effect of L-dopa in the graft uncertain without having lesion plus L-dopa treatment control 
group.   
Critically L-dopa administered once daily has no effect on the survival of the dopaminergic 
neurons derived from hESC even in a small graft. This is an important development in our 
understanding of the possible effects of L-dopa. Previous experiments in cell culture 
illustrated that L-dopa has neurotoxic effect on neural stem cells via increasing the oxidative 
stress and inducing the apoptotic pathways when used at high doses (Park et al. 2011; Jang 
et al. 2015; Liu et al. 2004; Maharaj et al. 2005). The evidence suggested that L-dopa possibly 
causes further degeneration of the nigral dopaminergic neurones in PD. However, studies on 
transplanted allogenic VM cell transplantation showed no effect of L-dopa on cell survival 
(Breger et al. 2016). The current data extends our understanding show that the hESC-DA 
grafts can survive in the host brain primed with L-dopa regardless of graft size as the results 
of Chapter 5 clarified that L-dopa also had no effect on the survival of the massive graft of H9 
hESC-derived dopaminergic neurons. However, the impact of L-dopa on graft survival also 
need to be explored in multiple dose administration of L-dopa. Because of logistical 
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complexities, the dose frequency of L-dopa used in this thesis was once daily or on alternate 
days which is less than what the patients usually received (3-4 times a day). L-dopa also had 
no interference on the survival of other cells in the graft allowing a constant ratio between 
the number or the volume of the dopaminergic neurons to the total cells population in the 
graft which is consistent with the results of the effect of L-dopa on H9 hESC (chapter 5).  
The effect of exendin-4 on the 6-OHDA lesion model:   
Exendin-4 is able to reverse motor deficits in a partially lesioned MPTP mice and 6-OHDA 
lesioned rats  resulting from the protection of the nigrostriatal dopaminergic neurons (Li et 
al. 2009; Harkavyi et al. 2008). In the present study exendin-4 had no effect on the motor and 
behavioural outcomes of the 6-OHDA lesioned rats who had lost more than 97% of their 
nigrostriatal dopaminergic neurons unilaterally. This supports that the effect of exendin-4 on 
the behavioural recovery tests in grafted rats’ results from its effects on the graft and not 
from affecting other brain regions. However, exendin-4 illustrated trend to reduce 
amphetamine rotations but this was marginal and noticed only after prolonged drug 
administration and not observed in other tests (apomorphine-induced rotation, stepping, 
vibrissae and cylinder). Because the confirmation of almost a complete loss of the TH+ cells in 
SN of the right side, this slight reduction in rotations could have result from the long-term 
effect of exendin-4 on dopamine release in the intact striatal side. Studies in mice have shown 
that exendin-4 attenuates dopamine release in nucleus accumbens after nicotine stimulation 
(Egecioglu et al. 2013). Even though this was in a different model it points to the possibility 
that exendin-4 has similar long term effects on reducing dopamine release from the 
dopaminergic neurons in the intact striatum.  
Effect of exendin-4 on RC17 hESC-derived dopaminergic neurons graft   
As in the previous chapters, GLP-1 receptors were localised on the dopaminergic neurons of 
the graft. Nevertheless, it was found that exendin-4 has no effect on TH survival or fibre 
projections. Given that the grafts in this experiment were small, any effect on 
supporting/enhancing cell survival would be more noticeable than in a large graft. this is 
consistent with the effect of on the survival and fibres outgrowth of the H9 hESC derived graft 
when used at similar dose. However, with H9 hESC-DA, exendin-4 did improve graft function 
in vibrissae test (discussed in chapter 5) which it was not the case with the RC17 graft. This 
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difference is possibly attributed to the difference between the cells, even though both are 
dopaminergic in phenotype and expressed the GLP-1 receptor. 
The other noticeable finding on the effect of exendin-4 on RC17 hESC- derived dopaminergic 
neurons graft is that it produced a significant reduction in the ratio of dopaminergic neuron 
graft volume to the total grafted cells volume (TH volume/ stem121 volume) and had a 
tendency to reduce the ratio of dopaminergic neurons counts to the total cell population 
count in the graft (TH/ HuNu). These changes in the ratio resulted from an improvement in 
volume and count of other cells in the graft by exendin-4 (without significant difference) with 
no or slight effect on the dopaminergic neurons leading to cause the reduction in the 
proportions of TH+ compared to the total cells population. This suggest that exendin-4 may 
have effect on other cells in the graft, like increasing their fibres density consequently diffuse 
the graft volume or it may improve the survival or increase proliferation of other non-
dopaminergic cells in the graft. Such events could reduce the purity of the graft which may 
have implications on the graft. For instance, the ratio of serotonergic neurons to 
dopaminergic neurons in the graft  is thought to be an important factor in triggering the 
development of GID  (Politis et al. 2011). A further study may be needed to sort out the kind 
of cells in the graft, especially serotonergic neurons, to determine whether exendin-4 had 
effect on them.  
The effect of L-dopa and exendin-4 on microglial reaction around the graft  
The present data also showed that L-dopa tended to increase the level of activated microglia 
around the graft (the p value of null hypothesis was 0.052). In Chapter 5, the large graft of H9 
hESC-DA has higher level of microglia around the graft compared to the intact side and L-dopa 
has no further effect on the level of microglia. However, in this chapter, the small RC17 hESC-
DA graft has no effect on microglial level around the graft compared to the intact side but L-
dopa has a clear trend to increase the level of microglia around the graft.  This may suggest 
that either the graft size and/ or the type of stem cell source have influence on the impact of 
L-dopa to inflammatory responses. In chapter 4 results of this thesis, the data showed that L-
dopa increase level of microglia around the allogenic VM graft. Previously, Breger and 
colleagues (2016) used the same model and demonstrated that L-dopa increased the levels 
of microglia around the xenografts but not allografts following VM cells transplantation which 
pointed to the importance of the histological compatibility on determining the L-dopa effect 
175 
 
on microglial reaction. They hypothesised different mechanisms by which L-dopa induced the 
inflammatory reaction around the graft including that: L-dopa may stimulate proliferation or 
activation of the inflammatory cells; L-dopa may interact with cyclosporine-A lead to reduce 
the later action in the brain; L-dopa may alter blood brain barrier function leading to influx of 
the immune cells (Breger et al. 2016). They also showed that this increment induced by L-
dopa had no deteriorating effect on graft survival or function of the graft which is consistent 
with the current results that illustrated that L-dopa has not reduced graft survival or function 
but rather it has tendency to improve graft function in the amphetamine-induced rotation 
test (discussed above).  
Like its effect on H9 hESC-DA graft (chapter 5), the current data showed that exendin-4 has 
no effect on microglial level around the RC17 hESC-DA graft and the interaction between L-
dopa and exendin-4 does not change the effect of L-dopa on microglial level. This in contrast 
with the results of chapter 4 which showed that exendin-4 enhance the effect of L-dopa on 
increasing the level of microglia around the allogenic VM graft significantly (discussed in 
chapter 4). The same reasons suggested in chapter 5 could be also responsible for the non-
further elevation of microglial level around the RC17 hESC-DA grafts in presence of exendin-
4 including: the presence of cyclosporine-A in the model may interact with exendin-4 lead to 
halt the action of the latter on the microglia; the reduced dose of exendin-4 may reduce its 
effectiveness on the microglial level.  
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 Conclusion  
The current data demonstrated that RC17 hESC-derived dopaminergic neurons can survive in 
the striatum of 6-OHDA rat model throughout 16 weeks of experimental time, but it has low 
survival rate and produce small graft. The data also showed that the duration of the 
experiment was not long enough for the graft to reach maximal efficacy in reversing the 
deficits in most of the motor tasks. Insufficient graft maturation was suggested to be the 
reason for the incomplete graft function. Importantly the current data, consistent with 
chapter 5 results, confirmed the ability of hESC-derived dopaminergic neurons to reduce L-
dopa induced abnormal involuntary movements despite the small graft size. It also confirmed, 
taken together with results of chapter 5, that the transplantation of dopaminergic neurons 
derived from different hESC cell lines can survive and function in in the 6-OHDA lesioned rat 
model exposed to chronic L-dopa treatment, regardless of graft size. The present chapter also 
demonstrated that administration of exendin-4 has no effect on graft survival and function. 
Although, it supported H9 hESC-DA graft function and fibre outgrowth to a degree suggesting 
that the supportive action of exendin-4 depends on the source of transplanted cells.  
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Table 8 summary of the behavioural and histological findings from H9 and RC17 hESC 
transplantation in 6-OHDA rat model. In addition to the summarise the effect of L-dopa and exendin-
4 treatments on these findings. 
 
  
Tested Factor RC17 
hESC 
graft 
H9 hESC 
graft 
L-dopa effect 
on 
Exendin-4 effect 
on 
Rc17 H9 RC17 H9 
B
eh
av
io
u
ra
l r
ec
o
ve
ry
 t
es
ts
 Amphetamin
e rotation 
Trend to 
recover 
(week 
16) 
Recovered 
(week 12) 
Trend to 
reduce 
No No No 
Apomorphin
e rotation 
No Recovered No No Trend to 
reduce 
No 
Stepping, 
vibrissae, 
cylinder 
No Improve 
vibrissae  
 Increase 
in 
vibrissae 
and 
cylinder 
No Increase in 
vibrissae 
AIMs reduction Reduced Reduced   No No 
L-dopa rotation reduced reduced   No No 
TH count 532 16,118 No No No No 
HuNu count 2004 72,000 No No No No 
TH volume 0.066m
m3 
1.27mm3 No No No No 
% of survival 0.1% 5%     
% of 
striatum 
covered 
by Fibres 
Medially M 5% 50% No No  No Trend to 
increase 
Laterally L 2% 29% No No No No 
% of Fibres M / graft 
volume 
75 39     
TH/HuNu 0.46 0.22 
 
No No Trend to 
reduce 
No 
TH/stem121 0.88 0.8 No No Reduced No 
Microglial level (around 
graft/ intact side) 
1 1.7 Trend to 
increase 
NO No No 
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7 Chapter 7: General discussion   
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Cell transplantation is one of the promising therapies in the treatment of Parkinson disease 
but it is still facing significant logistical challenges in terms of cell survival and efficacy. This 
thesis aimed to identify neuroprotective agents that would support transplanted cells and 
importantly understand the effects of the most commonly used drug in PD, L-dopa, on 
determining neuroprotective agents’ efficacy on the graft. Two families of agents were 
investigated in this thesis, ghrelin receptor agonists and glucagon-like peptide 1 receptor 
agonists. Both had previously showed evidence of neuroprotective capability to protect 
dopaminergic neurons in cell culture and animal models. Generally, both may have 
neuroprotective effects on transplanted dopaminergic neurons through peripheral 
administration that would improve cells survival and support graft function. The data in 
chapter 3 clarifies that peripheral administration of ghrelin receptor agonists have limited 
efficacy to support transplanted allogenic VM cell (discussed in chapter 3). In contrast, results 
in chapter 4 illustrated that peripheral administration of GLP-1R agonists could support graft 
survival and function, however their efficacy was determined by the presence of L-dopa 
treatment (discussed in chapter 4).   
 In the second part of the study I wanted to identify the consequence of the co-administration 
of L-dopa and the neuroprotective agents on the hESC-derived dopaminergic neuronal grafts. 
These are considered as one of the alternative cell sources for transplantation in PD that is 
expected to supersede primary foetal VM cells transplantation as a more reproducible source 
of cells. So, it was important to characterise survival, function and safety of these cells in an 
animal model that more closely mimicked the reality of patient, by exposing them to anti-
parkinsonian medications. In addition, it was important to consider the ability of the 
neuroprotective agents identified in first part of study to support survival and efficacy in this 
new model design. The results from chapter 5 and 6 demonstrate that hESC-DA neurons can 
survive and function in the presence of L-dopa and the addition of exendin-4 provided some 
support to these cells. 
This thesis identified that GLP-1 agonists (exendin-4 and liraglutide) have supporting effects 
on both primary and hES cell transplantation, and it is also recognised that L-dopa had a 
considerable impact on determining the protection status of these agents. In addition, the 
addition of L-dopa to the animal model answered important questions allowing more 
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clinically relevant evaluation of the functional capability and survival of hES-derived cell 
transplantation. This thesis made steps forward in the use of GLP-1R agonists, exendin-4 and/ 
or liraglutide, for clinical trials to support cell therapy in PD and raises issues of the importance 
around using L-dopa in the modelling of PD in animal models to evaluate cell therapy and 
both of these key issues are discussed in detail below. 
 Are GLP-1 agonists ready to support cell therapy in clinical trials 
of PD? 
As described in the introduction of chapter 4, exendin-4 and liraglutide are already used 
clinically to treat type 2 diabetes mellitus T2DM and their safety issue was approved for 
clinical use for T2DM treatment. However, the GLP-1 analogues were put under tier 2 
classification in the American Diabetes Association and European Association. This category 
is for treatments that are less well validated, in this case because the GLP-1R signalling 
pathways of these analogues are not fully understood and have different clinical sequelae in 
the severity of the side effects that are produced and the therapeutic value of each (Nathan 
et al. 2009; Weston et al. 2014). Currently, exendin-4 is also in clinical trials to treat PD 
patients and it has a beneficial effect on patients with Parkinson’s disease determined as an 
improvement in the Movement Disorders Society Unified Parkinson’s Disease Rating Scale 
(MDS-UPDRS) score compared to the placebo control group. Additionally, the safety 
assessments of exendin-4 in PD patients showed that it was generally well tolerated, the main 
notable side effects were reduction in body weight and gastric disturbances. The mean body 
weight reduction was 3.2 kg over 12 months compared to 0.8 kg loss in the placebo group. 
This reduction affected 19 patients out of 20 (the dose of exendin-4 was reduced in two 
patients to reverse this reduction in body weight after 10 month and one of them withdrew 
because of this issue) (I Aviles-Olmos et al. 2013).  
The effectiveness of GLP-1 agonist to support cell therapy in PD was explored in animal 
models throughout this PhD. Indeed, GLP-1 agonist was effective in supporting transplanted 
cells survival, improving fibre outgrowth and enhancing graft efficacy in behavioural tasks. 
This suggests that there may be the potential to use exendin-4 or liraglutide to support cell 
therapy in the clinic specifically exendin-4 which was safe and well tolerated by Parkinsonian 
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patients. However, this thesis raised some issues needed to be clarified before considering 
GLP-1 agonists (exendin-4 or liraglutide) for clinical trials as a support for cell therapy: 
1. The effectiveness was influenced by the presence of L-dopa treatment (chapter 4).  
2. Development of an insulin resistance due to interaction between exendin-4 and L-
dopa (chapter 4). 
3. A considerable body weight loss was recorded when co-administered with 
cyclosporine immunosuppression (chapter 5&6). 
4. The pattern of graft support was dependent upon the cell source for transplantation 
(chapters 4, 5, 6). 
The PD patients who undergo cell transplantation will be highly likely to already be on L-dopa 
treatment and will be administering immunosuppressants (mainly cyclosporine-A), to prevent 
graft rejection in the immediate post-graft period. Both these medications appeared to 
interfere with either efficacy or safety of exendin-4. The co-administration of L-dopa and 
exendin-4 illustrated that the latter has no effect on support survival or function of embryonic 
VM cell transplantation while it supported the functional and survival of the graft in the 
absence of L-dopa. Again, in H9 hESC-DA transplantation, the efficacy of exendin-4 at 
ameliorating deficits in behaviour in the vibrissae test was reduced in the presence of L-dopa. 
The reduction of exendin-4 efficacy in the presence of L-dopa was accompanied by an 
increase in glucose and insulin plasma levels, in addition a sign of insulin resistance was also 
detected on the grafted cells. Based on these finding it has been suggested that L-dopa may 
interact with exendin-4 causing insulin resistance on the transplanted cells leading to 
cessation of the protection effect of exendin-4. This raises concern about the safety and ability 
of exendin-4 to support cell therapy in the clinic. However, in the clinical trial conducted by 
Aviles-Olmos and colleague, insulin resistance was investigated in PD patients receiving L-
dopa and exendin-4 for 12 months using a glucose tolerance test. Only one participant 
reached the upper threshold of glucose levels out of 20 patients undergoing testing, all of 
whom were categorised as a moderately to severely parkinsonian. This suggests the 
possibility that the interaction between exendin-4 and L-dopa is less likely to appear in 
humans (Iciar Aviles-Olmos et al. 2013). However, the insulin resistance determined in this 
clinical study depended only on results from the glucose tolerance test, and no data available 
about insulin plasma levels or insulin resistance at the molecular level. In addition, the 
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interaction between L-dopa and exendin-4 could be different between PD patients receiving 
cell therapy or in the absence of cell therapy. An alternative hypothesis suggested in chapter 
4 is that the insulin resistance developed could be related to the interaction between exendin-
4 and benserazide (aminoacidic decarboxylase AADC inhibitor used in combination with L-
dopa to avoid peripheral L-dopa conversion to dopamine) rather than L-dopa itself. In clinic, 
Parkinson disease patients use L-dopa in different combination with AADC inhibitors like 
benserazide and carbidopa. Thus, more studies maybe needed to understand the 
mechanisms that lead to develop this insulin resistance in animal model and understand its 
possible incidence in parkinsonian patients.  
When co administered with cyclosporine, used to prevent rejection of transplanted cells, 
exendin-4 had a dramatic impact on rats’ body weight in two separate experiments (chapter 
5 & 6).  In chapter 5, after 10 days of starting exendin-4 and cyclosporine treatment 16 out of 
18 rats had severe weight loss in a short time, reaching more than 10% loss of body weight 
and in some cases reached to 20%, and similarly happened in chapter 6 experiment. However, 
this was remedied by using single daily dose of 0.5 µg/kg of exendin-4 rather than twice daily 
dose in both experiments. This is a concern for clinical translation, especially given that 
baseline weight loss was observed in the clinical trial in most of the PD participants and one 
of them withdrew from the trial after 10 months because of the severity of weight reduction. 
These patients were not on the additional cyclosporine required post-transplantation raising 
concerns that this could be problematic (I Aviles-Olmos et al. 2013). While this weight loss is 
considered beneficial in T2DM, it is much less acceptable as a side effect in PD. Clinically, this 
weight reduction recovered by reducing the dose or cessation of the exendin-4 administration 
(I Aviles-Olmos et al. 2013) and similarly by reducing the dose frequency in the 6-OHDA-
lesioned rats in this thesis (chapter 5 and 6). The reduced dose of exendin-4 was still effective 
in supporting graft efficacy of H9 hESC-DA in the vibrissae test and improved fibre innervation 
of the striatum however this effectiveness was not reflected in improved cell survival rats or 
other behavioural tests. This suggested that body weight can be monitored by reducing the 
exeindin-4 dose with the possibility of maintaining its therapeutic efficacy.  
Despite the fact that all cell types evaluated in this thesis (E14 VM cells, H9 hESC-DA graft, 
RC17 hESC-DA graft) expressed the GLP-1 receptor following transplantation, there was a 
clear difference in the impact of exendin-4 on graft survival and function. As an illustration, in 
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rat embryonic VM grafts (chapter 4), it improved dopaminergic neuronal survival and graft 
function; in H9 hESC-DA graft (chapter 5), it supported graft function in vibrissae test possible 
due to improve or accelerate graft maturation but without affecting cell survival or fibre 
outgrowth; in RC17 hESC-DA graft (chapter 6), it had no effect on graft survival, fibres 
outgrowth or graft function but rather it may have interfered with other cells in the graft 
rather than dopaminergic neurons (see Table 9 ). This difference in part may relate to the 
change in protocol required in the presence of cyclosporine in chapter 5 and 6 in which the 
dose frequency had to be reduced for welfare reasons; alternatively, a difference in the 
intracellular signalling pathway of the GLP-1 receptors may occur because of the different 
originating species of the cells (human and rat), development stage (primary VM and ESC-DA), 
or source of cell line (H9 and RC17).  
Table 9 main impacts of exendin-4 on graft outcomes of different cell sources for transplantation 
Main effects on the 
graft 
Type of transplanted cells 
E14 VM cells H9 hESC-DA RC17 hESC-DA 
Graft function  Improved  Some 
improvement  
No effect 
Dopaminergic 
neurons survival  
Improved  No effect  No effect  
 
The other GLP-1 agonist, liraglutide, was also supportive to the function of VM graft. However, 
it had no effect on graft survival which raises the question about what is the mechanism 
involved to support graft function. The data showed that it may support graft function 
through improving TH+ fibres density in the graft with a tendency to improve graft volume. 
Interestingly, liraglutide effectiveness on graft function (amphetamine rotation test) also 
interacted with L-dopa, as liraglutide produced best function in presence of L-dopa which may 
provide an advantage to supportive the graft function in “real world model”. In addition, there 
was no evidence of insulin resistance from this combination with L-dopa. One of the 
suggestions that liraglutide produced better effectiveness in presence of L-dopa was through 
modulation of the inflammatory reaction around the graft as there was a significant increase 
in infiltered leukocytes in the striatum resulting from interaction between L-dopa and 
liraglutide (discussed in chapter 4). This mechanism could be affected by the presence of 
184 
 
cyclosporine which acts through inhibition of  T cell activation and blocking transcription of 
cytokine genes like IL-2 and IL-4 (Matsuda & Koyasu 2000). Since patients received 
cyclosporine after cell transplantation, liraglutide needed to be tested in animal models 
exposed to cyclosporine-A. In addition, issues raised here from using exendin-4, such as 
weight reduction and variety in the pattern of effect by the difference in cell source also need 
to be considered before considering the use of liraglutide in clinical trial.  
It was originally intended to use liraglutide alongside exendin-4 to continue to evaluate its 
effect on hESC-DA transplantation in chapters 5 & 6 but because of practical and financial 
constraints only exendin-4 was selected to be tested on hESC-DA therapy in this thesis. The 
reasons for selection of exendin-4 over liraglutide were: first, exendin-4 is in clinical trials to 
treat PD which will help to give clearer evaluation to its value for support cell therapy in 
clinical trials; second, liraglutide showed no effectiveness on protecting and improving cell 
survival; third, the intention was to replicate the exendin-4 effect to get a greater 
understanding of the mechanisms underlying the intriguing results of development of insulin 
resistance from interaction between exendin-4 and L-dopa (note: liver and blood samples 
were collected from chapter 5 and 6 experiments and further investigations on involvement 
of insulin resistance and liver abnormalities on cell therapy will be conducted as soon as 
financial support is obtained). 
Taken together further studies need to be conducted to answer the validity of GLP-1R agonists 
on supporting cell therapy in clinical trials and it should consider the use the following: 
1. 6-OHDA animal model received L-dopa and cyclosporine because both treatments are 
used by patients in clinic after transplantation and both interacted with the 
effectiveness of exendin-4 and possibly liraglutide. 
2. normal (0.5 µg/kg twice daily) and reduced dose frequency (once daily) of exendin-4 
to compare its effectiveness with minimum dose that may be needed to avoid weight 
reduction.  
3. Carbidopa or other AADC inhibitors instead of benserazide in combination with L-dopa 
to avoid a hypothesised interaction between exendin-4 and benserazide. The later 
may be responsible for accumulation of exendin-4 metabolites that have an 
antagonistic effect on the GLP-1 receptors (discussed in chapter 4).  
185 
 
 New insights of using L-dopa in animal models of cell therapy in PD 
L-dopa treatments were used throughout this thesis to mimic the real clinical fact that 
administration of anti-Parkinsonian medications will continue for patients who receive cell 
therapy. It has been clarified previously that L-dopa is responsible for inducing changes at the 
host brain can affect evaluation of graft outcomes (Steece-Collier et al. 2009)(García et al. 
2011a). For instance, priming the rats with chronic L-dopa treatment before, and continuing 
treatment after VM cells transplantation led to a significant reduction in the ability of the 
graft to alleviate LID compared to non-primed rats(Steece-Collier et al. 2009) This indicated 
importance of using chronic L-dopa to estimate the real ability of the graft on reversing LID. 
In addition, the same study showed that rats primed with L-dopa have significantly less fibre 
outgrowth compared to non-primed rats. Such effects would reduce the grafts ability to cover 
an appropriate area of the striatum, and consequently might affect graft function. Other 
experiments showed that the severity of GID depends on the severity of pre-existing LID as 
more severe pre-transplantation LID would develop severe GID later (which need L-dopa 
treatment to develop) (García et al. 2011a). Thus, adding L-dopa treatment to develop pre-
existing LID would enable a real evaluation of the induction of the GID by the graft. Moreover, 
some studies conducted in cell culture and animal models suggested that L-dopa increases 
oxidative stress and has neurotoxic effects which would increase degeneration of the 
dopaminergic neurons (Maharaj et al. 2005; Jang et al. 2015; Liu et al. 2004; Park et al. 2011). 
This effect of L-dopa may change the host brain environment, a factor which would add 
complexity to determine the status of survival or function of transplanted cells dopaminergic 
neurons. Westin and colleague demonstrated that chronic L-dopa treatment in the 6-OHDA 
lesioned rat caused changes in blood brain barrier permeability and induced angiogenesis 
(Westin et al. 2006). This effect can also cause changes in the host brain environment as the 
changes in blood brain permeability may increase inflammatory cells infiltration that would 
affect graft function or survival. Breger and colleagues demonstrated that L-dopa treatment 
causes increases in the microglial level around the VM xenograft and increases in leukocyte 
infiltration (Breger et al. 2016). Similarly, in this thesis, a clear trend to increase the level of 
microglia by administration of L-dopa around RC17 hESC-DA graft was noticed (chapter 6). 
However, although L-dopa is capable of inducing these wide ranging and significant 
alterations to the host brain, the studies presented here show that once daily L-dopa has no 
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direct effect on behavioural recovery or survival of embryonic VM transplantation ((Chapter 
4) & (Breger et al. 2016; Steece-Collier et al. 2009)). Before this thesis work was conducted, 
there was no understanding of the effect of L-dopa on the hESC-DA grafts. Indeed, this PhD 
addresses an important question about the validity of hESC-DA grafts in the presence of L-
dopa treatment. Furthermore, it has highlighted the importance of using L-dopa in animal 
models to evaluate cell therapy which include the hypothesised mechanisms of findings that: 
1. L-dopa is being able to directly support to hESC-DA graft function or maturation.  
2. L-dopa induced dyskinesia recovery using hESC-DA graft helps in early prediction of 
the graft function.  
3. L-dopa induces or participates in inducing peripheral physiological changes that could 
impact on graft outcomes. 
This PhD has not only revealed that hESC-DA grafts can survive and function in the presence 
of L-dopa regardless of graft size, but it also showed that L-dopa can even support graft 
efficacy. In H9 hESC-DA graft (large graft), L-dopa had a positive effect on the vibrissae test 
and cylinder test; in RC17 hESC-DA (small graft) L-dopa showed a high tendency to ameliorate 
amphetamine rotation tests throughout the experimental time. The mechanism of this effect 
is not clear as there is no change in cell survival or fibre outgrowth by the effect of L-dopa. 
This suggested that this improvement is not related to the graft size but other factors may be 
involved like dopaminergic neurons subtype or synaptic integration which is needed for 
further investigation. In chapter 5, the supportive effect of L-dopa has high tendency (but not 
significant) to interact with the time as its effect diminished with extended post graft times, 
which suggested that the L-dopa may be accelerating graft maturation. In a slightly different 
profile, the supportive tendency of L-dopa on RC17 hESC-DA graft continued to the same 
extent throughout the experimental time.  Neither cell line is believed to be fully mature at 
16 weeks, but the RC17 appeared to take longer to develop to their full potential. The L-dopa 
effect could result from an interaction with the host environment or from a direct 
pharmacological action on the dopamine receptors on the grafted cells. Dopamine receptors 
subtypes (1 to 5) were identified on H9 hESC in vitro at all the stages of differentiation toward 
a mature dopaminergic phenotype. Importantly, dopamine receptor agonists affected the 
neuronal differentiation process and the subtype of the dopaminergic neurons as they 
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increased the number of TH neurons produced but reduced GIRK2 expression, a marker of 
the desirable A9 subtype (Belinsky et al. 2013).  
An unanticipated benefit to the use of L-dopa in the in vivo model is that it appeared to 
provide a very early indicator of hESC-DA graft function. LID and L-dopa-induced rotations 
were reduced weeks before a reversal of the motor and behavioural deficits was identified. 
This suggests that the cells are capable early on of re-uptaking extracellular dopamine, re-
store and releasing it again under an autoregulatory mechanism to decrease the pulsatile 
excitation of dopamine receptors after L-dopa administration (Björklund 1992). This improved 
management of L-DOPA would reduce the behavioural response. Moreover, the stem cell 
graft reversed LID regardless of the graft size or the maturation time required to reduce 
behavioural deficits. Thus, it will increase the potential of identifying the functionality of small 
grafts or slowly maturing grafts whose function may be underestimated throughout the 
experimental time (see chapter 6). This is in contrast with primary cell transplantation which 
required a large graft size and extensive innervation to reduce the LID score (Lane et al. 2006). 
This may suggest that the hESC-DA graft is more efficient than primary cells grafts in 
controlling postsynaptic dopamine levels elevated by L-dopa administration. 
The other notable effect of L-dopa was the development of the systemic changes of insulin 
resistance and increased peripheral inflammatory infiltration, only observed on co-
administration with GLP-1 agonists (exendin-4 and liraglutide).  This was accompanied by a 
modulation of the neuroprotective agents’ effect on the graft. The presence of L-dopa 
converted liraglutide from inactive neuroprotective agent to an active agent while vice versa 
happened with exendin-4. Although the exact mechanism is unknown, we can speculate that 
these systemic changes have a role in determining graft outcome (discussed in chapter 4). 
This highlighted the importance of considering L-dopa in evaluating graft outcomes in the 
presence of other factors. The candidate patients for cell therapy transplantation receive a 
range of medications including anti-parkinsonian medications (see table 1 in chapter 5) as 
well as other neuro-active and non-neuroactive medications (see below, Table 10). This 
complex of medications increase the likelihood of a drug interaction with L-dopa and 
possibility of inducing systemic changes comparable to those observed with the interaction 
of L-dopa and GLP-1 agonists. Since the mechanism by which the L-dopa interact with 
exendin-4, the anti-diabetic drug, to induce insulin resistance is unclear, any medication may 
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interfere with glucose-insulin homeostasis could possibly have the potential to interfere with 
L-dopa. For instance, some clinical cases have reported that MAO- inhibitors, selegiline and 
rasagiline, caused increased insulin release, insulin sensitivity and hypoglycaemia in non-
diabetic parkinsonian patients (Ibrahim et al. 2017; Rowland et al. 1994). In addition, 
developing insulin resistance is one of the side effects of the immunosuppressant regime used 
after transplantation like azathioprine and prednisolone (Prokai et al. 2012).  
Throughout this thesis, the L-dopa treatments were used in a once daily dose regimen while 
in clinic the reality is that patients receive more frequent doses, up to 4-5 times a day. This in 
turn could make the effect of L-dopa on the graft outcomes more robust and obvious. 
However, replicating this frequency of drug administration is not feasible in a long-term study 
for animal welfare reasons but looking to replicate this with more constant dopamine 
receptor stimulation would be desirable in the future. Moreover, the possible sensitivity of 
the graft efficacy by the systemic changes underline that not only L-dopa treatment should 
be considered in evaluation of graft function but all possible medications used by the patient 
that have a tendency to induce insulin resistance or inflammatory modulation.   
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Table 10 neuronal and non-neural medications used by 12 parkinsonian patients at the time of VM 
cells transplantation in TransEuro clinical trial (obtained from prof. Roger Barker, transEuro 
coordinator) 
Neuro medications (number of 
patients) 
Non-neuro medications (number of 
patients 
zopiclone 7.5 mg nocte (1) Prednisolone (6) 
citalopram 30mg OD (1) Omeprazole (6) 
flunitrazepam 1mg OD (1) Trimoxazole (5) 
Zolpidem 5mg OD (1) Cyclosporine (6) 
 Azathioprine (6) 
 Alendronate (2) 
 Anti-asthmatic medications (1) 
including: symbicort; terbutaline, 
fluticasone; cromoglicate 
 
 Experimental limitations  
There are some limitations underlined different experiments in the thesis mainly due to 
financial or practical reasons. The balanced design of the experimental chapters was lacking 
to 6-OHDA unilateral lesion control group treated with an appropriate drug used within the 
experiments. For instance, in chapter 3, there was no lesion control group treated with either 
ghrelin or JMV-2894 (long acting ghrelin); in chapter 4, there was a lack for lesion group 
treated with exendin-4, liraglutide, L-dopa, exendin-4 plus L-dopa and liraglutide plus L-dopa; 
in chapter 5 and 6 there was absence lesion group treated with exend-4, L-dopa exendin-4 
plus L-dopa, except in chapter 6 there was lesion plus exendin-4 group. The value of adding 
these treatments to lesion control group will help to confirm evaluation the effect of these 
treatment on the graft function and excluding any effect on the behavioural tests due to 
interaction with other targets. The behavioural data analysis was only depended on that there 
was a complete lesion for endogenous dopaminergic neurons (the main contributor that may 
change the behavioural outcomes in presence of these drugs) and assumed that these 
treatments had no interference with the behavioural tests through interaction with other 
systems rather than the graft. The effect some of these treatments was evaluated on the 
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behavioural tests of complete unilateral 6-OHDA lesioned rats in previous published papers, 
like L-dopa was tested in the stepping, cylinder, vibrissae and amphetamine rotation test 
(Breger et al. 2016); liraglutide was tested in amphetamine and apomorphine induced 
rotation tests (Hansen et al. 2016)), In addition exendin-4 which used in chapter 4, 5 and 6 
was tested in chapter 6. All these treatments showed they had no effect on the behavioural 
outcomes of the long lasting complete lesion 6-OHDA rat model. However, the effect of these 
treatments is still need to be tested in the same experiment at the same condition for better 
evaluation. So, it is recommended for future study to include control lesion group treated 
with these agents.  
The other limitation in this thesis was lacking adding cyclosporine-A treatment to the lesion 
control group in chapter 5 and 6. Cyclosporine-A was used in the grafted groups to avoid graft 
rejection and there was no need to added in the lesion control group where there is no graft. 
However, some papers showed that cyclosporine-A increase the rats’ hyperactivity 
(Borlongan et al. 1999), in addition it reduces the animal welfare with time. These may affect 
the rats’ response in the motor and behavioural tests. The data analysis of the graft function 
compared to the lesion control in chapter 5 and 6 assumed there was no effect of 
cyclosporine-A on rats’ response on the motor tests. However, for better evaluation, it is 
recommended to include cyclosporine treatment in the lesion control group in future study.  
 Thesis conclusion  
This PhD work identified the GLP-1R agonists as neuroprotective agents capable of supporting 
optimisation of cell therapy in PD. It also clarified that hESC-DA can survive and function in 
the presence of L-dopa treatment which was added to the 6-OHDA rat model to mimic the 
reality of patients’ clinical situation. It also verified that hESC-DA can ameliorate the L-dopa 
induced dyskinesia. This thesis confirmed the importance of adding L-dopa to the animal 
models to evaluate cell therapy in PD.  It is recognised that L-dopa participated in inducing 
peripheral changes that hypothesised to have determine effect on graft function and survival, 
in addition L-dopa may have supportive effect to the function of the hESC-DA graft.  This work 
also opened new questions need to address. For instance, GLP-1R agonists illustrated 
differences in their action and safety when co administrated with L-dopa and cyclosporine-A 
and when different cell sources were used for transplantation. These suggested further 
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studies need to validate the best GLP-1R agent’s effectiveness and safety to support 
transplanted cells. This thesis also raised other issues may require further investigations 
including whether GLP-1R agonists have interaction with other medications used by 
parkinsonian patients that might compromise its effectiveness or safety; whether L-dopa has 
interactions with other medications used by the parkinsonian patients which might induce 
peripheral changes that would affect graft survival and effectiveness.   
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8 Appendixes   
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 Appendix A: antibodies optimisation information and method of 
detection for the histological and cytological targets:  
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 Appendix B: products information of antibodies, chemical and 
materials: 
Chemicals, anti-bodies and instruments Company Product code 
6-OHDA Sigma H116-5mg 
Anti- goat Alex flour 488 Life Technologies  A-11055 
Anti- mouse Alex flour 488 Thermofisher Scientific A-11029 
Anti-rabbit Alex flour 594 Thermofisher Scientific A-11037 
BCA protein assay kit Thermoscientific Lab 23227 
Benserazide Sigma Aldarich B7283-5GM 
Biotinylated anti mouse Vector BA-2001 
Biotinylated anti rabbit Vector BA-1000 
Biotinylated Tomato lectin Vector labs B-1175 
DAB Sigma D5637-16 
DMEM-F12 Gibico 21331-020 
Dornase alpha (Accutase) Roche Batch: N0202 
DPX Fisher 12658646 
Exendin-4 Tocris 1933 
Fine tip Forceps F.S.T 11295.51 
Fine tip Scissors FST 15000-08 
Goat anti-SOX2 Santacruz Sc-17320 
Hamilton syringe (removable needles) Sigma 20697 
Hamilton needles  Sigma 19132-u 
HRP anti- rabbit Vector pI-1000 
HRP anti-goat Vector PI-9500 
Isopropanol Fisher P1274 
Laemmli lysis buffer Sigma 28733-5x 2 ml 
L-dopa Sigma Aldarich D1507-5GM 
Methylated spirit Fisher 11482874 
Mouse anti-  BIII tubulin Abcam Ab18207 
Mouse anti CD11b Ab Serotec MCA 275GA 
Mouse anti HuNu Millipore MAB 1281 
Mouse anti-CD45 Ab Serotec MCA 43R 
Mouse anti-stem121 Takara Y40410 
Mouse anti-TH Millipore MAB318 
Nitrocellulose bloting membrane GE- Healthcare 10600011 
PLL Sigma P1274 
Rabbit anti 5-HT Immnuostar 20080 
Rabbit anti DCX (doublecortin) Abcam AB18723 
Rabbit anti GIRK2 Alomone Labs APC-006 
Rabbit anti- GOAT Phoenix Pharmaceuticals H-032-12 
Rabbit anti- IRS1-pS1011 Cell signalling Technology 2385S 
Rabbit anti-GHSR1a Alomone Labs AGR-031 
Rabbit anti-GLP-1R Abcam Ab188605 
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Chemicals, anti-bodies and instruments Company Product code 
Rabbit anti-TH Millipore AB152 
Streptavidin Cy3 Stratech 016-160-084-
JIR 
SuperSingle west Dura kit Thermoscientific Lab 34075 
Texas Red Avidin Vector A-2006 
Trypan blue 0.4% sigma T8154-20ml 
tryplE Gibico 12604-013 
Xylene Fisher 10784001 
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